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Oxidative stress induced by glutathione depletion in the mouse HT22 neuronal cell line and 
embryonic rat immature cortical neurons causes a delayed, sustained activation of extracellular 
signal-regulated kinases-1/2 (ERK1/2), which results in cell death. Previous studies from our lab 
have shown that this sustained activation of ERK1/2 is mediated primarily by a selective, 
reversible inhibition of ERK1/2-directed phosphatases. However, the mechanisms underlying the 
inhibition remain unclear. 
Results from this thesis demonstrate that the inhibition of ERK1/2 phosphatases in HT22 
cells and immature neurons is a consequence of oxidative stress induced by glutathione depletion 
as phosphatase activity is restored in cells treated with the antioxidant BHA. This agent leads to 
reduced ERK1/2 activation and neuroprotection. However, we also show that an increase in free 
intracellular Zn2+ that accompanies glutathione depletion-induced oxidative stress in HT22 cells 
and immature neurons contributes to selective inhibition of ERK1/2 phosphatase activity and 
consequently ERK1/2 activation and cell death. ERK1/2 also functions to maintain elevated 
levels of Zn2+.  Thus the elevation of intracellular Zn2+ within neurons subjected to oxidative 
stress can trigger a robust positive feedback loop operating through activated ERK1/2 that 
rapidly sets into motion a Zn2+ -dependent pathway of cell death.  
Previous data from our lab have suggested that PP2A, a Serine/Threonine protein 
phosphatase, is the predominant ERK1/2 phosphatase in primary neurons. I have confirmed this 
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result by using specific peptide inhibitor of PP2A. Furthermore, I have revealed for the first time 
the reversible cysteine oxidation in the catalytic subunit of PP2A, suggesting that PP2A may be 
the phosphatase that is susceptible to oxidation and inactivation following glutamate treatment in 
HT22 cells and primary neurons. 
ERK1/2 activation contributes to neuronal death following focal ischemia/reperfusion. In 
the third part of my thesis, I investigated the mechanisms responsible for ERK1/2 activation 
following ischemia/reperfusion. I have demonstrated that the selective inhibition of ERK1/2 
phosphatases contributes to ERK1/2 activation following ischemia/reperfusion in both focal and 
global ischemia models. Altogether, these results implicate the inhibition of ERK1/2 
phosphatases as an important mechanism for ERK1/2 activation in oxidatively stressed neurons. 
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1.0  INTRODUCTION 
1.1 OXIDATIVE STRESS IN NEURONS 
1.1.1 ROS and oxidative stress 
Oxidative stress is the result of the accumulation of reactive oxygen species (ROS) and is 
brought about by a disruption of the physiological balance between normal oxidant production 
and the action of various anti-oxidant defense systems. ROS includes a family of chemically 
reactive oxygen containing molecules, such as superoxide (O2-), hydroxyl radical (OH-) and 
hydrogen peroxide (H2O2). As the major sites of energy generation in the cell, mitochondria are 
the most important sources of ROS generation during the process of oxidative phosphorylation 
(Jezek and Hlavata, 2005). Unstable oxygen radicals are generated as the by-products of 
oxidative phosphorylation due to the incomplete reduction of oxygen in mitochondria.  
 ROS react with and modify most macromolecules, such as proteins, lipids, and nucleic 
acids in the cell. Therefore, the accumulation of ROS will cause damage to those molecules and 
subsequently lead to the dysfunction of normal cellular activities. However, not all ROS are 
harmful. ROS generated by NADPH oxidase complex represents an important defense system in 
phagocytes to intruding bacteria (Nordberg and Arner, 2001). Moreover, ROS have been found 
to regulate a variety of signal transduction pathways as well as the activity of transcription 
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factors such as nuclear factor – kappa B (Kabe et al., 2005) and activator protein-1 (AP-1) 
(Nordberg and Arner, 2001). For example, H2O2 could activate tyrosine kinases such as Lck or 
Src and then tyrosine phosphorylate the inhibitor of NF-kB (IkB). The phosphorylation of IkB 
then releases NF-kB from its association and activate NF-kB (Kabe et al., 2005). Therefore, it is 
clear that ROS act as important regulators of signaling pathways in normal cellular functions as 
well as under stress conditions. 
1.1.2 ROS defense systems 
Several antioxidant ROS defense systems exist to protect cells from harmful effects of excessive 
ROS accumulation. The ROS defense systems can be widely divided into two groups: enzymatic 
and non-enzymatic. Superoxide dismutases (SODs) and catalase are the most important enzymes 
that scavenge specific ROS species (Nordberg and Arner, 2001). SOD specifically converts 
superoxide radicals to hydrogen peroxide and molecular oxygen. Several isoforms of SOD have 
been identified. Manganese SOD (Mn-SOD) is located in mitochondria and essential for normal 
cellular function. Specifically, Mn-SOD knockout mice die neonatally or develop severe 
neurodegenerative diseases (Li et al., 1995b; Melov et al., 1998). Cytosolic copper and zinc-
containing SOD (Cu/Zn SOD) and extracellular SOD also function together to scavenge 
superoxide radicals inside and outside of cells (Maier and Chan, 2002). Catalase is located in 
peroxisomes and specifically catalyzes the conversion of hydrogen peroxide to water and 
molecular oxygen. 
Non-enzymatic ROS defense systems include a network of low molecular weight 
antioxidants, such as ascorbic acid (vitamin C), glutathione (GSH) and thioredoxin. Glutathione 
and thioredoxin function as thiol-reducing agents in the cytoplasm. However, due to the high 
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concentration of GSH, the GSH system constitutes the predominant redox buffer in cells (Jezek 
and Hlavata, 2005). GSH is a tripeptide (Glu-Cys-Gly) with a free thiol group that functions to 
reverse oxidized thiols in target molecules. Once oxidized, two GSH molecules form glutathione 
disulfide (GSSH). GSSH is then recycled to GSH by glutathione reductase (GR). Therefore, the 
ratio of GSH/GSSH reflects the status and extent of oxidative stress. Ascorbic acid can reduce 
peroxide and superoxide as well as convert alpha-tocopherol (vitamin E) to its reduced form 
(Buettner, 1993). By reducing alpha-tocopherol radicals, ascorbic acid prevents lipid 
peroxidation in plasma lipoproteins such as LDL (Sies et al., 1992).  This may account for the 
proposed mechanism of vitamin C in preventing atherosclerotic plaque formation (Reaven and 
Witztum, 1996).  
1.1.3 ROS and chronic neurodegenerative diseases  
Due to its high consumption of oxygen as well as relative deficiency in antioxidant defense 
systems (low level of catalase activity and moderate SOD activity), the central nervous system 
(CNS) is particularly sensitive to ROS-induced damage (Rego and Oliveira, 2003).  Oxidative 
stress is implicated in the pathogenesis of a wide range of chronic neurodegenerative diseases, 
including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and Alzheimer’s disease 
(Simonian and Coyle, 1996; Mattson et al., 2001). These neurodegenerative diseases are 
characterized by progressive degeneration of specific neuronal populations and have familial and 
sporadic forms. Oxidative stress may play a role in some familial forms of these diseases. 
Mutations in the Cu/Zn SOD (SOD1) gene have been identified in a subset of familial ALS 
(Rosen et al., 1993). These mutations affect the structure of SOD and its activity (Deng et al., 
1993).  A familial form of Parkinson’s disease has been associated with mutations in the gene for 
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protein alpha-synuclein (Polymeropoulos et al., 1997). Selective and extensive alpha-synuclein 
nitration has been found in synuclein aggregates in sporadic Parkinson’s disease (Giasson et al., 
2000).  In vitro exposure to oxidative and nitrative species enhances stable formation of alpha-
synuclein polymers, which is necessary for their accumulation within aggregations (Souza et al., 
2000). Two major alpha-synuclein mutants, A30P and A53T, have an increased propensity to 
dimerization following oxidative exposure (Krishnan et al., 2003). Moreover, an increase in the 
expression of alpha-synuclein can itself induce oxidative stress (Hsu et al., 2000). Parkin is 
another protein whose mutations have been revealed to be responsible for a familial form of 
Parkinson’s disease (Kitada et al., 1998). Overexpression of wild type parkin protects 
dopaminergic neuroblastoma cells from dopamine-induced toxicity by decreasing ROS 
generation and attenuating protein oxidation, while mutant parkin abrogates these effects (Jiang 
et al., 2004b). Moreover, this protective effect of wild type parkin is achieved through the limit 
of ROS production by suppressing the expression of monoamine oxidase, which produces large 
amounts of ROS by oxidizing dopamine (Jiang et al., 2006).  
Apart from alpha-synuclein and parkin, the identification of mutations in DJ1 (Bonifati et 
al., 2003) and phosphatase and tensin homologue (PTEN)-induced kinase 1 (PINK1) (Valente et 
al., 2004) provides more evidences for a relation between the pathogenesis of Parkinson’s 
disease and oxidative stress. DJ1 has been found to exhibit antioxidant properties (Canet-Aviles 
et al., 2004). By upregulating glutathione synthesis, overexpression of DJ1 protects cultured 
dopaminergic cells from oxidative stress (Zhou and Freed, 2005).  DJ1 also protects cells from 
A53T alpha-synuclein-induced toxicity (Zhou and Freed, 2005). DJ1 knockout mice have an 
increased level of ROS generation and exhibit increased sensitivity to the exposure of an 
exogenous oxidative stress insult (Kim et al., 2005). Amyloid beta-peptide (1-42), which is 
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central to the pathogenesis of Alzheimer’s disease, has been found to induce oxidative stress, 
including ROS generation, protein oxidation, and lipid peroxidation (Butterfield et al., 2001; 
Butterfield, 2002). 
Although many genetic mutations are associated with the pathogenesis of 
neurodegenerative diseases, the majority of those diseases are still sporadic with no definitive 
known causes. The popular view is that the environment is the most influencing factor in disease 
etiology. Epidemiologic studies have suggested that environmental toxins that inhibit 
mitochondrial complex I contribute to the pathogenesis of Parkinson’s disease (Sherer et al., 
2002a). 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) inhibits complex I and 
reproduces Parkinson’s disease like symptoms in rats (Dawson and Dawson, 2003). The best 
animal model of Parkinson’s disease has been established by Greenamyre’s lab (Betarbet et al., 
2000). Rats chronically exposed to a commonly used pesticide, rotenone, develop Parkinson’s 
disease-like symptoms, including selective dopaminergic neuron degeneration and the formation 
alpha-synuclein rich inclusions (Betarbet et al., 2000). Rotenone is a highly selective complex I 
inhibitor. Inhibition of complex I by MPTP and rotenone has been shown to cause oxidative 
damage by increasing ROS generation or decreasing GSH levels (Cassarino et al., 1997; 
Votyakova and Reynolds, 2001; Sherer et al., 2002b). Therefore, deficits in mitochondrial 
complex I function establish a consistent connection between the pathogenesis of Parkinson’s 
disease and oxidative stress.  
1.1.4 ROS and ischemia 
The role of oxidative stress in the pathogenesis of acute neuronal injury, such as stroke, is well 
established. Reperfusion following ischemia causes a significant increase in ROS generation in 
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the perfusion territory of the occluded blood vessel, resulting in delayed neuronal cell death in 
that area (McCulloch and Dewar, 2001; Schaller and Graf, 2004). A series of complex 
neurochemical events occurs following ischemia/reperfusion, such as increased ROS generation, 
decreased GSH levels and antioxidant enzyme activities, and the impairment of mitochondrial 
functions. Various cellular events, such as the activation of the mitogen-activated regulated 
kinases (MAPK) signaling pathway, and initiation of protein synthesis machinery, such as 
eukaryotic initiation factors (eIFs), also occur (Schaller and Graf, 2004). Both apoptosis and 
necrosis are found in ischemia-induced neuronal death. While most cell death is necrotic in the 
ischemia core, apoptosis is more obvious in the penumbra zone, particularly the inner border 
regions surrounding the ischemia core (Li et al., 1995a).  Delayed cell death is another 
characteristic of ischemia cell death (Lipton, 1999; Schaller and Graf, 2004). The delay varies 
from hours (McGee-Russell et al., 1970) to days or even weeks (Kirino, 1982; Du et al., 1996), 
depending on the extent of the insult and the brain regions affected.  Animal models to study 
ischemia include global ischemia, which models cardiac arrest, and focal ischemia, which 
models stroke in human diseases. Global ischemia occurs when there is no blood flow to all or 
most of the brain and is most commonly produced by vessel occlusions (Lipton, 1999; 
Traystman, 2003). Focal ischemia is defined by a reduction in the cerebral blood flow to a 
distinct and specific brain area. Middle cerebral artery occlusion (MCAO) represents the most 
common model of focal ischemia (Lipton, 1999; Traystman, 2003). 
Due to the critical role of oxidative stress in the pathogenesis of ischemia, a variety of 
pharmacological and genetic manipulations to reduce oxidative damage have been shown to 
attenuate ischemia damage (Chan, 2001; McCulloch and Dewar, 2001; Margaill et al., 2005). 
SOD1 transgenic mice exhibit attenuated neuronal death in global and focal ischemia models 
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(Chan et al., 1998; Noshita et al., 2002). Various antioxidant strategies have been evaluated for 
their efficacy in attenuating ischemia, including the inhibition of free radical generation, 
scavenging of free radicals, and enhancement of free radical degradation (Margaill et al., 2005). 
Dehydroascorbic acid (DHA), a blood-brain-barrier (BBB)-permeable oxidized form of ascorbic 
acid, has been shown to significantly reduce infarct volume following ischemia (Huang et al., 
2001). Nitrone radical-trapping compounds, such as NXY059, have been reported to have 
significant neuroprotective effects following transient focal ischemia in rats (Kuroda et al., 
1999). Clinical trials have been performed or are being performed on four antioxidants for their 
efficacy in attenuating ischemia (Margaill et al., 2005). Ischemia-induced oxidative stress has 
been shown to activate various cellular signaling pathways, including the well-established 
extracelluar-regulated kinase (ERK) pathway. A recent report has revealed that pharmacological 
inhibition of the extracelluar-regulated kinase (ERK) pathways reduces the extent of ischemia 
damage (Namura et al., 2001). This study provides some insights into the new therapeutic targets 
of ischemia and demonstrates the effectiveness of targeting intracellular signaling events in 
attenuating ischemia. 
 
1.2 MAPK SIGNALING PATHWAYS  
1.2.1 MAPK signaling cascades  
The MAPKs family is a group of signaling modules involved in cellular responses to various 
stimuli and impacts diverse responses, such as adhesion, cell differentiation and proliferation, 
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synaptic plasticity, survival, and apoptosis. MAPK members include ERKs, Jun N-terminal 
kinase/stress-activated protein kinase (JNK/SAPK), and p38 MAPK kinase families (Pearson et 
al., 2001). Other new members of ERK family include ERK3 (Boulton et al., 1991; Gonzalez et 
al., 1992), ERK5 (Lee et al., 1995; Zhou et al., 1995), and ERK7 (Abe et al., 1999). The MAPKs 
are activated by dual-phosphorylation of a conserved Threonine-X-Tyrosine (T-X-Y) motif by 
upstream MAPK kinases (MEKs or MKKs), which are in turn, activated by their upstream 
kinases, MEK/MKK kinases (MEKKs or MKKKs) (Pearson et al., 2001).  
Different isoforms exist in each MAPK family. ERK1 (44kDa) and ERK2 (42kDa) are 
two closely related isoforms of ERK. In the activation loop of ERK1 and ERK2, threonine and 
tyrosine are separated by a glutamate residue which forms a T-E-Y motif (Payne et al., 1991).  
The ERK signaling pathway is an excellent example that illustrates how an outside stimulus is 
relayed and translated into cellular signals that induce expression of specific proteins for distinct 
cellular events. Activation of receptor tyrosine kinases or G protein-coupled receptors by outside 
signals leads to the formation of a multiprotein complex that includes monomeric G proteins 
such as Ras. Ras then activates various MEKK isoforms, including Raf-1, A-Raf, and B-Raf, 
which in turn, activate MEK1 and MEK2 for the activation of ERK (Pearson et al., 2001). Apart 
from phosphorylating cytosolic and membrane-bound targets, active ERK also translocates to the 
nucleus to phosphorylate various targets. Phosphorylation of nuclear targets by ERK1/2 is a 
prerequisite for the effects of ERK-dependent gene transcription and subsequent cellular 
response (Brunet et al., 1999). The known nuclear targets of ERK1/2 are predominantly 
transcription factors such as CREB, ELK-1, c-Fos, and the AP-1 family. This highlights the 
importance of the nuclear translocation of ERK in regulating gene transcription. ERK 
cytoplasmic targets include cytosolic phospholipase A2 and protein kinases, such as pp90 
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ribosomal S6 kinases (RSKs). Once activated, RSKs translocate into the nucleus and 
phosphorylate downstream targets, such as CREB, CBP and c-Fos.  
 
1.2.2 The regulation of MAPK signaling cascades  
A variety of extracellular stimuli can induce ERK activation but the cellular responses resulting 
from ERK activation vary from cell proliferation to cell differentiation and even to cell death. 
Given the ubiquitous expression and numerous substrates of ERKs, there must exist a precise 
and complex machinery operating to ensure the conduction and conversion of specific signals to 
specific cellular responses. The fidelity and spatio-temporal regulation of ERK pathways have 
been the subjects of many studies. MAPK pathways not only share a high homology in their 
module organization but also a high similarity in their protein primary sequences (Pouyssegur et 
al., 2002). Furthermore, all MAPKs share similar phosphorylation consensus sequences in their 
substrates: Ser/Thr-Pro (S/T-P) (Pouyssegur et al., 2002). Therefore, it is very important to 
prevent the inappropriate cross-talk between different MAPK pathways to ensure appropriate 
cellular response. One mechanism to ensure this precise regulation of MAPK signaling is by the 
action of scaffolding proteins that interact with and bring together components of each MAPK 
module (Morrison and Davis, 2003). The formation of these multi-enzyme complexes facilitates 
the rapid and precise transmission of signals through the individual cascade.  
Kinase suppressor of Ras (KSR) was identified as a positive regulator of Ras/MAPK 
signaling (Kornfeld et al., 1995). KSR deletion severely reduces ERK activation in both C. 
elegans and Drosophila, demonstrating the requirement of KSR for Ras-dependent ERK 
activation in these models (Anselmo et al., 2002; Ohmachi et al., 2002). β-arrestins have 
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important roles in G-protein-coupled-receptor (GPCR) signaling. Apart from interacting with 
GPCR and targeting it for endocytosis, β-arrestins can also mediate the interaction of GPCR with 
other signaling pathways, including ERK pathways (Morrison and Davis, 2003). It has been 
shown that β-arrestins can mediate GPCR signaling by the retention of active ERK in the 
cytoplasm, which results in a decrease in ERK nuclear translocation as well as subsequent 
transcriptional activities (Tohgo et al., 2002). Therefore, the affinity between GPCR/β-arrestins 
could determine the mechanisms of ERK activation and the subsequent biological outcomes 
(Tohgo et al., 2003).   
Specific protein interactions and subsequent enzyme reactions between MAPKs and their 
activators, substrates, and regulators depend on specific docking sites on both MAPKs and their 
interacting proteins. Almost all members of MAPK interacting proteins in MAPK modules, such 
as its activator MAPK kinases (MEKs), its downstream substrates (MAPKAPKS), as well as its 
regulator MAPK phosphatases (MKPs), have a MAPK-docking site (Tanoue and Nishida, 2002). 
Characterized by a cluster of positively charged amino acids, the docking sites of MAPK-
interacting molecules are necessary for the binding of these proteins to MAPK since mutations 
generated in these sequences result in the disruption of the interactions between MAPK 
interacting proteins and MAPKs (Tanoue and Nishida, 2002). The docking site on ERK2 
contains a group of negatively charged amino acids and serves as a common docking (CD) site 
for MEK1, MKP3 (a specific MKP for ERK), and Mnk1 (a substrate specifically activated by 
ERK and p38) (Tanoue et al., 2000). Similar to those docking sites on MAPK-interacting 
proteins, mutations in this common docking site on ERK markedly decreases the efficiency of 
this enzyme (Tanoue et al., 2000). A corresponding common docking site is also found in p38 
and JNK, suggesting that a common mechanism of increasing protein-protein interaction is 
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conserved in all MAPK pathways (Tanoue et al., 2000). The identification of these docking sites 
has provided new insights into the regulation of MAPK pathways. For example, injection of a 
peptide corresponding to the ERK1/2 binding site of MEK1/2 into the nucleus disrupts the 
association between ERK1/2 and MEK1/2, and therefore, inhibits the nuclear export of ERK1/2 
by MEK1/2 (Fukuda et al., 1996; Adachi et al., 2000). Similarly, the introduction of a peptide 
corresponding to the docking site of ERK1/2 on p90RSK to the nucleus disrupts the association 
between ERK1/2 and their specific phosphatases and, therefore, increases ERK phosphorylation 
and activation in the nucleus (Volmat et al., 2001).  
Because the substrates of ERK1/2 distribute in various cellular compartments, the 
subcellular localization of active ERK1/2 is very critical for its ability to gain access to its 
potential targets and determines the specific cellular responses and biological outcomes it will 
elicit.  As mentioned above, cytoplasmic sequestration of active ERK1/2 by β-arrestins blocks 
the nuclear translocation of ERK1/2 as well as ERK-dependent transcriptional activities (Tohgo 
et al., 2002). Enforced cytoplasmic retention of active ERK1/2 inhibits ERK1/2–mediated 
nuclear gene transcription and growth factor-induced DNA replication (Brunet et al., 1999). 
PEA-15, a cytoplasmic protein, has been shown to anchor active ERK1/2 in the cytoplasm and 
block ERK1/2-dependent gene transcription and cell proliferation (Formstecher et al., 2001). 
Deletion of PEA-15 restores the nuclear translocation of ERK1/2 and ERK-dependent cFos 
transcription as well as cell proliferation (Formstecher et al., 2001). These studies highlight the 
critical role of ERK1/2 nuclear translocation in mediating gene transcription and proper cellular 
responses.  
It is now known that ERK shuttles between the nucleus and the cytoplasm. However, the 
mechanisms governing ERK nuclear import and export have remained largely unknown. 
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Monomeric ERK2 can enter into the nucleus even when active nucleocytoplasmic trafficking is 
blocked (Adachi et al., 1999), which suggests that passive diffusion is a mechanism for ERK 
nuclear entry. However, when ERK2 is fused to beta-gal, a high molecular weight molecule, it 
can still enter into the nucleus (Adachi et al., 1999), suggesting that active nuclear transport is 
also responsible for translocating ERK into the nucleus. It has been reported that phosphorylation 
and homodimerization of ERK1/2 is necessary for its nuclear translocation (Khokhlatchev et al., 
1998). Dimerization motif mutants of ERK2, when fused to beta-gal, are unable to enter the 
nucleus (Adachi et al., 1999), further demonstrating that dimerization of ERK is prerequisite to 
its active nuclear transport. Recently, evidence has been presented that ERK can pass through the 
nuclear pore by direct binding with nuclear pore proteins (Matsubayashi et al., 2001), which 
suggests that ERK may not use a classical nuclear import transporter for its nuclear import. 
The mechanism responsible for ERK nuclear export is also not clear. Leptomycin B 
(LMB) blocks active nuclear export by interfering with the binding between proteins containing 
a nuclear export signal (NES) and their nuclear export receptor, exportin 1 (Ossareh-Nazari et 
al., 1997). It has been found that LMB traps ERK and MEK in the nucleus (Adachi et al., 2000; 
Volmat et al., 2001). MEK contains a nuclear export sequence (NES) and may play a critical role 
in nuclear export of ERK. Co-injection of ERK1/2 into the nucleus with wild-type MEK1/2, but 
not the NES-disrupted MEK1/2, triggers nuclear export of ERK1/2 (Adachi et al., 2000). 
Moreover, inhibiting the binding between ERK1/2 and MEK1/2 by introducing a peptide 
corresponding to the docking site of ERK1/2 on MEK1/2 blocks the nuclear export of ERK1/2 
(Adachi et al., 2000).  
The integration of spatial and temporal regulation of ERK activation in mediating ERK-
dependent specific biological outcomes is best illustrated in the classic example of the responses 
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of PC12 cells to EGF and NGF stimulation (Marshall, 1995). In this system, EGF induces 
transient cytoplasmic ERK activation and causes cell proliferation. In contrast, NGF stimulates a 
more prolonged and sustained nuclear ERK activation and triggers cell differentiation (Marshall, 
1995). The importance of regulating the duration of ERK activation in achieving different 
cellular responses is also demonstrated in many other systems, including hepatocytes, 
neuroepithelioma cell lines, and fibroblasts (Colucci-D'Amato et al., 2003). Recently, our lab has 
shown that the duration of ERK activation can determine the divergent effects of ERK to 
promote cell survival or cell death even within a single cell type (Luo and DeFranco, 2006).  
In summary, the regulation of MAPK activation is a very complex process, involving the 
integration of signal recognition, conveyance to appropriate pathways, localization and duration 
of the signals, cross-talk with other signaling pathways, and finally, signal relay to specific 
downstream effectors. The integration of all these factors determines the specificity of the signal 
transduction pathway in mediating specific biological outcomes. 
1.2.3 Functions of MAPK  
Compared with numerous in vitro studies on the physiological roles of MAPK pathways, gene-
targeting studies provide important information on the roles of these pathways in vivo. In the past 
10 years, mice genetically deleted for various MAPK members have been generated, allowing 
the examination of physiological roles of specific isoforms in each MAPK family (Pearson et al., 
2001; Kuida and Boucher, 2004). ERK1 knockout mice are fertile and normal in many aspects. 
However, defects in thymocyte maturation have been found, suggesting that ERK1 may play a 
role in the development of normal thymocytes (Pages et al., 1999). Interestingly, ERK1-deficient 
mice have been shown to exhibit enhanced synaptic plasticity in the striatum and increased 
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performance in striatum-mediated learning tasks (Mazzucchelli et al., 2002). In contrast, ERK2-
deficient mice exhibit abnormal placenta development and fail to induce the mesoderm, causing 
embryonic lethality (Hatano et al., 2003; Yao et al., 2003). This suggests an indispensable role of 
ERK2 in embryonic development. Although individual JNK1, JNK2, and JNK3 knockout mice 
are normal and viable, JNK1/JNK2 double knockout mice have embryonic lethality due to an 
abnormality in neural tube closure (Kuan et al., 1999; Sabapathy et al., 1999). JNK1/JNK2 may 
play an important role in regulating apoptosis, since fibroblasts from JNK1/JNK2 double 
knockout mice are resistant to stress-induced apoptosis (Tournier et al., 2000). Compared with 
JNK1 and JNK2, JNK3 is specifically expressed in the nervous system. JNK3 knockout mice 
exhibit a normal phenotype without embryonic lethality. However, deletion of JNK3 in mice 
causes resistance to excitotoxicity-induced apoptosis in the hippocampus (Yang et al., 1997), 
suggesting a role of JNK3 in mediating neuronal apoptosis.  
MAPK pathways are activated in response to a variety of stress signals, including heat 
shock, UV-radiation, inflammatory cytokines, DNA-damaging agents, and oxidative stress 
(Robinson and Cobb, 1997). Conventional views tend to associate the activation of JNK or/and 
p38 signaling pathways with cell death while correlating the activation of the ERK pathway with 
cell survival. For example, growth factor withdrawal-induced apoptosis in PC12 cells requires 
the activation of JNK and p38 pathways, whereas ERK activation is necessary for growth factor 
rescue of serum-starved neuronal cultures (Xia et al., 1995). However, this may represent an 
oversimplistic picture of the roles of MAPK family members under stress. Although JNK and 
p38 pathways are mainly involved with cell death, many recent studies have revealed a role for 
ERK1/2 in contributing to cell death (Colucci-D'Amato et al., 2003; Chu et al., 2004). These 
studies suggest that MAPK pathways may have multiples roles in response to stress. The final 
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cellular response may depend on the spatial and temporal pattern of the activation of each 
MAPK pathway, the specificity of the stimuli and cell type, and more importantly, the 
interactions and cross-talk between each MAPK pathway.   
1.2.4 Role of ERK activation in stressed neurons 
As mentioned above, ERK activation has been considered predominantly as transducing pro-
survival signals in stressed neurons in a variety of models (Hetman and Gozdz, 2004). For 
example, ERK1/2 activation is necessary for NGF-mediated pro-survival signaling in PC12 cells 
(Xia et al., 1995) and responsible for the neuroprotective effect of BDNF-mediated rescue of 
trophic factor-deprived neuronal cultures (Bonni et al., 1999). Furthermore, ERK1/2 activation 
also has been shown to be neuroprotective in a variety of neuronal damage models, including 
BDNF-mediated neuroprotection against DNA damage in cortical neurons (Hetman et al., 1999), 
estrogen-mediated neuroprotection against glutamate excitoxocity in neuronal cultures (Singer et 
al., 1999), as well as in vitro (Gonzalez-Zulueta et al., 2000) and in vivo (Han and Holtzman, 
2000) models of hypoxia-ischemia.  
However, ERK1/2 activation has also been found to contribute to neuronal cell death in a 
variety of in vitro and in vivo neurotoxicity models (Chu et al., 2004).  For example, ERK1/2 
activation has been shown to be necessary for glutamate-induced oxidative toxicity (Stanciu et 
al., 2000; Levinthal and DeFranco, 2004; Choi et al., 2006), zinc toxicity (Seo et al., 2001), 
methylisothiazolinone and Zn toxicity (Du et al., 2002), 6-hydroxydopamine toxicity (Kulich and 
Chu, 2001), amyloid β toxicity (Kuperstein and Yavin, 2002), tau-induced neurotoxicity 
(Amadoro et al., 2006), and focal ischemia (Alessandrini et al., 1999; Namura et al., 2001; 
Noshita et al., 2002). The opposing roles of ERK1/2 activation may depend on the spatial and 
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temporal pattern of ERK activation. Interestingly, our lab has recently shown that ERK1/2 
activation has dual roles in promoting cell survival and/or cell death even within the same cell 
type (Luo and DeFranco, 2006), which highlights the importance of the kinetics of ERK1/2 
activation in mediating divergent functions in neuronal survival or neuronal death. 
1.3 PROTEIN PHOSPHATASES AND OXIDATIVE STRESS 
1.3.1 Classification and catalytic mechanism of protein phosphatases 
Protein phosphorylation is regulated by two types of enzymes: protein kinases, which catalyze 
the covalent attachment of a phosphate group to an amino acid, and protein phosphatases, which 
catalyze the removal of the phosphate. Due to their important roles in regulating reversible 
phosphorylation of proteins in nearly every aspect of cellular signaling, protein phosphatases 
have been extensively studied. Most of the protein phosphatases fall into one of the three 
following categories in terms of their substrate specificity: protein serine/threonine phosphatase 
(PSTP), protein tyrosine phosphatase (PTP), and dual-specificity phosphatase (DSP), which can 
dephosphorylate both serine/threonine and tyrosine residues. 
Although all three types of protein phosphatases catalyze the same reaction of hydrolysis 
of phosphate monoesters, their structural organization and mechanisms for catalysis are distinct. 
PSTPs are metalloenzymes that contain two metal ions within their catalytic center. Depending 
on the identity of the metal ions, PSTPs can be divided into PPPs such as PP1, PP2A, PP2B 
(calcineurin) and PPMs such as PP2C. Although the specificity of the metal ions is still slightly 
controversial, it is generally accepted that PPPs contain various combination of Fe, Mn and/or Zn 
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dinuclear ion centers while PPMs contain Mn in their catalytic centers (Barford et al., 1998). 
Most PSTPs are holoenzymes that consist of multiple subunits, including catalytic subunits and 
regulatory subunits. Although catalytic subunits dictate the catalytic ability of the phosphatases, 
the regulatory subunits determine the substrate specificity as well as the subcellular trafficking of 
the enzymes. Therefore, the different combinations of catalytic subunits and regulatory subunits 
confer diverse functions of PSTPs. PTPs are composed of a single polypeptide chain and depend 
on structural variations in catalytic and regulatory domains built in the same peptide chain for the 
diversity of their functions. 
The catalytic mechanisms employed by PSTPs and PTPs/DSPs also are different. PSTPs 
depend on the metal center to activate its surrounding water molecule to attack directly the 
phosphoryl group of the substrate. PTPs/DSPs are characterized by a PTP signature motif 
HC(X)5R in their active sites, which contains cysteine (Cys) and arginine (Arg) residues that are 
essential for enzyme catalysis. PTPs/DSPs employ a two-step strategy for phosphate monoester 
hydrolysis (Fig 1). The first step involves a nucleophilic attack of the active site cysteine on the 
phosphate ester of the bound substrate. This step leads to the formation of a phosphocysteine 
intermediate between the substrate and the enzyme (Barford et al., 1998; Denu and Dixon, 1998). 
Arginine is important in substrate recognition and transient state stabilization. In the second step, 
the phosphoenzyme intermediate is hydrolyzed by the attack of a water molecule, which is 
activated by a conserved aspartic acid (Asp) in the phosphatase. This step results in the release of 
inorganic phosphate and restores the enzyme. 
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Figure 1.1. Reaction mechanism catalyzed by PTPs. 
Adapted from (Kolmodin and Aqvist, 2001).  
 
1.3.2 MAPK phosphatases 
The magnitude and duration of the activation of MAPK pathways determine the effects of 
MAPK-mediated biological outcomes. The phosphorylation and activation of MAPK pathways 
reflects a balance between their upstream kinase activators and downstream phosphatase 
inactivators. MAPK-directed phosphatases serves as negative regulators of MAPK activation and 
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therefore play critical roles in regulating the spatio-temporal pattern of MAPK activation, which, 
in turn, determines the diverse cellular responses mediated by MAPK activation. 
A variety of protein phosphatases can inactivate MAPKs. Among them, MKPs (MAPK 
phosphatases) are a group of DSPs that specifically dephosphorylate tyrosine and threonine in 
the P-loop of MAPK members. MKP members are distinct in their substrate (MAPKs) 
specificity, subcellular localization, as well as tissue distribution. For example, while most other 
MKPs act on all MAPK members with different affinities, MKP3, MKP-X and B23 are only 
specific for ERK1/2 dephosphorylation. MKP3 exists exclusively in the cytosol, whereas MKP1 
and MKP2 are only expressed in the nucleus. Apart from MKPs, several PTPs, such as He-PTP 
and STEP, and PSTPs, such as PP2A, are also able to inactivate MAPK members. Table 1 lists 
some MAPK phosphatases in terms of their substrate specificity, subcellular localization, and 
tissue distribution {Adapted from (Haneda et al., 1999; Camps et al., 2000; Keyse, 2000; Saxena 
and Mustelin, 2000; Farooq and Zhou, 2004)}. 
Although MAPK phosphatases have been shown to play important roles in various 
tissues and cell types, the roles of MAPK phosphatases in regulating neuronal function and 
development is still not well established. Recently, it has been shown that MKP1 and MKP3 are 
differentially activated in the acute induction period and chronic maintenance period following 
methamphetamine administration (Takaki et al., 2001). In the early induction period, MKP1 and 
MKP3 are activated in all brain regions, while during the chronic maintenance period, MKPs are 
only activated in restricted brain regions. This suggests a role for MKPs in behavioral 
sensitization induced by methamphetamine administration. Moreover, a striatal-enriched tyrosine 
phosphatase (STEP) has been shown to play important roles in regulating ERK activation in 
NMDA- and dopamine-mediated signaling in neurons (Paul et al., 2003; Valjent et al., 2005), 
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providing new insights into the roles of MAPK phosphatases in a variety of physiological and 
pathological neurological conditions, including long-term synaptic plasticity and drug abuse. 
 
Table 1. Characterization of MAPK phosphatases 
Name MAPK specificity 
Subcellular 
localization 
Tissue 
Distribution 
 
DSPs 
   
MKP1 JNK=P38>ERK Nucleus Ubiquitous 
MKP2 ERK=JNK=p38 Nucleus Ubiquitous 
MKP3 ERK Cytoplasm Ubiquitous 
MKP4 ERK>JNK=P38 Cytoplasm>nucleus Ubiquitous 
MKP5 JNK=P38>ERK Cytoplasm>nucleus Ubiquitous 
MKP6 ERK=JNK>p38 Cytoplasm Ubiquitous 
MKP-X ERK Not determined Ubiquitous 
B23 ERK Nucleus Ubiquitous 
PAC-1 ERK=p38 Nucleus Ubiquitous 
VHR ERK>JNK=P38 Cytoplasm Ubiquitous 
M3/6 JNK>p38>ERK 
Nucleus and 
cytoplasm Ubiquitous 
      
PTPs     
He-PTP ERK=P38 Cytoplasm Lymphoid-specific
STEP ERK  Cytoplasm Neuronal specific 
      
PSTPs     
PP2A ERK>P38=JNK Cytoplasm Ubiquitous 
PP2C p38,JNK Cytoplasm Ubiquitous 
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1.3.3 PP2A 
PP2A is the major Ser/Thr protein phosphatase in eukaryotic cells. As a holoenzyme complex, 
the core enzyme of PP2A consists of a 36kDa catalytic subunit (C subunit) and a 65kDa structure 
subunit, A subunit (PR65). The core enzyme forms complexes with a variety of regulatory 
subunits (B subunits) that regulate the substrate specificity and subcellular localization of the 
PP2A holoenzyme. Four different families of B subunits have been identified, including B 
family (PR55), B’family (PR61), B” family (PR72) and B”’ family (PR93/PR110) (Janssens and 
Goris, 2001). Multiple isoforms exist in each B subunit family, giving rise to a variety of 
holoenzyme combinations. Different holoenzymes dephosphorylate distinct substrates in specific 
cellular compartments, and this may explain the diversity of biological outcomes brought about 
by PP2A. It has been shown that overexpression of PP2A Bγ subunit in a stably transfected PC6-
3 neuronal cell line promotes cell differentiation (Strack, 2002), while in the same cell line, 
overexpression of neuronal-specific PP2A Bβ2 subunit promotes apoptosis induced by serum 
withdrawl (Dagda et al., 2003). The apoptosis induced by the latter is actually caused by the 
targeting to PP2A to mitochondria by PP2A Bβ2 subunits and probably is through the 
dephosphorylation of various mitochondrial pro- and anti-apoptotic proteins, such as proteins of 
the Bcl-2 family (Dagda et al., 2003).  
Substrates of PP2A are varied, ranging from protein kinases mediating cell growth to 
transcriptions factors regulating apoptosis. PP2A is the major PSTP that regulates the activation 
of protein kinases and signaling cascades in eukaryotic cells, in particular the ERK/MAPK 
cascade. Kinases in the ERK signaling modules, including Raf (Abraham et al., 2000; Kubicek et 
al., 2002; Ory et al., 2003), MEK (Westermarck et al., 2001; Yu et al., 2004), and ERK1/2 
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(Alessi et al., 1995; Zhou et al., 2002), are all substrates of PP2A. PP2A can both positively and 
negatively regulate ERK activation, depending on the entry points into the ERK pathway. PP2A 
dephosphorylates and inactivates MEK and ERK1/2 in vitro (Anderson et al., 1990; Gomez and 
Cohen, 1991). Transient expression of SV40 small T antigen (which inhibits PP2A by displacing 
the PR55-B subunit) activates the MEK1-ERK1/2 pathway (Sontag et al., 1993). Recently, it has 
been revealed that PP2A can positively regulate the ERK pathway by activating Raf-1 and 
subsequent MEK/ERK pathways through the dephosphorylation of the inhibitory Ser 259 in Raf-
1 (Abraham et al., 2000; Kubicek et al., 2002; Ory et al., 2003). Impairment of PP2A has been 
implicated in a variety of oxidative stress-induced neurodegenerative diseases. Reduced PP2A 
activity has been associated with an enhanced activation of ERK and hyperphosphorylation of 
Tau, a specific ERK1/2 target, in Alzheimer’s disease (Gong et al., 1995; Zhao et al., 2003). 
Transgenic mice expressing a mutant PP2A catalytic unit exhibit activation of ERK and JNK 
pathways as well as the phosphorylation of endogeneous tau, similar to the key pathological 
features in Alzheimer’s disease (Kins et al., 2001; Kins et al., 2003). These results suggest that 
oxidative stress-induced PP2A inhibition in AD may be responsible for the enhanced ERK1/2 
activation and subsequent tau hyperphosphorylation and neurofibrillary tangle formation.  
 
1.3.4 Inhibition of protein phosphatases by oxidation 
Over the past several years, it has been realized that ROS play an important role in regulating 
signal pathways. This has been referred to as redox signaling. By modifying the structure and 
function of specific proteins, ROS regulate signaling pathways involved in a variety of cellular 
responses. Recently, various protein phosphatases have been identified as targets of ROS, thus 
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establishing a critical link between oxidative inhibition of phosphatases and ROS-mediated 
signaling pathways. 
Most results on the redox regulation of protein phosphatases are based on the study of 
redox regulation of PTPs (den Hertog et al., 2005; Tonks, 2005). PTPs and DSPs share a 
signature motif HC(X)5R in their active catalytic site. As mentioned above, the cysteine residue 
is critical for the formation of a cysteine-phospho intermediate for the catalytic function of PTPs. 
Distinct from cysteines in other proteins with a pKa ~8.5, the low pKa (~4.5) of cysteines in the 
signature motif of PTPs and DSPs renders them more vulnerable to oxidation. Oxidation of the 
catalytic cysteine residue then inactivates the phosphatase.   
ROS transiently inactivate PTPs, leading to an imbalance between the activity of protein 
tyrosine kinases (PTKs) and PTPs and a subsequent enhancement of tyrosine phosphorylation of 
potential targets. Therefore, reversibility of the oxidative inhibition of PTPs is very important for 
regulating redox signaling. The oxidation of catalytic cysteines to sulfenic acid is reversible 
while further oxidation to sulfinic acid and sulfonic acid are all irreversible (Denu and Tanner, 
1998). Another reversible oxidation mechanism is the intramolecular formation of disulfide 
bonds between the catalytic cysteine and its neighboring cysteine. This has been demonstrated in 
several non-classical PTPs, including LMW-PTP (Chiarugi et al., 2001), PTEN (Lee et al., 
2002b), and Cdc25C (Savitsky and Finkel, 2002). Recently, the crystal structure of oxidized 
PTP1B has been revealed, suggesting a new form of reversible oxidation in PTPs (Salmeen et al., 
2003; van Montfort et al., 2003). This formation has been termed sulfenylamide and is formed by 
the oxidized catalytic cysteine and the nitrogen backbone of the adjacent serine residue. 
Sulfenyladmide is not susceptible to further oxidation into sulfinic acid and sulfonic acid, 
establishing the basis for reversible oxidation of PTP1B. In contrast to other PTPs, receptor 
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protein tyrosine phosphatases (RPTPs) can be regulated negatively through the oxidation of a 
catalytic cysteine in a domain (D2 domain) that lacks phosphatase activity. Dimerization of 
RPTPα is stabilized by the oxidation of catalytic cysteines in the D2 domain, resulting in the 
activation of RPTPα (Blanchetot et al., 2002; van der Wijk et al., 2003). Various oxidation states 
of cysteines are listed in Table 2 {Adapted from (Barford, 2004)}.  
Table 2. Oxidation states of cysteine 
 Formulae Oxidation state Reversibility 
with thiols 
Catalytically 
active 
Cysteine -SH or -S- Reduced state Not applicable Yes 
Sulfenic acid -SOH Single oxidation Yes No 
Sulfinic acid -SO2 Double oxidation No No 
Sulfonic acid -SO3 Triple oxidation No No 
Disulfide Cys-S-S-R1 Converted from 
Sulfenic acid 
Yes No 
Cyclic 
sulfonamide 
Cys-S-NH-R1 Converted from 
Sulfenic acid 
Yes No 
 
The critical role of the oxidative inhibition of phosphatases in ROS-mediated signal 
transduction is best illustrated in the example of growth factor signaling (Aslan and Ozben, 
2003). Fig 2 is a schematic diagram of the redox regulation of PTPs in a model of ligand-
activation of receptor tyrosine kinase (RTK) signaling, which is the model employed by most 
growth factors, hormones, and cytokines. Ligand binding to RTK activates membrane NADPH 
oxidase, triggering the generation of ROS. By oxidizing the active cysteine site in PTP members 
to inactive sulfenic acid, ROS inhibits the activity of PTPs and therefore enhances tyrosine 
phosphorylation of RTKs.  Due to the reversible oxidation property of sulfenic acid, intracellular 
reducing molecules, such as glutathione and thioredoxin, could reduce sulfenic acid to thiolate 
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anion and therefore restore the activity of PTPs. This results in the termination of tyrosine-
phosphorylation-dependent signaling. Therefore, ROS generated in response to a physiological 
stimulus could inhibit specific PTPs that are responsible for constraining the signal pathways 
induced by that stimulus through the dephosphorylation of RTKs. This thus leads to the 
augmentation of tyrosine phosphorylation and subsequent signaling transduction. 
 
Figure 1.2 Regulation of Protein Tyrosin Phosphatase (PTP) activity by reversible oxidation. 
Adapted from (Tonks, 2003). 
 
ROS are necessary for EGF signaling since antioxidants prevent the signal transduction 
mediated by EGF in A431 human epidermoid carcinoma cells (Bae et al., 1997). Moreover, 
oxidative inhibition of PTP1B contributes to EGF-mediated protein tyrosine phosphorylation. 
PDGF treatment induces a brief generation of ROS, which is associated with the inhibition of the 
tyrosine phosphatase, SHP-2, and the subsequent PDGF receptor activation in Rat-1 fibroblast 
cells (Meng et al., 2002). Recently, a role of oxidative inhibition of phosphatase activity that 
affects MAPK signaling has been demonstrated by Michael Karin’s group (Kamata et al., 2005). 
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In this study, TNF-α treatment was found to cause ROS production and oxidative inhibition of 
JNK phosphatases, including MKP1, MKP3, MKP5, and MKP7, which resulted in sustained 
JNK activation and subsequent cell death in fibroblasts.  
Compared with a well established role of oxidation in the inhibition of PTPs, the 
mechanism that regulates oxidative inhibition of PSTPs such as PP1, PP2A, and PP2B still 
remains vague. PP2B (calcineurin) has been shown to be oxidatively inhibited by H2O2 through 
the oxidation of its dinuclear metal center (Fe2+-Zn2+) (Wang et al., 1996) as well as the 
oxidation of two neighboring cysteines (Carballo et al., 1999; Bogumil et al., 2000). PP2A 
recently has been shown susceptible to H2O2 in aging fibroblasts (Kim et al., 2003) and brain 
tissue (Foley et al., 2004). Oxidation of cysteine residues may be responsible for oxidative 
inhibition of PP2A, since the inactivation of PP2A by ROS is thiol-dependent and reversible. 
However, the active site of PP2A does not contain an essential cysteine(Foley et al., 2004; Foley 
and Kintner, 2005). Thus, it is unclear which cysteine residue is oxidized and how that oxidation 
affects PP2A activity. 
1.4 ZINC HOMEOSTASIS AND OXIDATIVE STRESS-INDUCED NEURONAL 
DEATH 
1.4.1 Regulation of intracellular zinc homeostasis in neurons 
Zinc is the second most abundant trace element in the body, particularly in the brain, which 
contains highest concentration of zinc. Zinc is indispensable, since deficiency in dietary zinc 
causes growth retardation and severe symptoms in the body, particularly in the nervous system 
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(O'Dell, 1993; Prasad, 1995). As a structural element or co-factor for many proteins, including 
transcriptional factors or even as a second messenger itself, zinc participates in almost all levels 
of signaling events and plays a crucial role in a wide range of physiological and pathological 
conditions. 
In the CNS, free zinc is stored and released from presynaptic vesicles of neurons that also 
release glutamate (Frederickson et al., 2005; Mocchegiani et al., 2005).  Relative to synaptic 
vesicles, free zinc ion concentrations in the cytoplasm of cultured neurons is very low, roughly 
femtomolar to picomolar concentrations(Frederickson et al., 2005; Mocchegiani et al., 2005). 
This suggests that a precise mechanism exists for the regulation of intracellular zinc homeostasis. 
The maintenance of intracellular zinc homeostasis is a tightly controlled process that involves 
uptake and export mechanisms, as well as intracellular zinc-binding proteins (Frederickson et al., 
2005; Mocchegiani et al., 2005). Zinc taken up into neurons occurs by various routes, including 
the membrane zinc uptake transporters of the Zip family (Law et al., 2003; Seve et al., 2004) and 
several zinc-permeable membrane channels, including NMDA (N-methyl-D-aspartate) channels 
(Koh and Choi, 1994), Ca2+-permeable AMPA/kainate channels (Jia et al., 2002), and voltage-
gated Ca2+ channels (Sensi et al., 1997). The influx of zinc through these neurotransmitter 
receptors and channels implicates a role for zinc in modulating neurotransmission. To decrease 
cytosolic free zinc concentrations, zinc must be exported out of neurons or transported into 
intracellular synaptic vesicles by zinc transporters of the ZnTs family (Liuzzi and Cousins, 
2004).  Among the nine ZnT proteins that have been cloned, ZnT1 and ZnT4 are transporters 
mainly responsible for zinc efflux, whereas the brain and testis-specific ZnT3 regulates zinc 
transport into synaptic vesicles (Liuzzi and Cousins, 2004).  Genetic deletion of ZnT3 in mice 
results in the zinc accumulation in synaptic vesicles, which demonstrates that ZnT3 is necessary 
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for zinc transport into synaptic vesicles (Cole et al., 1999). A novel ZnT protein, ZnT7, has been 
shown to promote cytoplasmic zinc transport into the Golgi apparatus (Kirschke and Huang, 
2003). The variations in their regulatory control, tissue-specific expression pattern, as well as 
distinct target sites of the zinc transporters underlines the importance of the ZnT family in 
regulating intracellular zinc homeostasis. Recently, a putative mitochondrial transporter of zinc 
has been identified in prostate cells (Guan et al., 2003), which suggests that mitochondrial uptake 
of zinc may be another site for maintaining zinc homeostasis in cells.  
Apart from transporters regulating influx and efflux of zinc ions, the maintenance of 
intracellular zinc homeostasis is a very dynamic process, involving the intracellular binding and 
release of zinc by zinc-binding proteins in a precisely-regulated way. The major sources of this 
intracellular zinc pool are metallothioneins (MTs). MTs are small proteins having a very high 
affinity for zinc. Each MT binds up to seven zinc ions through cysteine residues (Maret and 
Vallee, 1998). The equilibrium between metallated thionein (MT) and unmetallated thionein (T) 
is specifically regulated by the redox status in the cells. Oxidation or nitryosylation of cysteine 
residues reduces the zinc binding affinity of MT and therefore results in zinc release from MT, 
whereas reducing agents, such as GSH, favor zinc transfer and binding to thionein (Jacob et al., 
1998; Jiang et al., 1998; Maret and Vallee, 1998).  
Oxidative stress can also affect zinc homeostasis by influencing the nuclear-cytoplasmic 
distribution of MTs (Spahl et al., 2003). It has been shown that activation of cytokine-induced 
inducible NO synthase (iNOS) results in nuclear translocation of MT and triggers intranuclear 
zinc release (Spahl et al., 2003). These studies point to the role of oxidative stress as an 
important regulator in modulating intracellular zinc homeostasis and subsequent zinc signaling. 
Interestingly, several recent reports have demonstrated that PKC is another source of zinc storage 
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in cytoplasm. Exposure to superoxide activates PKC by dissociating and releasing zinc from its 
zinc-finger domain (Knapp and Klann, 2000; Korichneva et al., 2002). These results not only 
provide new insights into a new source of regulating zinc homeostasis but also reveal a new 
mechanism for regulating PKC activation by zinc. 
Upon oxidative stress, zinc is released, activating a wide range of signaling pathways and 
influencing transcriptional regulation of various genes. A well established zinc-activated 
transcription factor is metal response element-binding transcriptional factor 1 (MTF-1).  After 
binding zinc, MTF-1 is translocated from the cytoplasm to the nucleus and induces the 
transcriptional activation of both metallothionein and zinc transporter 1 in response to the 
elevation of cellular zinc (Bittel et al., 1998; Langmade et al., 2000; Smirnova et al., 2000). This 
may represent an important auto-regulated negative feedback mechanism to respond to excessive 
intracellular free zinc.  
1.4.2 Oxidative stress and zinc-induced neuronal toxicity 
It is now known that oxidative stress can trigger the release of intracellular stores of zinc by 
altering the redox state of zinc-binding proteins, such as MT. Similar to elevation of cytosolic 
zinc, oxidative stress can rapidly induce MT gene expression by regulating the MTF-1 
transcriptional factor, which suggests that oxidative stress may lead to a rise of intracellular zinc 
concentrations (Dalton et al., 1996; Andrews, 2000). Several groups have shown that nitric oxide 
(NO) mediates intracellular zinc release by acting on the cysteine-rich zinc-binding protein, MT 
(Berendji et al., 1997; Cuajungco and Lees, 1998; Aravindakumar et al., 1999; St Croix et al., 
2002). Overexpression of MT-III (brain specific MT form) is protective against glutamate and 
NO-induced neuronal death (Montoliu et al., 2000), which further supports this idea. Aizenman 
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et al (2000) shave found that a thiol oxidizing agent, 2, 2’-dithioldipyridine (DTDP), induces 
intracellular zinc release from its binding protein in cortical neurons and that this oxidative 
stress-induced intracellular zinc release triggers neuronal apoptosis. Compared with numerous 
studies that simply added exogenous zinc to induce toxicity in various cell culture models, this 
study was the first one showing that zinc released from intracellular stores induces toxicity in 
neurons.  This has provided new insights into the mechanisms of zinc-induced neuronal toxicity. 
Sources of toxic zinc will be discussed in detail later. Moreover, this study demonstrated that 
intracellular zinc release is an important link and mediator between oxidative stress and neuronal 
injury. Given the abundant ROS generation and the role of zinc toxicity in acute brain injury and 
chronic neurodegenerative diseases, this study is of great significance in elucidating a potential 
mechanism for neuronal injury in vivo. Confirming the above findings, a more recent paper 
provides a link between NO and NO-triggered zinc release from intracellular stores in mediating 
neuronal death pathways that involve mitochondria dysfunction and MAPK activation (Bossy-
Wetzel et al., 2004).  
Zinc-induced neuronal toxicity has been reported to be mediated by oxidative stress and 
has characteristics of both necrosis and apoptosis (Kim et al., 1999a; Kim et al., 1999b; Noh et 
al., 1999; Seo et al., 2001). Zinc exposure induces ROS generation, which contributes to zinc-
induced neuronal toxicity, since antioxidants attenuate zinc-induced toxicity (Kim et al., 1999a; 
Kim et al., 1999b; Noh et al., 1999; Seo et al., 2001). NADPH oxidase, a membrane free-radical 
generating enzyme, is activated by zinc exposure in cortical neurons and astrocytes, which 
suggests that NADPH is one mediator of zinc-induced oxidative stress (Noh and Koh, 2000). 
The most likely sources of zinc-induced ROS are mitochondria. It has been reported that zinc 
inhibits mitochondrial respiration (Brown et al., 2000; Bossy-Wetzel et al., 2004) and induces 
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mitochondrial ROS production (Sensi et al., 1999). Combined with the studies on oxidative 
stress-induced zinc-mediated cell death, this suggests that zinc liberated from intracellular stores 
may not only act as a mediator but also as an amplifier of oxidative stress signals in forming a 
destructive cycle to execute subsequent neuronal death.  
1.4.3 Role of MAPK in zinc-induced neuronal death 
Zinc participates in a wide range of cellular signaling pathways, ranging from intracellular 
second messenger regulation, protein kinase and phosphatase cascade regulation, as well as 
transcription initiation, all of which result in a variety of cellular responses, from cell 
proliferation and differentiation  (Beyersmann and Haase, 2001) to cell death (Truong-Tran et 
al., 2001). For example, MAPKs have been shown to be activated by zinc in several models. In 
fibroblasts, zinc induces MAPK activation and protein tyrosine phosphorylation (Hansson, 1996) 
while the chelation of zinc decreases the activation of MAPK induced by insulin growth factor 1 
(IGF-1) (Lefebvre et al., 1999). Exposure to excessive zinc induces EGF receptor 
phosphorylation and MAPK activation and subsequent activation of transcription factors, such as 
Jun and ATF-2, in human bronchial epithelial cells (Samet et al., 1998; Wu et al., 1999). In 
recent years, the role of MAPKs in mediating zinc-induced neuronal toxicity has been revealed. 
Intracelllular zinc release induced by thiol oxidizing agents, including DTDP and peroxynitrite, 
leads to the activation of p38 MAPK and subsequent cell death in cortical neurons (McLaughlin 
et al., 2001; Zhang et al., 2004). Pyrrolidine dithiocarbamate (PDTC) has been shown to induce 
intracellular zinc release, which in turn, activates JNK and contributes to cell death in embryonic 
hippcampal progenitor cells (Min et al., 2003). In PC12 cells, excessive zinc-induced sustained 
ERK activation contributes to zinc-induced neuronal death, which may be mediated through the 
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induction of an ERK downstream target, Egr-1 (Park and Koh, 1999; Seo et al., 2001). A 
biocide, methylisothiazolinone (MIT), induces toxicity in cortical neurons through the induction 
of intracellular zinc accumulation and subsequent ERK activation (Du et al., 2002). Recently, 
ERK-dependent cell death has been observed in peroxynitrite-induced toxicity in mature 
oligodendrocytes via the elevation of intracellular zinc (Zhang et al., 2006).  Consistent with the 
roles of ERK activation in neuronal death in various models discussed earlier, ERK activation 
seems a prerequisite for zinc-induced neuronal death. However, the mechanisms responsible for 
ERK activation remain unknown. In Seo’s study, a dominant negative Ras mutant was found to 
block zinc-induced neuronal death in PC12 cells, which suggests the role of Ras/Raf/MEK 
activation in zinc-induced toxicity (Seo et al., 2001).  
1.4.4 Zinc and the inhibition of protein phosphatases 
Zinc has been shown to modulate a various cellular signaling cascades, including the IGF-1 and 
EGF signaling pathways, by affecting the phosphorylation of signaling proteins. In the cases of 
EGFR- and IGF-1-mediated signaling, zinc can mimic the effect of EGF and insulin in the 
regulation of both pathways by augmenting the phosphorylation of RTKs, which in turn, activate 
subsequent downstream signaling cascades (Wu et al., 1999; Tang and Shay, 2001; Samet et al., 
2003). Furthermore, it has been revealed that in both signaling pathways, the mechanism of zinc-
mediated increased phosphorylation of RTKs lies in the inhibition of opposing PTPs (Haase and 
Maret, 2003; Tal et al., 2006).  
Zinc inhibits PTPs at concentrations within the micromolar range (10 uM) (Brautigan et 
al., 1981) to nanomolar range (Maret et al., 1999; Haase and Maret, 2003). Given the fact that 
the concentration of cellular free zinc ions is in the nanomolar or picomolar range, zinc-mediated 
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inhibition of PTPs at either high or low concentrations of zinc may be mediated by distinct 
mechanisms. The inhibition of PTPs by high concentrations of zinc may occur under 
pathological conditions, where a huge influx or release of zinc is observed, such as in acute brain 
injury. This could result in an imbalance of phosphorylation-dependent signaling cascades and 
lead to the ultimate demise of neurons. On the other hand, zinc inhibition of PTPs at low 
concentrations of zinc may have more physiological relevance and represent the physiological 
role of zinc in regulating PTP activity, such as in IGF-1 mediated signaling (Haase and Maret, 
2005). The mechanism of zinc-mediated inhibition of PTP activity is not known. However, it 
seems that the cysteine residue in the catalytic site of PTPs is not involved in an inhibitory effect 
of zinc (Maret et al., 1999). 
As mentioned above, oxidative stress is an important regulator of PTP activity. Similar to 
other growth factors, insulin augments its signaling by the production of hydrogen peroxide, 
which provides a positive feedback by inhibiting PTP 1B (Mahadev et al., 2001). Given the fact 
that zinc is released from MT by oxidative stress and the inhibition of PTPs by zinc, IGF-1 
signaling represents an excellent example to illustrate the interaction and crosstalk between 
redox and zinc signaling in response to one signal.   
Much less is known about the effect of zinc on the activity of PSTPs. In one report, Zhuo 
and Dixon (1997) found that zinc has inhibitory effect on purified PSTPs including PP1, PP2A, 
and PP2B, in vitro and that this inhibition can be reversed by the addition of dithiothreitol 
(DTT), which is a chelator of zinc. This is the first evidence showing an inhibition of PSTP 
activity by zinc. Furthermore, it has been shown that zinc inhibits PSTP activity by competing 
with Mn2+ for the active site of PSTPs (Zhuo and Dixon, 1997). This is consistent with a more 
recent study showing that zinc inhibits calcineurin (PP2B) activity in vitro by competing with 
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Ni2+ for the active metal-binding site in calcineurin (Takahashi et al., 2003).   Recently, it has 
been shown that zinc activates ERK in human airway epithelial cells by inhibiting ERK-directed 
phosphatases, which may include PSTPs, PTPs, and DSPs (Kim et al., 2006). 
1.4.5 Roles of zinc toxicity in acute brain injury 
Apart from various in vitro models, zinc toxicity has also been shown to contribute to acute 
neuronal injury in vivo, including seizures (Frederickson et al., 1989), transient forebrain global 
ischemia (Tonder et al., 1990; Koh et al., 1996), focal ischemia (Lee et al., 2002a), traumatic 
head injury (Suh et al., 2000), and hypoglycemia-induced neuronal death in vivo (Suh et al., 
2004).  In these models, significant zinc accumulation has been observed in selective 
degenerating neurons. In an elegant experiment, Koh et al (1996) have shown that 
intraventricular administration of a cell-impermeable zinc chelator, CaEDTA, significantly 
prevents zinc accumulation and reduces neuronal death in a transient global ischemia model, 
which suggests a critical role of zinc in mediating neuronal death in this model.  Based on 
numerous studies, a “zinc-translocation” hypothesis has been proposed to explain the mechanism 
of zinc-induced neuronal death in vivo (Choi and Koh, 1998). This hypothesis proposes that 
following ischemia or other acute brain injury, zinc release is triggered from pre-synaptic 
vesicles. The presynaptic zinc then enters into postsynaptic neurons through various NMDA- or 
voltage-gated channels and results in neuronal injury. Chelating of extracellular zinc with 
membrane-impermeable agent CaEDTA reduces the entry of presynaptic zinc into postsynaptic 
neurons, thus preventing zinc-induced cell injury. However, in recent years, several studies have 
presented evidence that is inconsistent with this hypothesis. For example, zinc accumulation in 
degenerating neurons is still observed following kainate-induced seizures in selective vulnerable 
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neurons in ZnT3 knockout mice, which have no zinc in their presynpatic vesicles (Lee et al., 
2000). This questions the presynaptic origin of zinc in the “zinc-translocation” hypothesis. 
Furthermore, CaEDTA has been shown to be able to deplete zinc from inside cells and 
presynaptic vesicles (Frederickson et al., 2002), arguing against the conclusions that the 
neuroprotective effect provided by CaEDTA in transient forebrain ischemia is solely due to the 
chelation of extracellular zinc released by presynaptic neurons. Therefore, a new model of 
excitotoxicity involving zinc release has been proposed (Frederickson et al., 2004). According to 
this model, presynaptic vesicle zinc release, mobilization of postsynaptic intracellular zinc, and 
possibly mitochondrial release of zinc are all involved in the excitotoxicity-induced zinc release 
events following brain injury (Frederickson et al., 2004). Although the mechanisms of zinc-
mediated brain injury still remain controversial, we should bear in mind that chelation of zinc is 
effective in protecting neuronal death in various in vitro and in vivo models. This may provide 
some clues for developing therapeutic strategies in zinc-induced cell injury. 
1.5 MODELS OF OXIDATIVE STRESS IN NEURONS 
1.5.1 Oxidative stress models in neurons 
Various in vitro models have been developed to analyze the molecular mechanisms of cellular 
responses to oxidative stress that are particularly relevant for neurodegeneration, such as amyloid 
β-peptide (Aβ)-induced oxidative toxicity (Akterin et al., 2005; Fonfria et al., 2005), 6-
hydroxydopamine (6-OHDA)-induced toxicity (Kulich and Chu, 2001; Hanrott et al., 2006), and 
oxygen-glucose deprivation (OGD) reoxygenation-induced toxicity (Culmsee et al., 2005; Lim et 
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al., 2006) in neurons. Aβ is the major component in the plaque formation in AD and considered 
critical for the pathogenesis of AD, mostly probably through the generation of ROS (Butterfield, 
2003). Dysregulation of the thioredoxin antioxidant system plays a role in Aβ-mediated toxicity 
in neuronal cultures (Akterin et al., 2005). 6-OHDA is a dopaminergic neurotoxin that generates 
hydrogen peroxide, superoxide, and hydroxyl radicals following its metabolism under 
physiological conditions (Cohen and Heikkila, 1974). 6-OHDA has been utilized in various 
neuronal models of PD, including B65 neuronal cell line (Kulich and Chu, 2001), primary 
neurons of substantia nigra (Ding et al., 2004), human dopaminergic neuronal cell line SH-SY5Y 
(Chen et al., 2004), and PC12 cells (Hanrott et al., 2006). OGD reoxygenation is an excellent 
model to mimic the oxidative stress condition following ischemia-reperfusion (Culmsee et al., 
2005; Lim et al., 2006). 
1.5.2 Glutamate-induced oxidative toxicity in HT22 and primary immature cortical 
neurons 
Extracellular glutamate acts on neurons via three pathways which include the binding of 
glutamate to ionotropic receptor (i.e. NMDA, AMPA or kainate receptors), metabotropic 
receptors (mGluRs), and a cystine/glutamate antiporter (Xc-). Ubiquitously expressed in 
mammalian cells, the Xc-  system is responsible for cystine uptake into the cells coupled to the 
efflux of  glutamate (Bannai, 1986; Sato et al., 1999). The concentration of intracellular 
glutamate is much higher than that its extracellular concentration. In contrast, low intracellular 
concentrations of cystine are maintained by its rapid reduction to cysteine in cells. As cysteine is 
the rate-limiting precursor of glutathione synthesis, the activity of the Xc-  system regulates the 
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intracellular levels of glutathione. High concentrations of extracellular glutamate inhibit the 
exchange of the Xc-  system, thereby leading to the depletion of intracellular glutathione. 
Glutamate-induced oxidative toxicity in a HT22 hippocampal cell line (Li et al., 1997a) 
and primary immature cortical neurons (Murphy et al., 1990) has provided a useful model for 
studying the effects of oxidative stress on neuronal cell death. HT22 is a mouse hippocampal-
derived cell line that lacks ionotropic glutamate receptors. Excess exogenous glutamate inhibits 
the Xc- system of HT22 cells, which leads to the depletion of glutathione and subsequent ROS 
accumulation. The ROS accumulation then in turn activates signaling cascades that eventually 
contribute to a novel form of cell death that has features of both apoptosis and necrosis (Li et al., 
1997a, b; Sagara and Schubert, 1998; Tan et al., 1998; Tan et al., 2001). Similarly, primary 
immature cortical neurons (DIV 1-3) do not express functional ionotropic glutamate receptors, 
therefore rendering them sensitive to glutamate-induced oxidative toxicity (Murphy et al., 1990). 
Depletion of glutathione in HT22 and primary immature cortical neurons leads to a series 
of cellular events, including 12-LOX activation followed by a significant influx of calcium and 
ROS accumulation, resulting in cell death (Li et al., 1997a; Stanciu et al., 2000). Distinct from 
classical apoptosis or necrosis, glutamate-induced oxidative toxicity shares some features of both 
apoptosis and necrosis. Similar to necrosis in terms of morphological criteria, such as cell 
swelling during cell death, glutamate-induced oxidative toxicity also has some biochemical 
characteristics of apoptosis, including the requirement for synthesis of new proteins (Tan et al., 
2001).  Therefore, the term “oxytosis” has been proposed to reflect this unique form of cell death 
caused by glutathione-depletion and ROS-accumulation (Tan et al., 2001).  
The signaling events leading to cell death in glutamate-induced oxidative toxicity in 
HT22 cells and primary immature cortical neurons have been studied extensively although the 
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findings are somewhat controversial. PKC activation has been reported to be neuroprotective 
against glutamate-induced oxidative toxicity (Davis and Maher, 1994; Maher, 2001). The roles 
of various MAPK members have been investigated in this toxicity model and have led to the 
suggestion that p38 MAPK activation contributes to the toxicity while ERK1/2 activation is 
neuroprotective (Maher, 2001). However, numerous results obtained from our lab and several 
other labs have shown that sustained activation of ERK1/2 specifically contributes to the 
oxidative toxicity induced by glutamate in HT22 cells and primary immature cortical neurons 
(Satoh et al., 2000; Stanciu et al., 2000; Stanciu and DeFranco, 2002; Levinthal and DeFranco, 
2004, 2005; Choi et al., 2006; Luo and DeFranco, 2006). Furthermore, it has recently been 
shown that reversible oxidation of ERK-directed protein phosphatases contributes to ERK 
activation and subsequent neuronal death (Levinthal and DeFranco, 2005). However, the 
mechanisms regulating the oxidation and inactivation of ERK phosphatases remain elusive. A 
recent study has suggested that proteasome degradation of MKP1 may contribute to ERK1/2 
activation in glutamate-mediated oxidative toxicity model (Choi et al., 2006). 
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2.0   THESIS GOALS 
This thesis was mainly focused on two specific research goals. Previous studies in our lab had 
shown that specific reversible inhibition of ERK-directed phosphatases contributes to the 
persistent ERK activation in glutamate-induced toxicity in primary immature cortical neurons 
(Levinthal and DeFranco, 2005). However, the mechanism underlying the oxidation and 
inactivation of ERK-directed phosphatase is not known. Therefore, the first specific aim of my 
study was to investigate the mechanism of oxidative stress-induced inhibition of ERK 
phosphatases in glutamate toxicity models. Considering the role of oxidative stress in triggering 
intracellular zinc release and the inhibition of protein phosphatases by zinc, I first sought to 
establish whether there exists a connection between oxidative stress-induced intracellular zinc 
release by glutamate and the inhibition of ERK-directed phosphatases in HT22 cells and primary 
immature cortical neurons. My hypothesis was that selective zinc inhibition of ERK 
phosphatases is responsible for ERK-dependent oxidative toxicity in neurons. The results from 
this part of my studies are presented in Chapter 3.  
Second, I set out to determine the biochemical mechanisms underlying the oxidation and 
inactivation of ERK-directed phosphatases. Previous studies had shown that PP2A is the 
predominant ERK phosphatase in primary neurons (Levinthal and DeFranco, 2005). Therefore, I 
sought to examine cysteine oxidation of PP2A following oxidative stress, and the effects of 
PP2A oxidation on its catalytic activity. I hypothesized that the cysteine oxidation of PP2A may 
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contribute to the decrease of PP2A activity following oxidative stress.  The results of this part are 
described in Chapter 4. 
The second specific aim of my study focused on the inhibition of MAPK phosphatases in 
rodent ischemia models. ERK1/2 activation has been associated with neuronal death in the 
transient focal ischemia/reperfusion model (Alessandrini et al., 1999; Namura et al., 2001). In the 
first part of this study, I set out to investigate the inhibition of MAPK phosphatases in a focal 
ischemia (MCAO) model. I hypothesized that oxidative stress-induced oxidation and inactivation 
of ERK phosphatases contributes to ERK1/2 activation and subsequent neuronal death in this 
focal ischemia/reperfusion model. ERK1/2 activation also occurs following global 
ischemia/reperfusion, although the role of ERK1/2 activation in neuronal cell injury that results 
from this ischemic insult remains controversial. Therefore, I also examined the role of ERK1/2 
phosphatase inhibition in mediating ERK1/2 activation following global ischemia/reperfusion in 
rat. The results of these studies are presented in Chapter 5. 
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3.0  SELECTIVE INHIBITION OF MAPK PHOSPHATASES BY ZINC ACCOUNTS 
FOR ERK1/2-DEPENDENT OXIDATIVE NEURONAL CELL DEATH 
3.1 SUMMARY 
Oxidative stress induced by glutathione depletion in the mouse HT22 neuronal cell line and 
embryonic rat immature cortical neurons causes a delayed, sustained activation of the mitogen-
activated protein kinase (MAPK) family members, extracellular signal-regulated kinase 1/2 
(ERK1/2), which is necessary for cell death. This sustained activation of ERK1/2 is mediated 
primarily by a selective, reversible inhibition of ERK1/2-directed phosphatases. The inhibition of 
ERK1/2 phosphatases in HT22 cells and immature neurons subjected to glutathione depletion is 
indeed the result of oxidative stress, as phosphatase activity is restored in cells treated with the 
antioxidant BHA. This agent leads to reduced ERK1/2 activation and neuroprotection. 
Furthermore, we show that an increase in free intracellular Zn2+ that accompanies glutathione-
induced oxidative stress in HT22 cells and immature neurons contributes to selective inhibition 
of ERK1/2 phosphatase activity and ensuing ERK1/2 activation and cell death. ERK1/2 also 
functions to maintain elevated levels of Zn2+.  Thus, the elevation of intracellular Zn2+ within 
neurons subjected to oxidative stress can trigger a robust positive feedback loop operating 
through activated ERK1/2 that rapidly sets into motion a Zn2+ -dependent pathway of cell death. 
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3.2 INTRODUCTION 
Oxidative stress results from the accumulation of reactive oxygen species (ROS) and is brought 
about by a disruption of the physiological balance between normal oxidant production and the 
action of various anti-oxidant defense systems. The brain is particularly sensitive to ROS 
accumulation, and oxidative stress is implicated in the pathogenesis of a wide range of chronic 
neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and 
amyotrophic lateral sclerosis (ALS) (Simonian and Coyle, 1996; Mattson et al., 2001), as well as 
acute neuronal injury, such as stroke (McCulloch and Dewar, 2001; Cherubini et al., 2005). 
Various in vitro models have been developed to analyze the molecular mechanisms of cellular 
responses to oxidative stress that are particularly relevant for neurodegeneration (Akterin et al., 
2005; Hanrott et al., 2006; Lim et al., 2006).  
A number of cellular signaling pathways are activated by oxidative stress in neurons 
including the MAPKs. The MAPK family is a group of signaling modules involved in cellular 
responses to a wide range of stimuli that impact cell adhesion, cell differentiation and 
proliferation, synaptic plasticity, survival and apoptosis (Pearson et al., 2001; Thomas and 
Huganir, 2004).  MAPK members include extracelluar-signal regulated kinase (ERK), Jun N-
terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38 MAPK kinase families 
(Pearson et al., 2001). The MAPKs are activated by dual-phosphorylation of a conserved 
threonine-X-tyrosine motif by upstream MAPK kinases (MEKs or MKKs), which are in turn 
activated by their upstream kinases, MEK/MKK kinases (MKKKs) (Pearson et al., 2001).   
Individual MAPK family members were initially considered to serve distinct roles in 
neuronal responses to death-inducing stresses, with activation of the JNK/SAPK and p38 
pathways most often associated with neuronal cell death (Xia et al., 1995; Yang et al., 1997; 
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Borsello et al., 2003). In contrast, a neuroprotective role of ERK activation has been revealed in 
several models of neuronal toxicity, including growth factor rescue of serum-starved neuronal 
cultures (Xia et al., 1995), in vivo models of hypoxia-ischemia (Han and Holtzman, 2000), as 
well as the BDNF-mediated rescue of camptothecin-treated cortical neuronal cultures (Hetman et 
al., 1999). However, ERK1/2 activation has also been found to promote neuronal cell death in a 
number of in vitro models of neurodegeneration induced by oxidative stress (Satoh et al., 2000; 
Stanciu et al., 2000; Levinthal and DeFranco, 2004), zinc (Seo et al., 2001; Du et al., 2002), or 6-
hydroxydopamine (Kulich and Chu, 2001). In fact, pharmacological  inhibition of ERK1/2 
activation in vivo reduces neuronal cell injury in response to transient focal ischemia 
(Alessandrini et al., 1999; Noshita et al., 2002). The divergent effects of ERK1/2  to either 
promote cell death or survival, even within a single cell type are likely to be determined by 
multiple factors, including the kinetics of kinase activation and/or the subcellular localization of 
activated kinases (Luo and DeFranco, 2006). 
Glutamate-induced oxidative toxicity in the HT22 hippocampal cell line (Li et al., 1997a) 
and primary immature cortical cultures (Murphy et al., 1990) has provided a useful model for 
studying the effects of oxidative stress on neuronal cell death. Both HT22 cells and primary 
immature cortical neuronal cultures lack N-methyl-D-aspartate (NMDA) receptors (Murphy and 
Baraban, 1990). Therefore, glutamate treatment of these cells primarily inhibits a 
glutamate/cystine antiporter and blocks the uptake of cystine, a precursor of glutathione 
synthesis (Murphy et al., 1990). The resulting glutathione depletion triggers ROS accumulation, 
which activates signaling cascades that eventually contribute to a form of cell death that has 
features of both apoptosis and necrosis (Li et al., 1997a, b; Sagara and Schubert, 1998; Tan et al., 
1998; Tan et al., 2001). 
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We have previously reported that oxidative stress in HT22 cells and immature cortical 
neurons causes a delayed, sustained activation of ERK1/2, which is necessary for neuronal cell 
death (Stanciu et al., 2000; Stanciu and DeFranco, 2002; Levinthal and DeFranco, 2004). This 
sustained activation of ERK1/2 is mediated primarily by a selective, reversible inhibition of 
ERK1/2-directed phosphatases (Levinthal and DeFranco, 2005). In this study, we examined the 
mechanistic basis for oxidative inhibition of ERK1/2-directed phosphatases in HT22 cells and 
immature cortical neuron cultures. We demonstrate that the increased intracellular accumulation 
of Zn+2 in oxidatively stressed neuronal cells is responsible for the selective inhibition of ERK-
phosphatases and ensuing ERK1/2 activation and cell death. Surprisingly, ERK1/2 also functions 
to maintain elevated levels of Zn+2.  Thus, the elevation of intracellular Zn+2 within damaged 
neurons can trigger a robust positive feedback loop operating through activated ERK1/2 that 
rapidly sets into motion a Zn2+ -dependent pathway of cell death. 
3.3 MATERIALS AND METHODS 
Primary Cortical Cultures and Cell Lines 
Primary cultures were prepared from the cortices of embryonic day 17 Spague-Dawley 
rat fetuses (Hilltop Lab Animals). Briefly, the cortices of embryonic day 17 Spague-Dawley rat 
fetuses were dissected and dissociated by repeated trituration in Hanks’ balanced salt solution 
(5.4 mM KCl, 0.3 mM Na2HPO4, 0.4 mM KH2PO4, 4.2 mM NaHCO3, 137 mM NaCl, 5.6 mM 
D-glucose, pH 7.4) without Ca2+ or Mg2+ (GIBCO).  The cell suspensions then were passed 
through a 40-um cell strainer (BD Biosciences) to remove clumped cells. Cells then were 
counted and plated on 50 ug/ml poly-d-lysine coated cultures plates at a density of ~1x105 
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cells/cm2. Cell viability was assessed by the uptake of trypan blue dye and was usually greater 
than 80%. Cultures were maintained for 2-3 days in media (Dulbecco's modified essential 
medium [DMEM], 10% fetal calf serum (Hyclone), 10% Ham’s F12 nutrient supplement 
(Sigma), 1.9 mM glutamine, 24 mM Hepes buffer, and 4.5 mg/ml glucose) at 37ºC and 5% CO2. 
At this time, the mixed cortical cultures are ~80% neuronal, with ~20% glial fibrillary-associated 
protein staining cells (Murphy et al., 1990). HT22 cells were maintained in DMEM 
supplemented with 10% fetal bovine serum, 100 units of penicillin, and 100ug/ml streptomycin 
at 37ºC and 5% CO2. 
 
Cell Viability Assay 
The DNA dye propidium iodide (PI) was used to assess cell viability. PI is excluded from 
healthy, intact cells and can only get into cells with a compromised plasma membrane. Fourteen 
to 16 h after being treated with homocysteate (HCA), primary neurons were incubated for 10 min 
in media containing a final concentration of 6.25 ug/ml PI. Cells were observed under an 
inverted fluorescence microscope equipped with phase-contrast optics (Nikon Eclipse TE200). 
Multiple fields were counted for each condition in at least 3 independent cultures with a total 
cells population of at least 500 neurons per condition. Toxicity was assessed in HT22 cells after 
12 h’s glutamate treatment using the PI staining method described above.  
 
ERK2- and JNK3-directed Phosphatase Activity Assay 
A nonradioactive method has been modified for determining ERK2- and JNK3-directed 
phosphatase activity in cell lysates (Laakko and Juliano, 2003). This method is based on 
detecting dephosphorylation of a purified, dual-phosphorylated, His6-tagged ERK2 or JNK3 
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upon incubation with the cell lysates (Levinthal and DeFranco, 2005). The alterations of ERK2 
or JNK3 phosphatase activity within the cell lysates can be monitored by measuring changes in 
the phosphorylation state of the isolated phosphorylated ERK2 or JNK3 substrate, as shown by 
Western blotting with a phospho-specific ERK1/2 or JNK antibody. Briefly, 150 ug of cell 
lysates were diluted into a total volume of 250 ul in phosphatase assay buffer (10 mM MgCl2, 10 
mM Hepes, pH7.5 and 10 uM of the MEK inhibitor, U0126). Recombinant dual phosphorylated 
His6-ERK2 or His6-JNK3 (Biomol) was added to each sample (30 ng/sample), and the reactions 
were maintained at 37ºC for 15 min where indicated. For the in vitro Zn2+ inhibition experiment, 
different concentrations of ZnCl2 were pre-incubated with cell lysates for 10 min at 37ºC before 
the addition of purified pERK2 substrate. Following a 15 min incubation at 37ºC, reactions were 
stopped by the addition of 250 ul of wash buffer (8M urea, pH 8.6, containing 10 mM 
imidazole).  Thirty ul of Ni2+-conjugated, magnetic beads (Qiagen) was then added to each 
reaction. After 90 min of rocking at 4ºC, the samples were washed twice with wash buffer 
followed by one wash in 300 mM NaCl, 25 mM Tris, pH 7.5. The beads were then suspended in 
Laemmli sample buffer, boiled for 5 min, loaded onto a 10% polyacrylamide gel, transferred to a 
polyvinylidine fluoride membrane (Millipore) and subjected to Western blotting to detect 
phosphorylated ERK1/2, total ERK1/2, phosphorylated JNK3, or total JNK3. 
 
Western Blot Analysis 
Cells were treated with HCA or glutamate, scraped, and collected in 1x PBS and then 
centrifuged at 7000 rpm for 3 min. The pellets were then disrupted in lysis buffer (50 mM Tris-
Cl, pH 7.5, 2 mM EDTA, 100 mM NaCl, 1% Nonidet P-40, supplemented with protease 
inhibitor (Protease inhibitor cocktail, Sigma). The solubilized lysates were then centrifuged at 
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13,000 rpm for 5 min at 4ºC, and supernatants were collected for further analysis. Protein 
concentrations of the extracts were determined using the Bio-rad reagent. Equivalent amount of 
total protein (20-30 ug) were separated by SDS-PAGE on 10%-polyacrylamide gels and then 
transferred to polyvinylidine membranes. Membranes were blocked with 5% dry milk in 
PBS/0.1% (v/v) Tween 20 (PBST) for 1 h at room temperature. Membranes were then incubated 
with primary antibodies (anti-phospho-ERK1/2, anti-total ERK1/2, anti-phospho-JNK, anti-total 
JNK, all from Cell Signaling) overnight at 4ºC with 2% BSA in PBST. The membranes were 
then washed three times with PBST (10 min each time), incubated with the appropriate 
horseradish, peroxidase-conjugated secondary antibody for 40 min at room temperature and 
followed by three washes with PBST.  Immunoreactive bands were then revealed by enhanced 
chemiluminescence (ECL, Amersham Biosciences) using standard x-ray film (Eastman Kodak 
Co). Densitometry was performed using a Personal Densitometer SI (Amersham Biosciences) 
linked to the ImageQuant 5.2 software (Amersham Biosciences).  
 
Intracellular Zinc Imaging 
This part of work was performed by Dr Megan Knoch in Dr Elias Aizenman’s lab. 
Neuronal cultures were incubated in a Fluozin-3 AM (5 µM, Molecular Probes)-containing 
solution composed of HEPES-buffered saline supplemented with 5 mg/mL BSA for 
approximately 30 min.  Immediately following incubation, coverslips were submerged in a 
recording chamber (Warner Instruments) mounted on an inverted epifluorescence microscope 
(Nikon Eclipse TE200) equipped with a 10X and a 20X objective.  MEM-HEPES-BSA was 
continuously perfused through the recording chamber via a gravity-driven perfusion system.  
Using a computer-controlled monochromator (Polychrome II, TILL Photonics) and a CCD 
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camera (IMAGO, TILL Photonics), images were acquired with 490 nm excitation light.  Once a 
series of baseline fluorescence images were established, a 20 μM Tetrakis-(2-
pyridylmethyl)ethylenediamine (TPEN) solution was perfused through the chamber to chelate 
intracellular zinc and quench the fluorescent signal.  The relative fluorescence for all cells (n= 6-
40) was determined by subtracting the TPEN-quenched signal from the initial fluorescence and 
an average value was calculated for each coverslip (n=6).  Data were analyzed and plotted using 
Origin 6.0 (OriginLab Corporation). 
 
Statistics 
Comparison of two means was performed using a paired t test. Comparison of multiple 
mean values were performed by analysis of variance with either Turkey’s or Bonferroni’s post 
hoc tests for significance. A p-value of <0.05 was considered to be significant. All data were 
analyzed using the GraphPad Prism version 4.0 for Windows (GraphPad Software). 
3.4 RESULTS 
3.4.1 ERK2-directed phosphatase activity is inhibited during oxidative toxicity in HT22 
cells and primary immature cortical neurons 
We had previously reported that glutamate-induced oxidative stress in immature cortical neurons 
inhibits ERK2-directed phosphatases resulting in sustained activation of ERK1/2 (Levinthal and 
DeFranco, 2005). As HT22 cells exhibit analogous ERK1/2-dependent oxidative toxicity, we 
first set out to examine whether ERK1/2-directed phosphatases were similarly inhibited by 
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glutamate treatment in HT22 cells. We adopted an in vitro phosphatase assay described 
previously (Levinthal and DeFranco, 2005), which uses whole cell lysates to dephosphorylate 
purified, dual-phosphorylated, His6-tagged ERK2. A nonspecific dual-specificity phosphatase, 
lambda protein phosphatase, was employed as a positive control for ERK2 dephosphorylation 
(Figure 3.1A, lane 2).  
As shown in Figure 3.1A, whole cell lysates prepared from HT22 cells possess robust 
ERK2 phosphatase activity (Figure 3.1A, lane 3). When cell extracts were prepared from 
cultures treated with glutamate for 7.5 h, a decrease in ERK2-directed phosphatase activity was 
observed (Figure 3.1A, lane 6).  Quantification of four independent experiments revealed a 
significant increase (p<0.05) in the normalized levels of phosphorylated ERK2 in HT22 cell 
lysates exposed to glutamate for 7.5 h when compared to untreated cultures (Figure 3.1B). When 
cells were exposed to shorter treatments with glutamate (i.e. 2 h and 5 h), ERK2 phosphatase 
activity was not significantly affected (Figure 3.1A, lane 4&5). The length of glutamate exposure 
that leads to inhibition of ERK2 phosphatase activity in HT22 cells is coincident with that 
required for maximal oxidative stress (Tan et al., 1998) and enhanced ERK1/2 phosphorylation 
(Stanciu et al., 2000).  
To confirm the effect of glutamate on the inhibition of ERK2 phosphatase activity in 
primary immature cortical neurons, we used the glutamate analog homocysteate (HCA) to induce 
oxidative stress. HCA is a glutamate analog that has a relatively high binding affinity to 
glutamate/cysteine antiporter and has widely been used to induce oxidative toxicity to immature 
neurons (Ryu et al., 2003b; Ryu et al., 2003a). The ERK2 phosphatase assay was performed with 
whole cell lysates prepared from cultures treated with HCA for different times (i.e, 12 h, 14 h 
and 16 h). As shown in Figure 3.1C, we began to observe an inhibition of ERK2 phosphatase 
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activity in extracts prepared from neurons treated for 14 h with HCA. After a 16h treatment with 
HCA, a pronounced inhibition of ERK2 phosphatase activity was revealed (Figure 3.1C and Fig 
3.1D). 
3.4.2 An antioxidant that blocks oxidative toxicity reduces ERK1/2 activation and 
restores ERK2 phosphatase activity 
The antioxidant, butylated hydroxyanisole (BHA), has previously been shown to be protective 
against glutamate-induced oxidative toxicity in primary immature cortical neurons (Ryu et al., 
2003a). We confirmed the neuroprotective effects of BHA against glutamate toxicity in HT22 
cells (data not shown). BHA has also recently been shown to prevent the oxidative stress-
induced inhibition of JNK phosphatases and TNF-α induced cell death in fibroblast cell lines 
(Kamata et al., 2005). The effects of BHA in blocking ERK1/2 activation induced by oxidative 
stress has also been observed in other cell types, such as head and neck squamous carcinoma 
cells (Kim et al., 2006). We therefore used BHA to assess whether ERK1/2 activation and the 
inhibition of ERK2-directed phosphatase activity is mediated by ROS.  
As shown in Figure 3.2A, a 7.5 h glutamate treatment induced significant ERK1/2 
activation in HT22 cells. In primary cortical neurons, HCA activation of ERK1/2 was evident at 
14 h and peaked at 16 h (Figure 3.2B), analogous to the time course of ERK1/2 activation by 
glutamate in immature neurons (Stanciu et al., 2000; Levinthal and DeFranco, 2004, 2005). The 
administration of BHA blocked ERK1/2 activation induced by oxidative stress in HT22 cells and 
neurons (Figures 3.2A & 3.2B).  
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To investigate the mechanism responsible for BHA inhibition of ERK1/2 activation, we 
then performed ERK2 phosphatase assays on cell lysates prepared from HT22 cells and neurons 
subjected to oxidative stress in the presence or absence of BHA. As shown in Figure 3.2C, BHA 
prevented the inhibition of ERK2 phosphatase activity following glutamate treatment in HT22 
cells. Similarly, BHA abrogated the inhibition of ERK phosphatase activity in neurons subject to 
HCA treatment (Fig 3.2D). Thus, ROS-mediated inhibition of protein phosphatase activity is 
responsible, in part for the activation of ERK1/2 in oxidatively stressed neurons.  
3.4.3 Selective inhibition of ERK2 phosphatase activity by Zn2+ in neuronal cell extracts 
ERK1/2 phosphatases such as MKPs and PP2A are reversibly inactivated by thiol oxidation 
(Kim et al., 2003; Foley et al., 2004). Previously, we found that ERK2 phosphatase activity in 
extracts prepared from oxidatively stressed neurons was restored by the in vitro addition of DTT 
(Levinthal and DeFranco, 2005). This suggests that BHA-reversible oxidative stress may be 
acting to inhibit ERK1/2 phosphatases in HT22 cells and primary cortical neurons through direct 
or indirect thiol oxidation of the phosphatases. However, DTT in addition to its well-known thiol 
reducing properties is also an effective Zn2+ chelating agent (Cornell and Crivaro, 1972; Paoletti 
et al., 1997). Thus, restoration of ERK2 phosphatase activity in extracts prepared from 
oxidatively stressed neurons by DTT may not be solely due to reduction of oxidized thiols. 
Interestingly, Zn2+ is inhibitory to purified phosphatases that could act on ERK1/2, including the 
protein serine/threonine phosphatase (PSTP) PP2A (Zhuo and Dixon, 1997) and protein tyrosine 
phosphatases (PTPs) (Brautigan et al., 1981; Maret et al., 1999). As such, we investigated the 
effect of Zn2+ on ERK2 phosphatase activity.  
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Whole cell lysates prepared from untreated HT22 cells were pre-incubated for 10 min 
with different concentrations of ZnCl2 before performing the ERK2 phosphatase assay. As shown 
in Figure 3.3A, Zn2+ caused a concentration-dependent inhibition of ERK2 phosphatase activity 
with the maximal inhibition observed at 10μM. Quantification of several independent 
experiments revealed a significant inhibition of ERK2 phosphatase activity by zinc at 10μM 
(Figure 3.3B, p<0.01). To determine whether the Zn2+ inhibition of phosphatase activity is 
specific to ERK phosphatases, we examined Zn2+ effects on JNK3 phosphatase activity. As 
shown in Figure 3.3C, the addition of ZnCl2 to untreated HT22 cell lysates did not affect JNK3 
phosphatase activity. This suggests that exogenous Zn2+ is selective in inhibiting ERK2-directed 
phosphatases in HT22 cell extracts. This is not surprising since oxidative toxicity in HT22 cells 
and immature neurons is not associated with an increase in JNK activation or inhibition in JNK 
phosphatase activity (Levinthal and DeFranco, 2005). 
3.4.4 Oxidative stress triggers Zn2+ accumulation in HT22 cells and primary neurons  
Given the inhibitory effects of exogenous Zn2+ on ERK1/2 phosphatase activity in vitro, we set 
out to examine whether oxidative stress-induced phosphatase inhibition in HT22 cells and 
immature cortical neurons is due to increased accumulation of Zn2+ (Aizenman et al., 2000). The 
impact of oxidative stress in HT22 cells and primary neurons on intracellular Zn2+ accumulation 
was assessed using FluoZin 3-AM, a fluorescent Zn2+ indicator dye (Minta et al., 1989; 
Devinney et al., 2005). Relative intracellular Zn2+ levels were obtained by quantitative measures 
of fluorescence of FluoZin-3AM, which is quenchable by the Zn2+ chelator, N,N,N’,N’-Tetrakis-
(2-pyridylmethyl)-Ethylenediamine (TPEN), within individual cells. As shown in Figure 3.4A, 
oxidative stress in HT22 cells and immature neurons led to a doubling of the relative TPEN-
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quenchable FluoZin 3-AM fluorescence. In glutamate-treated HT22 cells, the relative 
intracellular Zn2+ levels increased from 7.8 + 1.5 to 15.5 + 1.7 (n=8), whereas HCA treatment of 
neurons led to an increase in the relative levels of intracellular Zn2+ from 14.6 + 1.6 to 29.2 + 4.2 
(n=6). Thus oxidative stress in both HT22 cells and immature neurons triggers the accumulation 
of intracellular Zn2+, similar to what we have reported in other systems (Aizenman et al., 2000; 
McLaughlin et al., 2001; Pal et al., 2004; Zhang et al., 2004). 
In order to determine the relationship between oxidant production, intracellular Zn2+ 
accumulation, and ERK1/2 activation, neurons were exposed to HCA in the presence or absence 
of either the antioxidant BHA or the MEK1/2 inhibitor U0126. As shown in Figure 3.4B, BHA 
treatment blocked HCA-induced intracellular Zn2+ accumulation and exerted no significant effect 
on the relative intracellular Zn2+ levels when given alone. Interestingly, U0126 treatment also 
reduced TPEN-quenchable Zn2+ fluorescence in HCA-treated neurons and did not alter Zn2+ 
levels when given alone (Figure 3.4B). Thus, Zn2+ accumulation triggered by ROS may be 
exacerbated through a positive feedback loop driven by activated ERK1/2. 
3.4.5 Chelation of intracellular Zn2+ blocks ERK1/2 activation and restores ERK2 
phosphatase activity  
Zn2+-induced ERK1/2 activation has been reported to contribute to neuronal cell death (Seo et 
al., 2001; Du et al., 2002; Zhang et al., 2004). Given the fact that oxidative stress triggers 
intracellular Zn2+ accumulation in HT22 cells and primary neurons (Figure 3.4) and sustained 
ERK1/2 activation (Stanciu et al., 2000), we sought to examine whether Zn2+ contributes to 
ERK1/2 activation.  To evaluate the role of Zn2+ accumulation in activating ERK1/2 in HT22 
cells and primary neurons, we employed the high affinity Zn2+ chelator TPEN. HT22 cells were 
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treated with glutamate, in the presence or absence of 1 μM and 5 μM TPEN for 8 h. Whole cell 
lysates were then subject to Western blot analysis to detect phosphorylated, activated ERK1/2. 
As shown in Figure 3.5A, exposure of HT22 cells to glutamate induced a large increase in 
ERK1/2 phosphorylation that was unaffected by the addition of 1 μM TPEN (Fig 3.5A). 
However, the addition of 5 μM TPEN significantly blocked glutamate-induced ERK1/2 
activation (Fig 3.5A). This result suggests that ERK1/2 activation is downstream of Zn2+ 
accumulation.  
Similar experiments were then extended to primary neurons, which were treated with 
HCA, HCA plus 1 μM TPEN, and HCA plus 5 μM TPEN for 16 h. Analogous to results 
obtained in HT22 cells, addition of 5 μM, but not of 1 μM TPEN, significantly blocked the 
activation of ERK1/2 following oxidative stress in primary neurons (Figure 3.5B). 
Given the fact that Zn2+inhibits ERK2 phosphatase activity in vitro (Figures 3.3A & 
3.3B), we set out to examine whether TPEN inhibition of ERK1/2 activation occurs through the 
reversal of Zn2+-mediated inhibition of ERK1/2 phosphatases. The ERK2 phosphatase assay was 
performed on whole cell lysates prepared from untreated HT22 cells, or cells treated with 
glutamate, or glutamate plus 1 μM or 5μM TPEN. As shown in Figures 3.5C and 3.5E, ERK2 
phosphatase activity was decreased following treatment with glutamate. The addition of 1 μM 
TPEN to HT22 cells did not reverse this inhibitory effect of glutamate (Figures 3.5C and 3.5E). 
However, the addition of 5 μM TPEN significantly reversed the inhibition of ERK2 phosphatase 
activity in HT22 cells that were treated with glutamate (Figures 3.5C and 3.5E). Similar results 
were obtained in primary neurons (Figures 3.5D and 3.5F). These results suggest that TPEN 
blocks Zn2+-induced ERK1/2 activation by reversing a Zn2+-mediated inhibition of ERK1/2 
phosphatase activity. 
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As U0126 has been found to block Zn2+accumulation in oxidatively-stressed cells, 
(Figure 3.4), we sought to examine whether U0126 could also reverse the inhibition of ERK2 
phosphatase activity. The ERK2 phosphatase assay was therefore performed on cell lysates 
prepared from untreated HT22 cells or cells treated with glutamate or glutamate plus U0126. As 
shown in Figures 3.5G and 3.5H, U0126 treatment of HT22 cells reversed the inhibition of 
ERK2 phosphatase activity induced by oxidative stress. This result reinforces the notion that 
activated ERK1/2 contributes to a positive feedback loop that maintains elevated levels of 
intracellular Zn2+and persistent inhibition of ERK1/2 phosphatases. 
3.4.6 TPEN protects neuronal cells from oxidative toxicity 
Since TPEN treatment blocks ERK1/2 activation following oxidative toxicity in HT22 cells and 
primary neurons (Figures 3.5A & 3.5B), we examined whether TPEN could also limit cell death. 
Due to the fact that Zn2+ is an essential metal, we limited TPEN treatment to less than 16 h in 
both HT22 cells and primary neurons. Prolonged exposure (i.e. 48 h) of HT22 cells and primary 
neuronal cultures with TPEN alone is toxic (data not shown).  HT22 cells were treated for 12 h 
with glutamate, glutamate plus 1 μM TPEN, glutamate plus 5 μM TPEN, as well as 1 μM TPEN 
or 5 μM TPEN alone. A propidium iodine (PI) staining method was then used to assess cell 
toxicity. PI is a DNA dye that only enters cells with compromised plasma membranes. 
Therefore, toxicity can be assessed by determining the percentage of PI+ cells in different 
treatment groups (Levinthal and DeFranco, 2005). As shown in Figure 3.6A, a significant 
proportion of HT22 cells stained positive for PI upon glutamate treatment. Cells treated with 
glutamate plus 1 μM TPEN exhibited a similar extent of cell death. However, a 5 μM TPEN 
treatment significantly protected HT22 cells from glutamate-induced cell death (Figure 3.6A, 
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p<0.001). This neuroprotective effect is similar to that provided by U0126 (Figure 3.6A). A 12 h 
treatment with 1 μM and 5 μM TPEN alone exhibited no toxicity in HT22 cells (Figure 3.6A).  
This paradigm was then extended to primary neurons. These cultures were subject to the 
same treatment as HT22 cells, and cell toxicity assessed after treatment for 16 h. Similar to the 
results obtained in HT22 cells, a 16 h treatment with HCA as well as HCA plus 1 μM TPEN 
induced significant cell death in primary neurons (Figure 3.6B). However, the addition of 5 μM 
TPEN significantly protected primary neurons from HCA-induced toxicity (Figure 3.6B). In 
summary, the dose of TPEN required to protect both HT22 cells and primary neurons from 
oxidative toxicity is coincident with that required to block ERK1/2 activation and ERK1/2 
phosphatase inhibition. 
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Figure 3.1 ERK2 phosphatase activity is inhibited upon oxidative toxicity in HT22 
and immature primary cortical cultures. 
A. HT22 cells were treated with 5mM glutamate for either 0, 2, 5, or 7.5h. Whole cell lysates 
were incubated with purified, phosphorylated ERK2 (pERK2) and phosphatase activity was 
assessed by Western blots that revealed pERK2 or total ERK2. I=phosphatase assay input;   
λ=lambda phage protein phosphatase (positive control).  
B. Quantification of the results from 4 independent experiments, revealing a significant decrease 
in ERK2 phosphatase activity following glutamate-induced oxidative toxicity in HT22 cells. 
P<0.05.  
C. ERK2 phosphatase activity is inhibited upon 5mM HCA treatment in primary cortical 
neuronal cultures. Immature primary neuronal cultures were treated with HCA for either 0, 12, 
14, 16h. Whole cell lysates were incubated with purified pERK2, and phosphatase activity was 
assessed by Western blots that revealed either pERK2 or total ERK2. I=phosphatase assay input.  
D. Quantification of the results from 3 independent experiments, revealing a significant decrease 
in ERK2 phosphatase activity following HCA-induced oxidative toxicity in immature primary 
cortical neuron cultures. P<0.05.  
 
 
 
 
 
 57 
 Figure 3.2  BHA blocks ERK1/2 activation and the inhibition of ERK2 phosphatase 
activity induced by oxidative stress in HT22 cells and immature primary cortical cultures. 
A. HT22 cells were treated with glutamate or glutamate plus BHA for 7.5h. Twenty ug of total 
protein lysate was separated by SDS-PAGE and subjected to Western blot analysis to detect 
pERK1/2 and total ERK1/2 on the same blots. C=control cell lysates. The addition of BHA 
blocked ERK1/2 activation following glutamate-induced oxidative stress.   
 B. Immature primary cortical neuronal cultures were treated with HCA for either 0, 12, 14, or 16 
hr in the presence or absence of BHA. Twenty ug of total protein lysate was separated by SDS-
PAGE and subjected to Western blot analysis to detect pERK1/2 and total ERK1/2 on the same 
blots. The administration of BHA significantly blocks ERK1/2 activation following HCA 
treatment.  
C. Whole cell lysates prepared from control untreated (C), glutamate (G)-treated, or glutamate 
plus BHA-treated HT22 cells were incubated with purified pERK2, and phosphatase activity was 
assessed by Western blot that revealed either pERK2 or total ERK2. IN=ERK2 input. The 
addition of BHA reverses the glutamate-induced inhibition of ERK2 phosphatase activity. 
D. Whole cell extracts prepared from the control (C), HCA-treated, and HCA plus BHA-treated 
primary neuronal cultures were incubated with purified pERK2, and phosphatase activity was 
assessed by Western blot that revealed either pERK2 or total ERK2. IN=ERK2 input. The 
administration BHA reverses the inhibition of ERK2 phosphatase activity following HCA-
induced oxidative toxicity. 
 58 
E. Quantification of the results from 3 independent experiments. Co-administration of BHA 
abrogates the inhibition of ERK2 phosphatase activity in glutamate-treated HT22 cells. P<0.01. 
 F. Quantification of the results from 3 independent experiments. Co-administration of BHA 
abrogates the inhibition of ERK2 phosphatase activity in HCA-treated immature cortical 
cultures. P<0.001. 
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Figure 3.3 Zn2+ specifically inhibits ERK2 phosphatase activity in neuronal cell 
extracts. 
A. Various concentrations of ZnCl2 were pre-incubated with whole cell lysates prepared from 
untreated HT22 cells for 10 min at 37ºC before the addition of pERK2 substrate. ERK2 
dephosphorylation was monitored by Western blot analysis as described previously.  
B. Quantification of the results from 3 independent experiments. 10uM ZnCl2 significantly 
inhibits ERK2 phosphatase activity in HT22 cells. P<0.01. 
C. Various concentrations of ZnCl2 were pre-incubated with whole cell lysates prepared from 
untreated HT22 cells for 10 min at 37ºC before the addition of pJNK3 substrate. JNK3 
dephosphorylation was monitored by Western blot analysis as described previously. ZnCl2 does 
not inhibit JNK3 phosphatase activity in HT22 cell extracts. 
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Figure 3.4 Oxidative stress triggers zinc accumulation in HT22 cells and immature 
primary cortical neurons. 
A. HT22 cells were treated with glutamate for 8 hr and primary neuronal cultures were treated 
with HCA for 12 hr and loaded with FluoZin-3 for 30 min. The fluorescence imaging of 
intracellular zinc was then monitored by digital fluorescence microscopy and relative 
fluorescence was measured. There is a significant increase in zinc accumulation following 
oxidative stress in both HT22 cells and primary immature cortical neurons. 
B. Primary immature cortical neurons were treated with HCA, HCA+U0126, HCA+BHA as well 
as U0126 only and BHA only and then were loaded with FluoZin-3 to measure the relative 
fluorescence. Co-administration of U0126 decreases the zinc accumulation in HCA-treated 
primary cortical neurons to basal level. Similarly, the co-administration of BHA also decreases 
the zinc release in HCA-treated primary cortical neurons. 
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 Figure 3.5. TPEN blocks ERK1/2 activation and reverses the inhibition of ERK2 
phosphatase activity following oxidative stress in HT22 cells and immature cortical 
cultures. 
A. HT22 cells were treated with either glutamate, glutamate plus 1uM TPEN, glutamate plus 
5uM TPEN, or glutamate plus U0126 for 8h. Twenty ug of total protein lysate was separated by 
SDS-PAGE and subjected to Western blot analysis to detect pERK1/2 and total ERK1/2 on the 
same blots. C=control cell lysates. 5uM TPEN blocks ERK1/2 activation following glutamate 
treatment in HT22 cells. 
B. Immature primary cortical cultures were treated with either HCA, HCA plus 1uM TPEN, 
HCA plus 5uM TPEN, or HCA plus U0126 for 16h. 20ug of total protein lysate was separated 
by SDS-PAGE and subjected to Western blot analysis to detect pERK1/2 and total ERK1/2 on 
the same blots. C=control cell lysates. 5uM TPEN blocks ERK activation following HCA 
treatment in immature primary cortical cultures. 
C. An ERK2 phosphatase assay was performed on whole cell lysates prepared from either 
untreated HT22 cells, or cells treated with either glutamate, glutamate plus 1uM TPEN, or 
glutamate plus 5uM TPEN. TPEN reverses the inhibition of ERK2 phosphatase activity 
following glutamate treatment in HT22 cells. 
D. An ERK2 phosphatase assay was performed on whole cell lysates prepared from either 
untreated primary immature cortical neurons, or cells treated with either HCA, HCA plus 1uM 
TPEN, or HCA plus 5uM TPEN. TPEN reverses the inhibition of ERK2 phosphatase activity 
following HCA treatment in primary immature cortical neurons.   
E. Quantification of the ERK2 phosphatase activity results from 3 independent experiments in 
HT22 cells. P<0.05. 
F. Quantification of the ERK2 phosphatase assays results from 3 independent experiments in 
primary immature cortical neurons. P<0.05. 
G. An ERK2 phosphatase assay was performed on whole cell lysates prepared from either 
untreated HT22 cells, or cells treated with either glutamate, or glutamate plus 10uM U0126. The 
administration of U0126 reverses the inhibition of ERK2 phosphatase activity following 
glutamate treatment in HT22 cells. 
H. Quantification of the ERK2 phosphatase assay results from 3 independent experiments in 
HT22 cells. P<0.05. 
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Figure 3.6. TPEN blocks oxidative toxicity in HT22 cells and immature cortical 
cultures. 
A. HT22 cells were treated with either 1uM TPEN, 5uM TPEN, glutamate, glutamate plus 1uM 
TPEN, glutamate plus 5uM TPEN, or glutamate plus U0126. Toxicity was measured as the 
percentage of PI-positive cells after treatment for 12 h in the above groups. ***p<0.001. 5uM 
TPEN blocks glutamate-induced oxidative toxicity in HT22 cells. 
B. Immature primary cortical cultures were treated with either 1uM TPEN, 5uM TPEN, HCA, 
HCA plus 1uM TPEN, HCA plus 5uM TPEN or HCA plus U0126. Toxicity was measured as the 
percentage of PI-positive cells after treatment for 16 h in the above groups. ***p<0.001. 5uM 
TPEN blocks HCA-induced oxidative toxicity in immature primary cortical cultures 
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Figure 3.7 Mechanism of ERK1/2-dependent neuronal cell death triggered by ROS-
mediated Zn2+ accumulation. 
Accumulation of intracellular Zn2+ brought about by oxidative stress (ROS) in neurons inhibits 
protein phosphatases that act selectively on ERK1/2. The persistent activation of ERK1/2 
(pERK1/2) functions to promote cell death in part through a positive feedback loop that 
maintains elevated Zn2+ levels. 
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3.5 DISCUSSION 
ERK1/2 functions in many cell types to promote proliferation or survival but can also be diverted 
to participate in certain cell death pathways (Colucci-D'Amato et al., 2003; Chu et al., 2004). For 
example, chronic activation of ERK1/2 is necessary for cell death induced by oxidative stress in 
immature cortical neurons and HT22 cells (Satoh et al., 2000; Stanciu et al., 2000; Luo and 
DeFranco, 2006). In these cases, the inhibition of select protein phosphatases is primarily 
responsible for the persistent activation of ERK1/2 (Levinthal and DeFranco, 2005). This 
conclusion was confirmed in a recent report, which also revealed the minimal contribution of 
upstream activating kinases (i.e. MEK1/2) to prolonged ERK1/2 activation in oxidatively 
stressed HT22 cells and immature neurons (Choi et al., 2006).  
I show here that the inhibition of ERK1/2 phosphatases in HT22 cells and immature 
neurons subjected to glutathione depletion is indeed the result of oxidative stress as phosphatase 
activity is restored in cells treated with BHA. This leads to reduced ERK1/2 activation and 
neuroprotection. The oxidative inhibition of protein phosphatase activity in TNF-alpha treated 
fibroblasts is also eliminated by BHA treatment (Kamata et al., 2005).  However in TNF-α- 
induced oxidative toxicity and Concanavolin A-induced liver toxicity in mice, cell death is 
associated with the selective inhibition of JNK phosphatases (Kamata et al., 2005). Glutamate-
induced oxidative stress in immature neurons does not significantly affect JNK phosphatase 
activity (Levinthal and DeFranco, 2005).  Therefore, even though MAPK phosphatases are 
oxidant sensitive, they are not globally inactivated by oxidative stress in cells. Depending upon 
the nature of the oxidative stress imposed upon living cells, select MAPK phosphatases may be 
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protected from the damaging effects of reactive species due to their sequestration within 
subcellular compartments or multi-subunit complexes that are inaccessible to short-lived 
oxidants.  
While several protein phosphatases are redox sensitive and inhibited by direct thiol 
oxidation of a catalytic-site cysteine (Meng et al., 2002; Leslie et al., 2003; Sohn and Rudolph, 
2003; Tonks, 2003; Persson et al., 2004), our results suggest that MAPK phosphatase activity 
may also be regulated in oxidatively stressed cells by the inhibitory effects of free Zn2+. The 
sensitivity of various MAPK phosphatases to inhibition by Zn2+ was established with purified 
phosphatase preparations suggesting that Zn2+ can act directly to impact the activity of these 
enzymes (Brautigan et al., 1981; Zhuo and Dixon, 1997). Zn2+ mediated inhibition of PTPs has 
been suggested to impact insulin/IGF (Haase and Maret, 2003) or IL-8 (Kim et al., 2006) 
signaling in C6 glioblastoma or BEAS-2B human airway epithelial cells, respectively. Thus, 
Zn2+-mediated inhibition of protein phosphatase activity may not always be linked to cell death 
responses but could play a role in facilitating hormone signaling (Haase and Maret, 2003) or 
participate in activity-dependent neuronal plasticity (Klann and Thiels, 1999). However, 
prolonged inhibition of select MAPK phosphatases and ensuing persistent activation of specific 
MAPKs that drives toxicity in oxidatively stressed cells may reflect an inability to restore Zn2+ 
homeostasis (see below). 
For PSTPs, Zn2+ may exert its inhibitory effects through the displacement of bound Mn+2 
at the active site of their catalytic subunits (Zhuo and Dixon, 1997). Interestingly, purified 
PSTPs, such as PP2A, are refractory to exchange by Mn2+ once bound by Zn2+ and therefore 
limited recovery of their activity can be achieved by Zn2+ chelation in vitro (Zhuo and Dixon, 
1997). These potent inhibitory effects of Zn2+ on ERK1/2 phosphatases, such as PP2A, may 
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explain the requirement for a 5 uM TPEN treatment to reverse the inhibition of ERK1/2 
phosphatase activity in oxidatively stressed HT22 cells and immature neurons. Importantly, 5 
uM TPEN was also required to block glutamate- and HCA-induced toxicity in HT22 cells and 
immature neurons, respectively, showing a close association between the inhibition of ERK1/2 
activation, restoration of ERK1/2 phosphatase activity, and protection from oxidative stress. 
The specific ERK1/2 phosphatase that is subjected to oxidative stress-induced Zn2+ 
inhibition is not known. Previous results from our group suggest that PP2A is the major ERK1/2 
phosphatase in primary immature cortical neurons (Levinthal and DeFranco, 2005) and HT22 
cells (data not shown), but other MAPK phosphatases in these cells may also contribute to the 
regulation of ERK1/2 activation. In a recent report, glutamate treatment of HT22 cells and 
immature neurons was found to trigger the degradation of MKP1 (Choi et al., 2006). Although 
MKP1 exerts a minor albeit significant effect on ERK1/2 activation and glutamate toxicity in 
HT22 cells (Choi et al., 2006), the loss of this enzyme cannot be solely responsible for 
heightened ERK1/2 activation since ERK12 phosphatase activity in extracts from oxidatively 
stressed neurons can be restored in vitro with DTT (Levinthal and DeFranco, 2005). 
Furthermore, the JNK family of MAPKs is the preferred substrate of MKP1, which is 
inconsistent with the selective effects of oxidative stress in HT22 cells and immature neurons on 
ERK1/2 phosphatases. PP2A, the major ERK1/2 phosphatase in HT22 cells and immature 
neurons (Levinthal and DeFranco, 2005), exerts minimal effects on JNK activation, and thus is 
a better candidate for the selective MAPK phosphatase that is affected by Zn2+ in oxidatively 
stressed neuronal cells. 
Oxidative stress can trigger the release of intracellular stores of metal ions such as Zn2+ 
from redox-sensitive metal binding proteins. For example, a thiol oxidant, 2,2’-dithhildipyridine 
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(DTDP), has been shown to induce neuronal cell death by liberating Zn2+ from metal-containing 
proteins (Aizenman et al., 2000). Protein kinase C (PKC) delta can also release its bound Zn2+ 
when exposed to oxidants or lipid-derived signaling molecules (Knapp and Klann, 2000; 
Korichneva et al., 2002). Interestingly, PKC delta has recently been reported to be responsible 
for ERK1/2 activation and glutamate toxicity in HT22 cells and primary cortical neurons (Choi 
et al., 2006). Since activation of PKC delta is associated with release of its bound Zn2+ (Knapp 
and Klann, 2000; Korichneva et al., 2002), PKC delta could participate in ERK1/2-dependent 
toxicity through triggering the enhanced degradation of a dual-specificity protein phosphatase 
(DSP) acting on ERK1/2 (i.e. MKP1; (Choi et al., 2006) and/or providing free Zn2+ for 
reversible inhibition of an ERK1/2-selective PSTP (e.g., PP2A). Future work examining the 
impact of PKC delta on Zn2+ release may reveal whether such a dual regulation of ERK1/2 
activation by PKC delta operates in oxidatively stressed neurons.  
The decreased accumulation of free Zn2+ upon inhibition of ERK1/2 activation by U0126 
supports the existence of a positive feedback loop that not only provides conditions for the 
maintenance of ERK1/2 activation (i.e., through phosphatase inhibition) but also exacerbates 
cellular exposure to neurotoxic levels of free Zn2+ (Figure 7). In this case, ROS provide the 
trigger that acts to promote the release of protein-bound Zn2+, perhaps through thiol oxidation of 
specific cysteine residues that participate in Zn2+ binding (Aizenman et al., 2000; St Croix et al., 
2002). This model would be consistent with the failure of transfected constitutively active 
MEK1 to induce toxicity in HT22 cells despite a robust, persistent activation of ERK1/2 within 
either the cytoplasmic or nuclear compartment (Luo and DeFranco, 2006). Thus, ERK1/2 may 
prevent the repair of oxidatively damaged Zn2+ binding proteins or limit their expression (Jiang 
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et al., 2004a).  In the absence of oxidative damage to these proteins, chronic ERK1/2 activation 
may not impact intracellular Zn2+ homeostasis and promote cell death. 
In summary, we have identified an important regulatory feature of protein phosphatase 
regulation, namely, reversible Zn2+ inhibition, that triggers the persistent activation of a select 
MAPK signaling module in neurons. Furthermore, the oxidative induction of Zn2+ accumulation 
predisposes neurons cells to a positive feedback loop driven by ERK1/2 that disrupts Zn2+ 
homeostasis and further exacerbates cellular exposure to neurotoxic levels of free Zn2+.  
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4.0  MECHANISM OF PHOSPHATASE INHIBITION IN OXIDATIVELY 
STRESSED NEURONS 
4.1 SUMMARY 
Previous studies have shown that the reversible inhibition of ERK1/2 phosphatases contribute to 
ERK1/2-dependent oxidative toxicity in neurons. However, the specific ERK1/2 phosphatases 
and the mechanism of the oxidation and inactivation of ERK phosphatases have not been 
identified. This study examined the role of PP2A as the possible candidate for ERK 
dephosphorylation by utilizing specific inhibitors of PP2A. Using the method of thiol affinity 
chromatography, I have identified the thiol oxidation of cysteines in the PP2A catalytic subunit. 
Moreover, I have detected different patterns of migration of various PP2A regulatory subunits 
under reducing and non-reducing conditions, which suggests that PP2A regulatory subunits are 
differentially regulated by oxidative stress. However, the activity of the PP2A catalytic subunit is 
not affected following glutamate-induced toxicity in neurons. Altogether, these results suggest 
that thiol oxidation of cysteine residues in the catalytic subunit of PP2A may affect the activity 
of PP2A by affecting the association between regulatory subunits or associated factors with 
catalytic subunits, rather than by directly inactivating the total cellular pool of PP2A catalytic 
subunits.  
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4.2 INTRODUCTION 
In recent years, ROS have emerged as important regulators of many signaling pathways. For 
example, protein phosphatases have been identified as targets of ROS, suggesting that ROS 
mediate signaling pathways by changing the phosphorylation status of the signaling proteins. 
The mechanism of ROS-mediated inhibition of protein tyrosine phosphatases has been studied 
extensively (den Hertog et al., 2005; Tonks, 2005). PTPs bear a signature motif HC(X)5R in their 
active catalytic site and these cysteine residues are critical for the formation of a cysteine-
phospho intermediate involved in the catalytic function of PTPs. Due to the low pKa (~4.5) of 
these cysteines, they are very susceptible to oxidation, which leads to inactivation of the 
phosphatase.  DSPs have similar signature motif as PTPs and share the same mechanism of 
oxidation inhibition by ROS. Compared with PTPs/DSPs, the mechanism regulating oxidative 
inhibition of PSTPs, such as PP1, PP2A and PP2B (calcineurin), still remains vague. Calcineurin 
has been shown to be oxidatively inhibited by H2O2 through the oxidation of its dinuclear metal 
center (Fe2+-Zn2+) (Wang et al., 1996; Namgaladze et al., 2002) as well as the oxidation of two 
neighboring cysteines (Carballo et al., 1999; Bogumil et al., 2000).  
As the major PSTPs in eukaryotic cells, PP2A is composed of a core enzyme and various 
regulatory subunits. The core enzyme consists of a catalytic subunit (C subunit) and a structure 
subunit (A subunit) and forms complexes with a variety of regulatory subunits (B subunits) that 
regulate the substrate specificity and subcellular localization of the PP2A holoenzyme. Four 
different families of B subunits have been identified and each B subunit family contains multiple 
isoforms, resulting in a variety of holoenzyme combinations (Janssens and Goris, 2001). The 
specificity of the regulatory subunits determines the specificity of the substrates as well as the 
subcellular localization of PP2A. It has been shown that overexpression of PP2A Bγ subunit in 
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stably transfected PC6-3 neuronal cell line promotes cell differentiation (Strack, 2002), while in 
the same cell line, overexpression of neuronal-specific PP2A Bβ2 subunit promotes apoptosis 
induced by serum withdrawl (Dagda et al., 2003). The apoptosis induced by the latter is actually 
caused by the targeting to PP2A to mitochondria by PP2A Bβ2 subunits and mostly likely is 
through the dephosphorylation of various mitochondrial pro- and anti-apoptotic proteins (Dagda 
et al., 2003). Recently, it has been found that a PP2A associated factor α4 is required for the 
inhibition of apoptosis in thymocytes (Kong et al., 2004).  
ERK1/2 is one of the major targets of PP2A. Different subunits of PP2A have been 
associated with ERK1/2-dependent apoptosis or survival (Silverstein et al., 2002; Adams et al., 
2005; Van Kanegan et al., 2005), suggesting an important role of PP2A in regulating ERK1/2-
mediated signaling pathways as well as cellular responses. Recently, impairment of PP2A has 
been involved in a variety of oxidative stress-induced neurodegenerative diseases. Reduced 
PP2A activity has been associated with an enhanced activation of ERK1/2 and 
hyperphosphorylation of Tau, a specific ERK1/2 target, in Alzheimer’s disease (Gong et al., 
1995; Zhao et al., 2003). Transgenic mice expressing a mutant PP2A catalytic unit exhibit 
activation of ERK1/2 and JNK pathways as well as the phosphorylation of endogeneous tau, 
similar to the key pathological features in Alzheimer’s disease (Kins et al., 2001; Kins et al., 
2003). PP2A recently has been shown susceptible to H2O2 in aging fibroblasts (Kim et al., 2003) 
and brain tissues (Foley et al., 2004). Oxidation of cysteine residues may be responsible for 
oxidative inhibition of PP2A, since the inactivation of PP2A by ROS is thiol-dependent and 
reversible. However, the mechanism of thiol-oxidation mediated inactivation of PP2A by 
oxidative stress has not yet been elucidated.  
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We previously have shown that glutamate-induced oxidative stress reversibly inhibits 
ERK1/2 phosphatases activity in immature cortical neurons (Levinthal and DeFranco, 2005). 
However, the specific ERK1/2 phosphatase being inhibited as well as the mechanism of 
oxidation and inhibition of ERK1/2 phosphatase have not been identified yet. In the current 
study, we demonstrated that PP2A is the predominant ERK phosphatase in neurons. Moreover, 
cysteine thiol-oxidation of PP2A has been revealed although the association between thiol-
oxidation of PP2A, and its catalytic activity remains unclear.  
4.3 MATERIALS & METHODS 
ERK-directed phosphatase assay 
An ERK2-directed phosphatase assay was performed as described in the previous 
chapter. Where indicated, 2.5ug of SV40 small T antigen was incubated with control cell lysates 
of HT22 cells for 10 min at 37ºC before adding the pERK2 substrate. 1nM okadaic acid (OA) 
was incubated with control lysates from HT22 or primary neurons for 30 min on ice before 
adding the pERK2 substrate. 1ug of purified Inhibitor-2 (I2) was incubated with control lysates 
of primary neurons for 30 min on ice before adding the pERK2 substrate.  
 
Thiol affinity chromatography 
In collaboration with Drs. Pier Mastroberardino and Timothy Greenamyre, I adopted a 
thiol-affinity chromatography to enrich for proteins containing reversibly oxidized thiols 
following glutamate treatment in primary immature cortical neurons. Generally, cytosolic 
extracts cleared of intracellular organelles were subjected to iodoacetamide (IAA)/N-
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ethylmaleimide (NEM) treatment which could react and block reduced thiols in the extracts. The 
modified proteins were then precipitated by cold acetone to remove the excess IAA/NEM. 
Tributylphosphine (TBP) was then added to modified protein samples to reduce oxidized thiols. 
TBP treatment could only reduce the oxidized thiols formed before IAA/NEM blocking. TBP-
treated samples were then loaded to thiol-activated Sepharose 6B affinity columns (Upstate 
Biotechnology) for enrichment of proteins with TBP-reduced thiols. Then the proteins were 
eluted by the addition of 50 mM DTT. Eluted samples were then subjected to Western blot 
analysis using the antibody against the catalytic subunit of PP2A to detect the presence of 
reversibly oxidized thiols in PP2A C subunit. To show the equivalence of protein loading, same 
amounts of total protein were subjected to SDS-PAGE and silver staining.   
Details of the procedure are as follows. Firstly, dry thiol-sepharose resin (SIGMA, St. 
Louis, MO, USA) was rehydrated in milliQ grade distilled water for 30 min with gently shaking 
at 4°C. After centrifugation for 5 min at 500g, the sedimented resin was resuspended in 10 
volumes of 100mM TrisHCl, pH7.4, SDS 1% and incubated for 5 min with gently shaking at 
room temperature. This step was repeated for a total of three times. Cytosolic extracts cleared of 
intracellular organelles were then prepared from glutamate-treated or non-treated primary 
cortical neurons by ultracentrifugation at 100,000g for 1hr at 4ºC. The extracts were resuspended 
in 100mM TrisHCl, pH7.4, SDS 1% at the final concentration of 1mg/ml. Proteins were 
denatured heating the solution at 70°C for 5 min. N-ethylmaleimide (NEM) and iodoacetamide 
(IAA) were added at the final concentration of 50mM each. The mixture was incubated for 30 
min at 37°C and precipitated with 5 volumes of ice cold precipitation solution (50% acetone, 
25% methanol, 25% ethanol, 1 hr at  -80°C). After spinning (25 min, 3200g, 4°C), the pellet was 
resuspended in 1 ml Tris/SDS. As a pre-clearing step, the sample was then incubated with the 
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thiol-sepharose medium (200 ul, about 50 mg of dry resin) for 2 hrs at room temperature. After 
centrifugation for 5 min with 500g at room temperature, the supernatant was saved and 
tributylphosphine (TBP) in dimethylformamide (DMF) (20mM final concentration) was added to 
reduce cysteines previously engaged in disulfides. The mixture was incubated for 15 min at room 
temperature. A control reaction was performed incubating proteins in DMF omitting TBP. 
Proteins were then precipitated as above and resuspended in 4 ml of Tris/SDS. Affinity 
purification was performed with incubation for 2 hrs at room temperature, with the proteins 
mixed with 1ml of equilibrated resin (about 125mg of dry resin). To wash the resin after 
incubation, the sample was spun for 5 min with 500g at room temperature. The supernatant 
(unbound) was saved, the sedimented resin was resuspended in 10 volumes of Tris/SDS and 
shaken for 3 min at room temperature and spun again. A total of 3 washes were performed. 
Bound proteins were eluted incubating the resin (5 min with shaking at room temperature) with 
Tris/SDS buffer containing 40mM TBP or 100mM DTT. After centrifugation (5 minutes, 500g, 
room temperature), the supernatant (eluate) was saved and the sedimented resin was incubated 
again with Tris/SDS buffer containing 40mM TBP or 100mM DTT. The pooled supernatants 
were precipitated as above and used for electrophoresis. 
 
IP-PP2A phosphatase assays 
This assay was performed following the product protocol of an IP-PP2A phosphatase 
assay kit (Upstate Biotechnology, Catalogue number: 17-313). Briefly, cell extracts were 
prepared from untreated and glutamate 8-hr treated HT22 cells in a phophatase extraction buffer 
containing 20mM imidazole-HCl, 2mM EDTA, 2mM EGTA, pH 7.0, 1mM benzamidine, 1mM 
PMSF and supplemented with protease inhibitor cocktail (Sigma). The extracts were then 
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sonicated for 10 sec and centrifuged at 2000g for 5 min. The supernatants were used for 
phosphatase activity assays. Two hundred and fifty ug of cell extracts were immunoprecipitated 
with commercially available PP2A C subunit antibody and protein A agarose beads for 2 hr at 
4ºC. The immunocomplex was then washed three times with 1x TBS before incubating with a 
threonine phosphopeptide (K-R-pT-I-R-R) for 10 min at 30ºC. The activity of the PP2A C 
immunocomplex was then measured by dephosphorylation of this phosphopeptide with a 
colormetric assay using Malachite Green. 
4.4 RESULTS 
4.4.1 PP2A is the predominant ERK1/2 phosphatase in neuronal cells 
Using okadaic acid (OA), an inhibitor of PP2A, previous results from our lab suggested that 
PP2A is the major ERK1/2 phosphatase in primary immature cortical neurons (Levinthal and 
DeFranco, 2005). However, the dosage of OA (100nM) used in those studies was too high to 
determine the selectivity of OA in inhibiting PP2A or PP1. Therefore, in the current study, I 
utilized a specific peptide inhibitor of PP2A, SV40 small T antigen, to determine the contribution 
of PP2A to ERK1/2 phosphatase activity in neuronal cells. Small T antigen specifically inhibits 
PP2A by displacing the PR55-B subunit from PP2A holoenzymes (Sontag et al., 1993). In 
addition, I used the pharmacological inhibitor, OA, at a low dosage of 1nM, which specifically 
inhibits PP2A but not PP1. To determine the contribution of PP1 to ERK1/2 phosphatase 
activity, a specific peptide inhibitor of PP1, Inhibitor-2 (I2) was utilized. As shown in Fig 4.1, 
ERK2 phosphatase activity in HT22 cell extracts was inhibited by the addition of 1 nM OA or 
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SV40 small T antigen. Similarly, we have confirmed the role of PP2A in ERK2 
dephosphorylation in primary neurons (Fig 4.2). Treatment of extracts with the selective peptide 
inhibitor of PP1, Inhibitor-2 (I2), did not block ERK2 phosphatase activity (Fig 4.2). These data 
confirm that PP2A is the predominant ERK2 phosphatase in HT22 cells and primary cortical 
neurons. 
4.4.2 Reversible thiol oxidation of PP2A C subunit following glutamate treatment in 
primary immature cortical neurons 
Cytosolic extracts from 14-hr glutamate-treated or non-treated primary immature cortical 
neurons were subjected to thiol affinity chromatography (performed by Dr Pier Mastroberadino), 
and the eluates were analyzed for the presence of oxidized PP2A catalytic (C)-subunit by 
Western blots. As shown in Figure 4.3A, the signal of PP2A C-subunit in the eluates of the 
thiol-activated Sepharose 6B column was enhanced following glutamate treatment for 14 hr, 
which demonstrates the reversible thiol-oxidation in PP2A C subunit. Fig 4.3B showed the 
Commassie blue-staining following SDS-PAGE of 25% of eluate fractions loaded for Western 
blot analysis, which demonstrates the equivalence in the total loading protein. 
4.4.3 PP2A activity is not changed following glutamate treatment in HT22 cells 
To determine the effect of thiol-oxidation on the activity of PP2A C subunit, we performed an 
IP-PP2A phosphatase assay, which depends on the dephosphorylation of a threonine 
phosphopeptide (K-R-pT-I-R-R) to determine the activity of the immunoprecipitated PP2A 
complex. Cell lysates prepared from 8-hr glutamate-treated or non-treated HT22 cells were 
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immunoprecipitated with a commercially available PP2A C subunit antibody. The activity of the 
immunocomplex was then measured by the dephosphorylation of the phosphopeptide with a 
colormetric assay using Malachite green. As shown in Fig 4.4A, following glutamate treatment, 
there was no change in the activity of immunoprecipitated PP2A. The equivalence in the 
immunoprecipitated PP2A C subunit from glutamate-treated or non-treated HT22 cells was 
revealed by the Western blot analysis of the immunocomplex using antibody against PP2A C 
subunit (Fig 4.4B).  
4.4.4 Subunits of PP2A are differentially oxidized by glutamate-induced oxidative toxicity  
To further demonstrate the thiol oxidation of PP2A following glutamate-induced oxidative 
toxicity, SDS-PAGE was performed on either glutamate-treated or non-treated cell lysates in the 
absence of the reducing agent DTT. Western blot analysis was then performed using antibodies 
against different subunits of PP2A. As shown in Fig 4.5, PP2A C subunit could not be detected 
in SDS-PAGE in glutamate-treated cell lysates in the absence of DTT. Thus, in the absence of 
the reducing agent, PP2A may form into a high-molecular weight complex that can not enter into 
the gel. Similar results were also observed for the PP2A Bγ2 subunit (Fig 4.5). However, there 
was no difference between the migration patterns of the PP2A Bδ subunit, which suggests that 
different subunits of PP2A may be differentially susceptible to glutamate-induced oxidative 
stress. 
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Figure 4.1 PP2A is the predominant ERK phosphatase in HT22 cell extracts 
Whole cell lysates prepared from HT22 cells (HT) were incubated with purified pERK2 and 
phosphatase activity was evaluated by Western blot. Specific inhibitors of PP2A, 1nM okadaic 
acid (OA) or 2.5ug of purified small T antigen (tAg), were included with cell extracts. 
IN=phosphatase assay input. 
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Figure 4.2 PP2A contributes to ERK-directed phosphatase activity in immature 
primary cortical neurons. 
Whole cell lysates prepared from primary neuron culture (C) were incubated with purified 
pERK2 and phosphatase activity was assessed by Western blot. 1nM okadaic acid or 2 ug 
purified Inhibitor 2 (I2) was included with the neuronal cell extracts. IN=phosphatase asay input. 
λ=lambda phage protein phosphatase (positive control). 
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Figure 4.3 Reversible thiol-oxidation of PP2A C subunit following glutamate 
treatment in primary immature cortical neuronal cultures.  
Primary immature cortical neurons were either untreated (-) or treated with 5mM glutamate 
(Glu) for 14 hr. Cytosolic extracts underwent IAA/NEM modification followed by TBP 
reduction of reversibly oxidized thiols. Protein samples were then subjected to thiol-affinity 
chromatography and eluted with 50 mM DTT. 
A. Eluates from the column were detected with an antibody against the PP2A C subunit (*36 
kDa) by Western blot. C stands for control lysates which were not treated with TBP before 
affinity chromatography. This is a result representative of 3 independent experiments. 
B. Commassie blue-staining of SDS-PAGE loaded with 25% of eluate fractions for Western blot 
analysis 
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Figure 4.4 PP2A activity is not changed following glutamate treatment in HT22 
cells. 
A. Glutamate-treated or non-treated HT22 cell lysates were immunoprecipiated with an anti-
PP2A C subunit antibody. The activity of the immunocomplex was then assessed by measuring 
the dephosphorylation of a phosphopeptide by the immunocomplex with a colormetric assay 
using Malachite Green (Upstate Biotechnology). No change in PP2A activity was detected 
following glutamate treatment in HT22 cells (n=3). 
B. The equivalence in the immunoprecipitated PP2A C subunit from glutamate-treated or non-
treated HT22 cells was revealed by the Western blot analysis of the immunocomplex using an 
antibody against PP2A C subunit. 
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Figure 4.5 Subunits of PP2A are differentially susceptible to glutamate-induced 
oxidative toxicity. 
SDS-PAGE were performed on either glutamate-treated (Glu) or non-treated cell lysates (C) in 
the presence or absence  of the thiol-reducing agent DTT and Western blot analysis were 
performed using antibodies against different subunits of PP2A. The experiment on PP2A C 
subunit has been performed twice, whereas the experiment on PP2A B subunits has been 
performed once. 
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4.5 DISCUSSION 
Cellular redox status has long been known as an important regulator of a variety of normal 
cellular signaling events. Transient and reversible thiol oxidation and inactivation of protein 
tyrosine phosphatases regulates the tyrosine phosphorylation-dependent signaling pathways 
mediated by numerous growth factors. Thiol oxidation of the sensitive catalytic cysteines in 
protein tyrosine phosphatases involves both reversible and irreversible mechanisms (Barford, 
2004). Reversible mechanisms include the oxidation of catalytic cysteines to sulfenic acid (Meng 
et al., 2002),  the intramolecular formation of disulfide bonds between catalytic cysteine and its 
neighboring cysteine (Savitsky and Finkel, 2002), as well as  the formation of a novel structure, 
sulfenylamide, which is not susceptible to further oxidation (Salmeen et al., 2003; van Montfort 
et al., 2003). Further oxidation of sulfenic acid to sulfinic acid and sulfonic acid are all 
irreversible (Denu and Tanner, 1998).  
Mechanisms of oxidative inhibition of PSTPs are not well understood. Due to the 
presence of the bi-nuclear metal clusters in the active site of STPPs, one mechanism responsible 
for oxidative inhibition of the activity of STPPs may involve the oxidation of these catalytic 
metal centers. Redox regulation of calcineurin has been shown to occur through the targeting of 
the Fe2+-Zn2+ center at the active site of the enzyme (Namgaladze et al., 2002). Recently, 
cysteine oxidation and inactivation of calcineurin (Bogumil et al., 2000) and PP1 (Kim et al., 
2003) have been revealed, which suggests that thiol oxidation may be another mechanism for 
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inhibiting these enzymes. The role of thiol oxidation in regulating the activity of PP2A remains 
unclear, although PP2A inactivated by H2O2 in Caco-2 cells (Rao and Clayton, 2002) and brain 
extracts (Foley et al., 2004) is reversible by the thiol reducing agent DTT. The current study 
shows the first direct evidence of reversible cysteine thiol oxidation in PP2A C subunit following 
oxidative stress. However, these modifications of PP2A C subunit were not associated with 
alterations in the overall PP2A activity following glutamate-induced oxidative stress.  
There are six conserved cysteine residues in the catalytic subunit of PP2A although they 
are not considered critical for the catalysis of PP2A (Green et al., 1987). It is possible that the 
modification of PP2A C subunit may not change its overall activity but affect its association with 
various B regulatory subunits or selective substrate as well as subcellular localization. Therefore, 
it would be essential to identify the specific cysteine residue being thiol-oxidized and examine 
the effects of these modifications on the activity of PP2A. Furthermore, the antibody we used in 
IP-PP2A phosphatase assay detects the total PP2A pool. It is possible that only a subset of PP2A 
was oxidized and inactivated while the changes in total PP2A activity could not be detected. 
Indeed, it has been shown that only the sub-pool of PP2A associated with the rebinoblastoma 
protein (pRb), but not the total PP2A pool, is specifically modulated by H2O2 in HUVEC 
endothelial cells (Cicchillitti et al., 2003). Therefore, it might be useful for future studies to 
examine the activity of PP2A associated with ERK following glutamate-induced oxidative stress. 
 Since we have observed different susceptibility of PP2A B subunits to oxidative stress 
(Fig 4.5), it may be very possible that only a certain B subunit is sensitive to oxidation. This 
affects the activity of the subset of PP2A holoenzymes associated with this specific B subunit. 
PP2A B subunits are critical in regulating PP2A holoenzyme’s activity. First, B subunits 
determine the distinct subcellular compartmentalizations of PP2A holoenzymes. For example, 
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Bα and Bγ have been found to direct PP2A to microtubules and cytoskeletal substrates (Sontag 
et al., 1995; Strack et al., 1998). B’α, B’β and B’ε subunits target PP2A to the cytosol, whereas 
B’δ and B’γ target PP2A to the nucleus (McCright et al., 1996). A recent report has shown that 
the Bβ2 subunit, a neuronal-specific regulatory subunit of PP2A, localizes and targets the PP2A 
holoenzyme to the outer membrane of mitochondria (Dagda et al., 2005). Second, B subunits 
determine the substrate specificity of PP2A. It has been shown that in PC6-3 neuronal cell lines, 
Bα and Bδ subunits target PP2A to the dephosphorylation of ERK whereas specific B’ subunits 
regulate Akt activity (Van Kanegan et al., 2005). Third, even in the same cell type and in the 
regulation of the same specific target, distinct B regulatory subunit confers different effects. For 
example, in PC6-3 cells, overexpression of the Bγ subunit activates ERK signaling (Strack, 
2002) whereas silencing of Bα and Bδ subunits disinhibits ERK activation (Van Kanegan et al., 
2005). This suggests that by regulating different targets in the ERK signaling pathways, B 
subunits of PP2A are involved in both positive and negative regulation of the ERK cascade. 
Fourth, the regulation of specific targets by the same B regulatory subunits is cell-type specific. 
Strack’s group has found that Bα and Bδ subunits negatively regulate ERK activation in PC6-3 
cells (Van Kanegan et al., 2005), whereas they positively regulate ERK activation in HEK cells 
through the dephosphorylation of phosphor-Ser-259 inhibitory site in Raf1, which results in the 
subsequent MEK1 and ERK1/2 activation (Adams et al., 2005) Taken together, these studies 
point to the complexity of regulating PP2A holoenzyme activity by distinct B subunits. By 
bringing PP2A to appropriate cellular sites and dephosphorylating distinct substrates in different 
compartments in a cell-specific way, B subunits determine the diverse biological effects brought 
about by PP2A. Therefore, future studies will focus on the regulation of distinct B subunits by 
glutamate-induced oxidative stress. It might be useful for future studies to detect the PP2A 
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phosphatase activity associated with specific B subunits by immunoprecipitating the PP2A 
holoenzyme with specific B subunit antibodies. 
DSPs bear the same signature motif HC(X)5R in their active catalytic site as PTPs. 
Therefore, DSPs may share the same mechanism of thiol oxidation of PTPs. A recent report has 
shown that proteasomal degradation of MKP1, an ERK1/2 phosphatase, contributes to 
glutamate-induced neuronal death in HT22 cells and primary immature cortical neurons (Choi et 
al., 2006). This suggests that MKP1 is another ERK1/2 phosphatase susceptible to oxidation. 
Indeed, previous studies have shown that a pool of ERK1/2 phosphatases are composed of PTPs 
and DSPs that are sensitive to orthovanadate (Levinthal and DeFranco, 2005). Moreover, a 
recent study has demonstrated that thiol oxidation and inhibition of MKPs, including MKP1, 
contribute to TNFα-mediated sustained JNK activation and subsequent cell death in fibroblast 
(Kamata et al., 2005). All these clues point to the possible role of MKP1 as a possible candidate 
of ERK phosphatase that is thiol-oxidized and inactivated in HT22 cells and primary immature 
cortical neurons. Further study will be focused on revealing the reversible thiol oxidation of 
MKP1 using thiol affinity chromatography as well as non-reducing SDS-PAGE. Moreover, the 
activity of MKP1 following glutamate-induced oxidative stress could be investigated using an 
IP-phosphatase assay. 
The results presented here have confirmed that PP2A contributes to ERK-directed 
phosphatase activity in HT22 cells and primary cortical neurons as shown in previous studies 
from our lab (Levinthal and DeFranco, 2005). Moreover, we have provided the first direct 
evidence of reversible thiol oxidation of the cysteine residues on PP2A C subunit by using a 
novel thiol-affinity chromatography procedure. The feasibility of this method could be extended 
to the study of thiol oxidation of other possible candidates of ERK phosphatases, such as MKP1. 
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The thiol modification of PP2A C subunit may not directly affect its catalytic activity but more 
likely alters the association with regulatory subunits or specific substrates. We are now engaged 
in determining the effect of oxidative stress in altering the association between the PP2A C 
subunit and its selective substrate, ERK1/2, in our model. 
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5.0  INHIBITION OF MAPK PHOSPHATASES IN RODENT ISCHEMIA MODELS 
5.1 SUMMARY 
Oxidative stress after cerebral ischemia and reperfusion activates ERK1/2 in the brain. However, 
the mechanism of this activation has not been elucidated. We have previously reported that in an 
in vitro model of oxidative stress in immature cortical neuronal cultures, the inhibition of 
ERK1/2 phosphatase activity contributes to ERK1/2 activation and subsequent neuronal toxicity. 
The current study examined whether ERK1/2 activation was associated with altered activity of 
ERK1/2 phosphatases in a transient focal ischemia (middle cerebral artery occlusion – MCAO) 
model in mice and a global ischemia model in rat (asphyxia-induced cardiac arrest model). 
Consistent with previous reports, significant ERK1/2 activation was detected in ischemic cortex 
following MCAO. Furthermore, ERK1/2 phosphatase activity was inhibited in ischemia cortex 
but not affected in the contralateral non-ischemic side. This phosphatase inhibition was selective, 
as JNK phosphatase activity was not affected by ischemia/reperfusion. I then proceeded to 
examine the role of ERK1/2 phosphatase inhibition in activating ERK1/2 following 
ischemia/reperfusion in rat cardiac arrest model. ERK1/2 activation was revealed in both 
ischemic cerebral cortex and ischemic hippocampus. However, reversible inhibition of ERK1/2 
phosphatase activity was only observed in the cerebral cortex but not affected in the 
hippocampus following ischemia/reperfusion. MEK1/2 was activated in both the cerebral cortex 
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and the hippocampus following ischemia/reperfusion. Using a specific inhibitor of protein 
phosphatase 2A (PP2A), okadaic acid (OA), I established that PP2A is the major ERK1/2 
phosphatase that is responsible for regulating ERK1/2 activation in ischemic brain tissues. 
Orthovanadate inhibited ERK1/2 phosphatase activity in brain tissues, which suggests that PTPs 
and DSPs may also contribute to the ERK1/2 phosphatase activity in brain tissues.  Together, 
these data establish a role of a specific inhibition of ERK1/2 phosphatase in ERK1/2 activation 
following ischemia/reperfusion. Moreover, different mechanisms for regulating ERK1/2 
activation in distinct brain regions following global ischemia/reperfusion have been revealed.  
5.2 INTRODUCTION 
Oxidative stress is generated in many tissues including in brain following ischemia and 
reperfusion.  Increased levels of oxidized lipids, proteins, and nucleic acids are observed after 
reperfusion with oxygenated blood but do not accompany the initial ischemic event. The 
depletion of antioxidants observed soon after reperfusion (i.e., 10 min) contributes to the 
accumulation of damaging ROS (Katz et al., 1998). In reperfusion that occurs in brain tissue 
following global ischemia, antioxidants recover within 120 min. Nonetheless, this transient 
reperfusion-induced oxidation appears to contribute to neuronal injury that occurs following both 
transient global and focal ischemia. 
Cerebral ischemia and reperfusion produces multiple changes in cellular signaling.  
Specifically, kinases in the MAPK family are activated during reperfusion after both focal 
(Alessandrini et al., 1999; Noshita et al., 2002) and global ischemia (Hicks et al., 2000b; Hu et 
al., 2000). Members of the MAPK family that are activated during reperfusion include ERK and 
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JNK. The activation of MAPKs after ischemia is multiphasic, including both an early-onset, 
rapid increase during the first 30-60 min of reperfusion, and a later-onset, more protracted 
increase between 12 and 24 hours after reperfusion (Hicks et al., 2000a; Hicks et al., 2000b). In a 
transient focal ischemia model, ERK1/2 activation was found 5 min following 
ischemia/reperfusion and persists for several hours (Alessandrini et al., 1999; Namura et al., 
2001; Noshita et al., 2002). After global ischemia/reperfusion, ERK1/2 activation has also been 
noted both at 30 min and to persist up to 24 hours (Hicks et al., 2000b; Hu et al., 2000; D'Cruz et 
al., 2002). 
ERK1/2 activation is a well-established response in many cells to stimulation by 
mitogens, such as neurotrophins, and results in neuronal proliferation and differentiation in vitro 
(Pearson et al., 2001). Increased ERK1/2 activation also is associated with cell survival in some 
in vivo systems.  After global ischemia ERK1/2 was activated after 30 min of reperfusion in 
surviving dentate gyrus (DG) cells, but not in vulnerable hippocampal CA1 neurons (Hu et al., 
2000). We previously reported that in a rat asphyxial cardiac arrest model, a regimen of 
hypothermia that decreases hippocampal neuronal death increases ERK activation in the 
hippocampus (Hicks et al., 2000b).  
In contrast, a growing body of studies has revealed a role of ERK1/2 in neuronal death. 
For example, pharmacological inhibition of ERK1/2 activation using U0126, a specific MEK1/2 
inhibitor, reduced neuronal injury that results from focal ischemia (Alessandrini et al., 1999; 
Namura et al., 2001). ERK1/2 activation has been found to be necessary for neuronal toxicity in 
vitro in response to various cell death inducing stimuli, such as glutamate (Stanciu et al., 2000; 
Levinthal and DeFranco, 2004), zinc (Seo et al., 2001), Fe/Amyloid beta (Kuperstein and Yavin, 
2002), 6-hydroxydopamine (Kulich and Chu, 2001), and methylisothiazolinone (Du et al., 2002). 
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ERK1/2 activity is regulated by its phosphorylation state, which is the result of the 
balanced action of both ERK1/2 kinases and ERK1/2-directed protein phosphatases. The 
immediate upstream kinase of ERK1/2 is MEK1/2. MEK1/2 is also activated by phosphorylation 
utilizing kinases in the Raf family including A-Raf, B-Raf and Raf-1 (Pearson et al., 2001).   
Protein phosphatases that can affect ERK1/2 phosphorylation include PTPs, PTSPs, and DSPs 
(Keyse, 2000). PP2A (Silverstein et al., 2002; Kim et al., 2003) and MKP3 (Camps et al., 2000) 
are two major ERK phosphatases. 
We have previously shown that ERK1/2 activation following oxidative stress in 
immature primary neuronal cultures is driven by the oxidative inhibition of ERK1/2 
phosphatases (Levinthal and DeFranco, 2005). However, whether the inhibition of ERK1/2 
phosphatase is associated with ERK1/2 activation following oxidative stress conditions in vivo, 
i.e., after ischemia/reperfusion, is not known. Moreover, the relative contribution of upstream 
kinases and phosphatase activity to ERK1/2 activation after ischemia/reperfusion remain elusive. 
Therefore, this study tested whether ERK1/2 activation was associated with altered activity of 
ERK1/2 phosphatases in an in vivo ischemia/reperfusion model. A mouse transient focal 
ischemia (middle cerebral artery occlusion – MCAO) model and a global ischemia model in rat 
(asphyxia-induced cardiac arrest model) have been employed for the study.  
5.3 MATERIALS AND METHODS 
MCAO model of focal ischemia 
In collaboration with Dr Jun Chen in the Department of Neurology in the University of 
Pittsburgh, transient focal cerebral ischemia was produced by intraluminal occlusion of the left 
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middle cerebral artery (MCA) as described (Yang and Betz, 1994; Cao et al., 2002). The animals 
undergo left MCA occlusion for 60 min and then reperfusion for certain period of time. Control 
animals are sham animals with anesthesia and surgical procedure without MCAO.  Changes in 
regional cerebral blood flow (rCBF) before, during, and after MCAO will be monitored by laser-
Doppler flowmetry (Cao et al., 2002). If the laser Doppler signal declines >75% from baseline, 
MCAO surgery is considered successful.  All the surgery procedures were performed by Dr. 
Feng Zhang in Dr. Jun Chen’s lab. 
 
Global ischemia model- asphyxia-induced cardiac arrest 
Male Sprague-Dawley rats (n=18) weighing 300-350 g were housed individually with food and 
water ad libitum. Rats were randomly assigned to three treatment groups: sham (n=6), asphyxial 
cardiac arrest without resuscitation (n=6), or asphyxial cardiac arrest followed by 30 min of 
reperfusion (n=6). Sham rats received anesthesia and surgery but were not subjected to asphyxia.  
All the surgery procedures were performed by Rick Logue in Dr. Cliff Callaway’s lab. During 
procedures, body temperature was monitored by computer and regulated via computer-driven 
relays connected to a 100-W heating lamp and a cooling fan (Hicks et al., 2000a). At least 3 days 
prior to the procedure, a 5-mm, 20-gauge stainless steel guide-cannula was stereotactically 
placed over the parietal cortex to allow placement of a battery-operated, wireless temperature 
probe (XH-FM-BP, MiniMitter, Sun River, OR, U.S.A.). All rats were maintained at 37ºC 
during procedures until sacrifice. 
In order to induce asphyxia, rats were anesthetized with halothane, orotracheally 
intubated, and mechanically ventilated as described previously (Hicks et al., 2000a; Hicks et al., 
2000b).  Ventilation was titrated to blood gases monitored via femoral arterial catheters.  Rats 
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were paralyzed chemically with vecuronium (2 mg/kg), halothane was discontinued, and the 
fraction of inspired oxygen was reduced to 0.21 (room air) for 2 min.  Mechanical ventilation 
was discontinued at end-expiration for 8 min, resulting in bradyasystolic circulatory arrest.  For 
rats undergoing resuscitation, ventilation resumed with 100% oxygen, chest compressions were 
delivered at 200/min, and intravenous epinephrine (0.005 mg/kg) and bicarbonate (1 mEq/kg) 
were injected.  These interventions reliably restored pulses within 30-60 sec.  Rats were 
supported with mechanical ventilation until sacrifice. 
Sham rats were sacrificed by decapitation after surgery and vecuronium administration, 
but prior to asphyxia.  Asphyxia rats were sacrificed by decapitation after 8 min of asphyxial 
cardiac arrest.  Resuscitated rats were sacrificed 30 min after restoration of circulation by 
restarting halothane and then decapitation. Brains were dissected into chilled phosphate buffered 
saline (PBS) and cooled for 1 min. The cerebral cortex and hippocampus were dissected onto a 
cold metal stage and then frozen at -70ºC. 
 
ERK1/2-directed phosphatase activity assay  
Frozen tissues were solubilized by sonication for 5 sec on ice in 0.5ml of lysis buffer (50mM 
Tris-Cl, pH7.5, 2mM EDTA, 100mM NaCl, 1% Nonidet P-40, supplemented with protease 
inhibitor (Protease inhibitor cocktail, Sigma). The solubilized tissues were then centrifuged at 
13,000 rpm for 5 min at 4ºC and supernatants were collected for further analysis. 
We have modified a nonradioactive method for determining ERK1/2-directed 
phosphatase activity in tissue extracts (Laakko and Juliano, 2003). This method relies on 
detecting dephosphorylation of a purified, dual-phosphorylated, His6-tagged ERK2 upon 
incubation with the tissue extracts (Levinthal and DeFranco, 2005). The alterations of ERK2 
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phosphatase activity within the tissue extracts can be monitored by measuring changes in the 
phosphorylation state of the isolated pERK2 substrate, as shown by Western blotting with a 
phospho-specific ERK1/2 antibody. Briefly, 150ug of tissue extracts were diluted into a total 
volume of 250ul in phosphatase assay buffer (10mM MgCl2, 10mM Hepes, pH7.5 and 10uM of 
the MEK inhibitor, U0126). Recombinant dual phosphorylated His6-ERK2 (Biomol, Plymouth 
Meeting, PA) was added to each sample (30ng/sample), and the reactions were maintained at 
37ºC for 15 min where indicated. Either 50mM DTT or 10nM okadaic acid (OA) or 1mM 
Na3VO4 was added to the sample for 30 min on ice, prior to the addition of purified pERK. 
Following a 15-min incubation at 37ºC, the reactions were stopped by the addition of 250ul of 
wash buffer (8M urea, pH8.6, containing 10mM imidazole). 30ul of Ni2+-conjugated, magnetic 
beads (Qiagen, Valencia, CA) were then added to each reaction. After 90 min of rocking at 4ºC, 
the samples were washed twice with wash buffer followed by one wash in 300mM NaCl, 25mM 
Tris, pH7.5. The beads were then suspended in Laemmli sample buffer, boiled for 5 min, loaded 
onto a 10% polyacrylamide gel, transferred to a polyvinylidine fluoride membrane (Millipore, 
Bedford, MA), and subjected to Western blotting to detect phosphorylated ERK and total ERK. 
 
JNK3-directed phosphatase activity assay  
This method was performed exactly the same as described for ERK2 phosphatase assay, except 
that the samples were incubated with 30ng of purified, dual-phosphorylated His6-tagged JNK3 
protein (Upstate, Waltham, MA), and immunoblotted with anti-phospho-JNK and total JNK 
antibodies (from Cell Signaling). 
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Immunoblot analysis  
The tissue extracts were obtained as described above. Protein concentrations of the extracts were 
determined using the Bio-rad reagent. Equivalent amounts of total protein (20-30ug) were 
separated by SDS-PAGE on 10% polyacrylamide gels and then transferred to polyvinylidine 
membranes (Millipore). Membranes were blocked with 5% dry milk in PBS/0.1% (v/v) Tween 
20 (PBST). Membranes were then incubated with primary antibodies (anti-phospho-ERK, anti-
total ERK, anti-phospho-MEK1, anti-total MEK1, all from Cell Signaling) overnight at 4ºC with 
2% BSA in PBST. The membranes were then washed three times with PBST (10 min each time), 
incubated with the appropriate horseradish, peroxidase-conjugated secondary antibody for 40 
min at room temperature and followed by three time washes with PBST.  Immunoreactive bands 
were then revealed by enhanced chemiluminescence (ECL, Amersham Biosciences) using 
standard x-ray film (Eastern Kodak Co., Rochester, NY). Densitometry was performed using a 
Personal Densitometer SI (Amersham Biosciences) linked to the ImageQuant 5.2 software 
(Amersham Biosciences).  
 
Statistical Analysis 
Comparison of two means were performed using a paired t-test. Comparison of multiple mean 
values were performed by analysis of variance with Bonferroni’s post hoc tests for significance. 
A p-value of <0.05 was considered to be significant. All data were analyzed using GraphPad 
Prism version 4.0 for Windows (GraphPad Software, San Diego, CA).  
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5.4 RESULTS 
5.4.1 ERK2 phosphatase activity is specifically inhibited in ischemic/reperfusion cerebral 
cortex following MCAO 
I have utilized a transient focal ischemia model (i.e. MCAO) in mice to evaluate the effects of 
oxidative stress induced by acute brain injury on MAPK phosphatases. Western blot analysis has 
been performed on lysates from ischemic tissues and contralateral non-ischemic tissues as well 
as tissues from control animal. Increased activation of ERK1/2 has been revealed in the ischemic 
cortex as early as 5 min and 60 min after initiation of reperfusion following MCAO (Fig 5.1). 
These data are consistent with previous reports of ERK1/2 activation during 
ischemia/reperfusion following transient MCAO (Alessandrini et al., 1999; Namura et al., 2001; 
Noshita et al., 2002). I then proceeded to examine whether inhibition of ERK1/2-directed 
phosphatase activity contributes to ERK1/2 hyperphosphorylation following 
ischemia/reperfusion. Phosphatase activity was measured in brain extracts using His6-tagged 
pERK2 as a substrate. As shown in Fig 5.2, ERK1/2 phosphatase activity was inhibited in 
extracts isolated from the cerebral cortex of the ischemic hemisphere of MCAO mice. To assess 
if the inhibition of phosphatase activity was specific to a ERK2 phosphatase, JNK3 was used as a 
substrate in the in vitro phosphatase assays (Fig 5.3). There is no difference between the JNK3 
phosphatase activity in the extracts from cerebral cortex in the ischemic hemisphere and the 
contralateral hemisphere (Fig 5.3). Therefore, these results suggest that selective inhibition of 
ERK1/2 phosphatase may contribute to the ERK1/2 activation in vulnerable brain regions 
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following transient focal ischemia.  The result is still preliminary since one more set of samples 
will be needed to perform statistical analysis (n=2). Moreover, I am currently investigating the 
effects of longer reperfusion (3h and 6h) on the inhibition of ERK phosphatases following 
MCAO in mice. 
5.4.2 ERK2 phosphatase activity is specifically inhibited in ischemic/reperfusion cerebral 
cortex in cardiac arrest model 
We previously reported that increased activation of ERK1/2 occurs within 12 h of reperfusion 
following asphyxial-induced cardiac arrest and persists for at least 24 h post-
ischemia/reperfusion (Hicks et al., 2000b). It has been shown that the early post-ischemic period 
is associated with a large increase in oxidation (Katz et al., 1998). To investigate the effect of 
ischemia-induced oxidation stress on ERK1/2 activation in global ischemia, I first examined 
whether ERK1/2 activation was associated with the early post-ischemic period in brain tissues 
following cardiac arrest. As the cerebral cortex is one of the major sites of damage following 
cardiac arrest, extracts were prepared from adult male rat cerebral cortex isolated 30 min 
following global ischemia/reperfusion or from the cortex of control rats. Western blot analysis 
was performed to detect pERK1/2 and total ERK1/2. We found that ERK1/2 was dramatically 
activated in cortex following ischemia/reperfusion but not in the cortex of sham animals or the 
cortex of ischemia/non-reperfusion animals (Fig 5.4A). To reveal whether the inhibition of ERK-
directed phosphatases by ischemia-induced oxidative stress contributes to the post-ischemic 
ERK1/2 hyperphosphorylation, ERK2 phosphatase activity was measured in extracts prepared 
from adult male rat cerebral cortex isolated 30 min following global ischemia/reperfusion or 
control groups using His6-tagged pERK2 as a substrate. Compared with the robust ERK2 
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phosphatase activity in extracts of sham and ischemia/no reperfusion animals, ERK2-directed 
phosphatase activity in extracts from animals subjected to ischemia and a 30-min reperfusion 
decreased significantly (Fig 5.4B, C). The effect of ischemia/reperfusion on ERK2-directed 
phosphatases is selective as the phosophatases in cortical extracts that act on the MAPK family 
member JNK were not affected (Fig 5.4D). 
5.4.3 DTT can reverse the inhibition of ERK2 phosphatase activity in cerebral cortex 
following ischemia/reperfusion 
The selective inhibition of ERK1/2-directed phosphatase activity that occurs in oxidatively 
stressed primary neuronal cultures can be reversed upon the addition of DTT to neuronal extracts 
(Levinthal and DeFranco, 2005). I therefore added 50mM DTT to extracts of the cerebral cortex 
prepared following 30 min post-ischemia to examine whether the inhibition of ERK1/2 
phosphatase activity following ischemia/reperfusion is reversible. The inhibition of ERK2-
directed phosphatase activity could be reversed by the addition of 50mM DTT to extracts 
prepared from ischemic cortical tissues (Fig 5.5A, B). Together with Fig 5.4, these results 
suggest that analogous to in vitro models of neuronal oxidative toxicity, the activation of 
ERK1/2 in cerebral cortex 30 min following global ischemia/reperfusion is driven in part by 
reversible inhibition of some ERK1/2-directed phosphatases. 
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5.4.4 ERK2 phosphatase activity is not changed in hippocampus following 
ischemia/reperfusion hippocampus 
In addition to the cortex, global ischemia can affect multiple brain regions, including the  
hippocampus (Katz et al., 1998). As observed in cortex, ERK1/2 is significantly activated in the 
hippocampus 30 min following ischemia/reperfusion (Fig 5.6A). I therefore examined that 
whether the inhibition of ERK phosphatase activity in the hippocampus contributes to ERK 
activation 30 min following ischemia/reperfusion. Interestingly, unlike the cortex, ERK 
phosphatase activity in hippocampus was not altered within 30 min of ischemia/reperfusion (Fig 
5.6B, C). Thus, the robust activation of ERK1/2 in hippocampus at early times of reperfusion 
following global ischemia was not due to effects on ERK phosphatase activity, at least as 
measured in crude extracts.  
5.4.5 pMEK is activated in cerebral cortex and hippocampus following 
ischemia/reperfusion 
The activation state of ERK1/2 reflects the balance of its upstream activating kinase and 
inhibiting phosphatase. MEK1/2 is the upstream activating kinase of ERK1/2, and the activation 
state of MEK1/2 is reflected by its phosphorylation. Therefore, I examined whether MEK1/2 was 
activated in brain regions following ischemia/reperfusion. The level of activated MEK1/2 is 
increased in both cerebral cortex and hippocampus following ischemia/reperfusion when 
compared with control groups (Fig 5.7). Together with previous results on ERK2 phosphatase 
activity, these results strongly suggest that different mechanisms account for ERK1/2 activation 
in distinct brain regions following ischemia/reperfusion in global ischemia.  
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5.4.6 PP2A is the predominant ERK2 phosphatase in rat brain 
A major component of ERK phosphatase activity in neurons is contributed by PP2A, a PSTP 
(Millward et al., 1999; Virshup, 2000). To determine the contribution of PP2A to ERK1/2 
dephosphorylation in rat brain tissues, a specific inhibitor, OA, was utilized. OA is a well-
characterized PSTP inhibitor with a high degree of selectivity at low concentrations for PP2A. 
The addition of OA at the concentration that selectively blocks PP2A (10nM) , inhibited the 
robust ERK2-directed phosphatase activity in extracts prepared from normal cerebral cortex (Fig 
5.8A, 8B) and hippocampus (Fig 5.8D, 8E) in rats, suggesting that PP2A is likely to be the 
predominant ERK2-directed phosphatase in these brain regions. Furthermore, these results show 
that both hippocampus and cortex contain active PP2A, although it is differentially responsive to 
ischemia/reperfusion injury in these tissues (see Fig 5.4C, 5.7C). Western blot using an antibody 
against the PP2A C-subunit showed that the level of PP2A did not change following 
ischemia/reperfusion in both cerebral cortex and hippocampus (Fig 5.8C, 8F).  
5.4.7 Tyrosine and dual-specificity phosphatases also contribute to ERK2 phosphatase 
activity in rat brain 
Sodium orthovanadate is a potent inhibitor of PTPs and DSPs and does not affect PSTPs. To 
examine the role of PTPs and DSPs in the observed ERK2 phosphatase activity in rat brain, we 
treated lysates from the cortex of sham animals with 1mM Na3VO4. Orthovanadate dramatically 
inhibited ERK2 phosphatase activity in extracts from cortex in sham animals (Fig 5.9A&B). The 
extent of inhibition observed with orthovanadate was less than that observed with OA, 
confirming the predominant role of PP2A in ERK2-directed phosphatase activity in rat brain 
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(Fig 5.9C). However, PTPs and/or DSPs seem to play some roles in dephosphorylating ERK1/2 
in rat brain. 
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Figure 5.1 Activation of ERK1/2 in cerebral cortex following MCAO. 
Western blot analysis was performed using extracts prepared at various times of reperfusion 
following MCAO mice from ischemic (I) and contralateral (C) non-ischemic tissue. Cerebral 
cortical tissue was also isolated from normal animals (N). ERK1/2 phosphorylation (pERK1/2) 
and total ERK1/2 levels were determined in same blot following the stripping of phospho-
ERK1/2 antibody (n=2). 
 
 
 
Figure 5.2 Inhibition of ERK2 phosphatase activity in cerebral cortex following 
MCAO. 
ERK2 phosphatase assays were performed using cerebral cortical extracts prepared at various 
times of reperfusion following MCAO in mice from ischemic (I) and contralateral (C) non-
ischemic tissue. Cerebral cortical tissue was also isolated from normal animals (N). Input (In) of 
purified pERK2 is included. Western blots (representative of 2 separate experiments) revealed 
either pERK2 or total ERK2 (n=2).  
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Figure 5.3 No inhibition of JNK3 phosphatase activity in cerebral cortex following 
MCAO. 
JNK3 phosphatase assays were performed using cerebral cortical extracts prepared at various 
times of reperfusion following MCAO in mice from ischemic (I) and contralateral (C) non-
ischemic tissue. Cerebral cortical tissue was also isolated from normal animals (N). Input (In) of 
purified pJNK3 is included as well as control reactions with purified l phosphatase. Western 
blots (representative of 2 separate experiments) revealed either pJNK3 or total JNK3 (n=2). 
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Figure 5.4 Inhibition of ERK2-directed phosphatase activity in reperfused cerebral 
cortex following global ischemia. 
A. Endogeneous pERK1/2 and tERK levels were measured by Western blot in corresponding 
extracts from adult male rat cortical tissue isolated 30 min following either ischemia/reperfusion 
(I), control sham operations (C) or ischemia/without reperfusion (I/NR).  
B. Extracts prepared from adult male rat cerebral cortex isolated 30 min following either global 
ischemia/reperfusion (I), control sham operations (C), or ischemia/without reperfusion (I/NR) 
were incubated with His6-tagged pERK2. Western blot analysis was then performed of affinity 
purified His6-tagged pERK2 to reveal phospho-ERK2 (pERK2) or total ERK2 (ERK2) levels. 
IN: phosphatase assay input; C: control sham; I: ischemia/reperfusion; I/NR: ischemia without 
reperfusion. 
C. Statistical analysis of two independent ERK2 phosphatase assays (n=6 in each group). 
p<0.001. 
D. Extracts prepared as described in B were incubated with His6-tagged phospho-JNK3. Western 
blot analysis was then performed of affinity purified His6-tagged JNK3 to reveal phospho-JNK3 
or total JNK3 levels. IN: phosphatase assay input; C: control sham; I: ischemia/reperfusion; 
I/NR: ischemia without reperfusion. 
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Figure 5.5 Recovery of ERK2-directed protein phosphatase activity in the cerebral 
cortex following ischemia/reperfusion. 
A. Ischemic/reperfusion extracts from cerebral cortex shown in Fig 1 were incubated with 50 
mM DTT where indicated, prior to assaying for pERK2 phosphatase activity.  
B. The statistical analysis of two independent ERK2 phosphatase assays (n=6 in each group). 
p<0.05.  
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Figure 5.6 ERK2 phosphatase activity in hippocampal extracts is unaffected by 
ischemia/reperfusion. 
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A. Endogenous pERK1/2 and ERK levels were measured by Western blots in corresponding 
extracts from adult male rat hippocampal tissue isolated 30 min following either 
ischemia/reperfusion (I), control sham operations (C), or ischemia/without reperfusion (I/NR). 
B. Extracts prepared from adult male rat hippocampus isolated 30 min following either 
ischemia/reperfusion (I), control sham operations (C), or ischemia/without reperfusion (I/NR) 
were incubated with His6-tagged pERK2. Western blot analysis was then performed of affinity 
purified His6-tagged pERK2 to reveal total ERK2 (tERK) or pERK2 levels. IN: phosphatase 
assay input. C: control sham; I: ischemia/reperfusion; I/NR: ischemia without reperfusion.  
C. Statistical analysis of two independent phosphatase assays (n=6 in each group). There is no 
significant difference between the groups. 
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Figure 5.7 MEK is activated  in both ischemic cortex and hippocampus. 
Endogenous pMEK1/2 and MEK1/2 levels were measured by Western blot in corresponding 
extracts from adult male rat in cortical (CTX: A) or hippocampal (HPC: C) extracts isolated 30 
min following either ischemia/reperfusion (I), control sham operations (C), or ischemia/without 
reperfusion (I/NR). Statistical analysis of two independent Western blot analysis in B and D (n=6 
in each group). P<0.05. 
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Figure 5.8 PP2A is the predominant ERK2-directed phosphatase in rat cerebral 
cortex and hippocampus. 
A & D. Extracts prepared from control sham operated adult male rats in corresponding tissues 
(CTX & HPC) were incubated with 10nM OA where indicated prior to assaying for pERK2 
phosphatase activity. Input pERK2(IN) as well as pERK2 digested with purified phosphatase 
(lambda) were included.  
 112 
B & E. The statistical analysis of two independent phosphatase assays in corresponding tissues 
(n=6 in each group). ***: p<0.001; **: p<0.01.  
C & F. Western blot analysis of PP2A C-subunits in corresponding ischemia/reperfusion tissues 
(I), control sham (C) or ischemic without reperfusion (I/NR). 
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Figure 5.9 Tyrosine phosphatases also contribute to ERK-directed phosphatase 
activity in rat cerebral cortex. 
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A. Extracts prepared from control sham operated adult male rat in cerebral cortex were incubated 
with 1mM VO4 where indicated prior to assaying for pERK2 phosphatase activity. Input pERK2 
(IN) was included.  
B. Statistical analysis of two independent ERK2 phosphatase assays (n=6 in each group). 
P<0.001. 
C. Statistical analysis of two independent ERK2 phosphatase assays between OA inhibition and 
VO4 inhibition experiment. The effect of OA inhibition of ERK2 phosphatase activity was 
statistically significant than that of VO4. p<0.001. 
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5.5 DISCUSSION 
ERK1/2 activation occurs in a variety of brain regions in response to ischemia/reperfusion but 
the mechanism of this activation has not been analyzed thoroughly. In the preceding studies, I 
demonstrated that the inhibition of ERK1/2 phosphatases contributes to ERK1/2 activation 
following ischemia/reperfusion in both transient focal ischemia and global ischemia models. 
Furthermore, this inhibition of phosphatases is selective, since JNK phosphatases were not 
affected. I also revealed regional differences in the response of the ERK1/2 signaling pathway to 
ischemia/reperfusion and a differential sensitivity of ERK1/2 phosphatases to oxidative stress 
that accompanies reperfusion. The reversible inhibition of ERK1/2 phosphatases by 
ischemia/reperfusion in a cardiac arrest model contributes to early ERK1/2 activation in the rat 
cerebral cortex but not in the hippocampus. Further examination of the profile of MEK1/2 
activation has revealed the activation of MEK1/2 in both cerebral cortex and hippocampus 
following ischemia/reperfusion. These data strongly suggest that different mechanisms account 
for ERK activation in distinct brain regions following ischemia/reperfusion. In the cerebral 
cortex, ischemia/reperfusion-induced oxidative stress results in both the activation of MEK1/2 
and the inhibition of ERK1/2 phosphatases, leading to the ultimate hyperphosphorylaton of 
ERK1/2. In hippocampus, ERK1/2 activation following ischemia/reperfusion is achieved solely 
through the activation of MEK1/2 but not with inhibition of ERK1/2 phosphatases.  PP2A 
appears to be the major ERK phosphatase that is responsible for regulating ERK1/2 activation in 
ischemic brain tissues.  
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ERK1/2 activation has been associated with neuronal death in several transient focal 
ischemia models (Alessandrini et al., 1999; Namura et al., 2001; Noshita et al., 2002). ROS play 
a critical role in mediating ERK1/2 activation and subsequent neuronal death in this model since 
overexpression of SOD1 in mice attenuates ERK1/2 activation and the subsequent neuronal 
death following transient ischemia/reperfusion (Noshita et al., 2002). However, the mechanism 
of ROS-mediated ERK activation following ischemia/reperfusion remains largely unknown. 
Previous studies utilizing an in vitro neuronal model have shown that selectively reversible 
oxidation and inhibition of ERK1/2 phosphatases contributes to ERK1/2 activation and 
subsequent neuronal toxicity following oxidative stress (Levinthal and DeFranco, 2005).  This 
study provided the first link between ROS-mediated dysregulation of ERK1/2 phosphatases and 
ERK1/2-dependent neuronal toxicity. The current study extends the above findings to in vivo 
models of ischemia/reperfusion, particularly in transient focal ischemia where ERK1/2 is thought 
to contribute to neuronal toxicity in vitro. Taken together, we have established the role of 
oxidative stress in the selective inhibition of ERK1/2 phosphatases both in vitro and in vivo, 
providing new insights into the regulation of ERK1/2 activation by ROS. 
It has long been known that ROS regulate protein phosphatases, mainly based on the 
study of PTPs. Oxidative stress can inhibit the activity of PTPs by oxidizing and inactivating the 
catalytic cysteines on these phosphatases. Since both PTPs and DSPs have the same HC(X)5R 
motif in their catalytic sites, they may share the same mechanism of oxidative inhibition. Thiol 
oxidation and inactivation of PTPs/DSPs can be reversible or irreversible. Oxidation of the 
catalytic cysteine to sulfenic acid or the formation of intramolecular disulfide bonds or the 
formation of a novel reversible intermediate sulphenylamide are all reversible modifications of 
thiol groups (Barford, 2004). However, further oxidation of sulfenic acid to sulfinic acid and 
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sulfonic acid are irreversible. Compared with PTPs/DSPs, the mechanisms regulating the 
oxidative inhibition of PSTPs are much less known. Due to the lack of the presence of catalytic 
cysteines in the catalytic active sites of these enzymes, it is most likely that oxidation inhibits 
their activity through the oxidant-sensitive regulatory subunits or associated factors. Another 
important mechanism responsible for oxidative inhibition of the activity of PSTPs may lie on the 
oxidation of bi-nuclear metal clusters in their active site. Redox regulation of calcineurin has 
been shown through the targeting of Fe2+-Zn2+ center at the active site of the enzyme 
(Namgaladze et al., 2002). Recently, reversible thiol-oxidation has been reported regulating the 
activity of PP2A, although the exact mechanism is not known (Kim et al., 2003; Foley and 
Kintner, 2005).  
Apart from directly attacking catalytic cysteines or binuclear metal centers in protein 
phosphatases, oxidative stress can affect the activity of phosphatases through other signaling 
molecules such as zinc. Zinc is known as a key regulator of many signaling pathways, with the 
best example being its involvement in insulin signaling. Zinc has been found augmenting insulin 
signaling pathways through the inhibition of PTPs that dephosphorylate insulin receptor (Haase 
and Maret, 2005). It is interesting to note that insulin-stimulated ROS generation also plays a 
role in oxidizing and inactivating PTPs and, therefore, providing a positive feedback loop to 
insulin signaling.  Furthermore, it should be borne in mind that oxidative stress is very important 
in mediating zinc release from its intracellular binding proteins. Therefore, the combination and 
the interactions between redox signaling and zinc signaling may consistently drive and augment 
the insulin-mediated signaling pathway. 
Zinc release and accumulation has been associated with neuronal injury in various 
models of ischemia/reperfusion, although the origins of zinc remain controversial. Apart from 
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entering into postsynaptic neurons from presynaptic neurons, zinc has also been shown to be 
released from its intracellular stores by oxidative stress (Aizenman et al., 2000). ERK1/2 
activation has been involved in zinc-induced neuronal toxicity in neuronal cultures (Park and 
Koh, 1999; Seo et al., 2001), although the mechanism of zinc-induced ERK1/2 activation is not 
known yet. Due to the role of zinc in inhibiting phosphatases and a recent report showing the 
inhibition of ERK1/2 phosphatases by zinc in human bronchial epithelial cells (Kim et al., 2006), 
it is tempting to hypothesize that the inhibition of ERK1/2 phosphatases by the combination of 
oxidative stress itself and zinc released following ischemia/reperfusion contribute together to 
ERK1/2 activation and subsequent neuronal toxicity in ischemia/reperfusion. To confirm the role 
of zinc in inhibiting ERK1/2 phosphatases in ischemia model, it will be interesting for the future 
study to examine the ERK1/2 phosphatases activity following the chelation of zinc by in vivo 
administration of either CaEDTA or TPEN. Future studies could also focus on the identification 
of the specific ERK1/2 phosphatases that are reversibly oxidized or inactivated in the 
ischemia/reperfusion model. 
Impairment of PP2A activity has been associated with an enhanced activation of ERK1/2 
and hyperphosphorylation of tau, a specific ERK1/2 target, in Alzheimer’s disease (Gong et al., 
1995; Zhao et al., 2003). Transgenic mice expressing a mutant PP2A catalytic unit exhibited 
activation of ERK1/2 and JNK pathways as well as the phosphorylation of endogeneous tau, 
similar to the key pathological features in Alzheimer’s disease (Kins et al., 2001; Kins et al., 
2003). Although PP2A is the major phosphatase contributing to ERK1/2 dephosphorylation in 
cortical and hippocampal extracts, it appears that ischemia/reperfusion injury selectively affects 
this phosphatase in cortex but not in hippocampus. Since both hippocampus and cortical tissues 
are subjected to oxidative stress at early times after reperfusion, PP2A may be differentially 
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sensitive to oxidative inhibition in different brain regions. This implies that the response of 
individual signaling molecules to oxidative stress within individual neurons may be subjected to 
multiple levels of regulation that are not reflected strictly in the levels of oxidants. In addition to 
ERK1/2, JNK has also been shown to be a substrate of PP2A (Shanley et al., 2001). However, 
ischemia/reperfusion does not appear to impact the activity of protein phosphatases to 
dephosphorylate JNK3 (Fig 5.3 and Fig 5.4). Unlike dominant negative PP2A C subunit-
expressing transgenic mice which globally induced the hyperphosphorylation of the substrates of 
PP2A, including ERK1/2, JNK and tau (Kins et al., 2001; Kins et al., 2003), our results suggest 
that the inhibition of PP2A activity that occurs upon ischemia/reperfusion injury applies only to 
select substrate, i.e., ERK1/2. Given the fact that PP2A is the major ERK1/2 phosphatase in 
neurons and involved in the dephosphorylation of all levels of ERK1/2 signaling cascade, it is 
possible that ischemia/reperfusion-induced oxidative stress impact PP2A-associated ERK1/2 
signaling cascade more than the JNK pathway. 
It was previously reported that in an in vitro model of oxidative stress in immature 
cortical neuronal cultures, inhibition of ERK2 phosphatase activity contributes to ERK1/2 
activation and subsequent neuronal toxicity (Levinthal and DeFranco, 2005). In this report, I 
have established for the first time a role for phosphatase inhibition in ERK1/2 activation 
following transient focal ischemia and global ischemia.  Furthermore, my data provide insights 
into the different regulating mechanisms on ERK1/2 activation in distinct brain regions 
following global ischemia/reperfusion. Considering the important association between ERK1/2 
activation and neuronal toxicity or neuronal survival in various ischemia models, a better 
understanding of the mechanisms regulating ERK1/2 activation following ischemia/reperfusion 
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could lead to new therapeutic strategies that target specific molecules that regulate selective 
responses to oxidative stress.  
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6.0  GENERAL DISCUSSION 
As an important signaling molecule activated by various extracellular stimuli, ERK1/2 is 
traditionally associated with cell proliferation and differentiation as well as cell survival. In 
recent years, a role of ERK1/2 activation in contributing to cell death under various stresses has 
begun to emerge (Chu et al., 2004). However, due to the individualized responses induced by 
specific stimuli in different cell types, the mechanisms regulating ERK1/2 activation remains 
poorly understood. Previous studies in our lab have definitely established a role of ERK1/2 in 
contributing to neuronal cell death in response to glutamate depletion. The data presented here 
provide insights into the mechanism of regulating ERK activation in oxidatively-stressed 
neurons. Oxidation-induced inactivation of ERK1/2 phosphatases results in the 
hyperphosphorylation of ERK1/2 and subsequent ERK1/2-dependent neuronal cell death. 
Furthermore, an increase in intracellular free zinc also contributes to the inhibition of ERK 
phosphatases in neuronal cells following glutamate toxicity. The administration of either an 
antioxidant or zinc chelator restores the activity of ERK phosphatases and protects neuronal cells 
from oxidative stress-induced cell death. Moreover, studies examining the role of oxidative 
inhibition of ERK1/2 phosphatases in driving neuronal cell death have been extended to an in 
vivo model of MCAO. Specifically, I found that ERK phosphatase activity is inhibited following 
ischemia/reperfusion in an MCAO model, in which ERK1/2 activation contributes to neuronal 
cell death (Alessandrini et al., 1999). Altogether, these results establish a clear role for the 
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inhibition of ERK1/2 phosphatases in driving ERK1/2-dependent neuronal toxicity during 
oxidative stress. 
6.1 OXIDATIVE INHIBITION OF ERK-DIRECTED PHOSPHATASES 
In recent years, ROS have been recognized as important second messengers in mediating specific 
cellular signaling events. By changing the phosphorylation status of signaling proteins, several 
protein phosphatases have been identified as the key links between oxidative stress and 
regulation of specific signaling pathways. Due to the low pKa of their catalytic cysteines, PTPs 
are very sensitive to oxidation, which suggests that cysteine oxidation is important in regulating 
the activity of PTPs. Reversible or irreversible cysteine oxidation of specific PTPs then 
determines the distinct biological outcomes mediated by PTP-regulated signaling pathways. This 
has established a role for protein phosphatases as a redox sensor to mediate and regulate oxidant-
induced signaling cascades. 
The best example of the role of oxidative inhibition of protein phosphatases in mediating 
physiological responses is ligand-receptor interactions in growth factor-mediating signaling 
events (Droge, 2002). Growth factor-receptor binding on the plasma membrane leads to the local 
generation of ROS, which in turn, inactivate specific phosphatases. This leads to the 
augmentation of membrane receptor autophosphorylation and facilitation of ensuing signaling 
cascades. One intriguing problem in these models is how the specificity of the oxidative 
inhibition of specific phosphatase is achieved. In one single cell type (Rat-1 cells), PDGF 
induces the oxidation of SHP-2 (Meng et al., 2002), whereas insulin induces the oxidation of 
PTP1B (Meng et al., 2004). Moreover, it has been shown that a NADPH oxidase, Nox4, is co-
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localized with PTP1B on intracellular membranes (Martyn et al., 2006). Nox4 has been reported 
to play an important role in ROS generation and oxidation inhibition of PTP1B in the insulin-
mediated signaling pathway (Mahadev et al., 2004). Therefore, the local regulation of ROS 
generation and the proximity between ROS and phosphatases may be important in regulating the 
specificity of the phosphatases being affected, rather than indiscriminate inhibition of all 
phosphatases. A recent report revealed that distinct domains of receptor-like PTPs (RPTPα) are 
differentially sensitive to oxidation (Groen et al., 2005) by using a novel antibody against the 
oxidized form of the active site of cysteine residues. These results suggest that intrinsic 
difference in the susceptibility of PTP to oxidation may also determine the specificity of 
oxidative inhibition of distinct signaling pathways.  
Our study was the first to reveal a role for oxidative inhibition of protein phosphatases in 
mediating neuronal death (Levinthal and DeFranco, 2005). Consistent with our study, a recent 
report showed that activation of MEK1 is modest in HT22 cells and primary immature cortical 
neurons (Choi et al., 2006), further supporting the notion that oxidative inhibition of ERK1/2-
directed phosphatases is largely responsible for persistent ERK1/2 activation following 
glutamate-induced oxidative toxicity. Similarly, persistent JNK activation is mainly driven by 
the oxidative inhibition of JNK phosphatases in TNF-α treated fibroblasts and liver cells 
(Kamata et al., 2005). Furthermore, the administration of a broad spectrum antioxidant, BHA, 
restores the activity of specific MAPK phosphatases and prevents subsequent cell death in our 
models (results in Chapter 3) and in Kamata’s study (Kamata et al., 2005). Thus, oxidative 
inhibition of specific protein phosphatases may represent a general mechanism for prolonged 
activation of protein kinases that drive cell death. 
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Since BHA is a broad spectrum antioxidant, it is not known which specific reactive 
oxygen or nitrogen species is generated following glutamate-induced oxidative toxicity and 
responsible for the inhibition of ERK phosphatase. Various strategies could be utilized to address 
this question. Specfic ROS or RNS could be detected by a variety of detection systems such as 
coelenterazine-enhanced chemiluminescence method to measure changes in intracellular O2-
levels (Tarpey et al., 1999). Moreover, specific ROS generated could be characterized by various 
oxidant scavenging systems. Purified SOD1 or the transfection of SOD1 expression plasmid will 
be utilized to evaluate the role of O2- on glutamate-induced oxidative toxicity and the inhibition 
of ERK phosphatase. The role of H2O2 on oxidative toxicity could be determined by using its 
scavenger, catalase or catalase expression vectors.  
Although in vivo administration of antioxidant BHA and in vitro addition of a thiol-
reducing agent DTT could reverse the inhibition of ERK1/2 phosphatase activity following 
glutamate toxicity, the mechanism of oxidation inhibition of ERK1/2 phosphatases still remains 
unclear. In Chapter 4, I provided the first clear evidence of reversible cysteine thiol oxidation in 
PP2A C-subunit under conditions of glutamate toxicity. Moreover, more recent study in the lab 
has shown that the phosphatase activity of PP2A was indeed decreased following glutamate-
induced oxidative toxicity by using the IP-PP2A phosphatase assay (data not shown). It still 
remains unclear whether the inhibition of PP2A phosphatase activity may be due to the oxidation 
of reactive site cysteine residue(s) in PP2A following oxidative stress. Kim et al (2003) have 
shown that ROS accumulation during cellular senescence in fibroblast cells inhibited PP1 
activity and this might be due to the oxidation of Cys62 and Cys105 in PP1. Since there is 49% 
homology in the catalytic domains of PP1 and PP2A, it is very possible that the oxidation of 
Cys62 may also be critical for the impairment of PP2A phosphatase activity in our case. Future 
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studies will be directed to identify the specific cysteine residue(s) in PP2A which is (are) 
modified by oxidative stress. Since BHA restores ERK phosphatase activity and PP2A is one of 
the major ERK phosphatases in neurons, it would be interesting to evaluate the effect of 
antioxidant (BHA) on restoring the activity of PP2A following glutamate-induced oxidative 
toxicity. Apart from directly affecting the activity of the catalytic subunit of PP2A, thiol 
oxidation of PP2A C subunit may affect its association with the B regulatory subunits, which 
determines the substrate specificity as well as subcellular compartmentalization of the PP2A 
holoenzyme. Future studies will also be directed towards the examination of the association 
between different PP2A subpopulation and its specific substrate, ERK1/2, following glutamate-
induced oxidative toxicity.  
Using specific peptide and pharmacological inhibitors of PP2A, I have demonstrated that 
PP2A is a major ERK1/2-directed phosphatase that may be susceptible to oxidation inhibition. 
However, previous studies suggest that some orthovanadate-sensitive phosphatases, such as 
MKPs or PTPs, may also contribute to ERK1/2-directed phosphatase activity (Levinthal and 
DeFranco, 2005). Indeed, a recent report has demonstrated the role of MKP1 in contributing to 
glutamate-induced toxicity in HT22 cells and primary immature cortical neurons (Choi et al., 
2006). Furthermore, oxidation inactivation of MKP1 has been demonstrated in TNF-α treated 
fibroblasts, and this inhibition of MKP1 contributes to persistent JNK activation that leads to 
apoptosis (Kamata et al., 2005). Due to the similar structure in catalytic sites as PTPs, MKPs is 
reversibly inhibited through the oxidation of catalytic cysteines to sulfenic acid (Kamata et al., 
2005).  Altogether, these results suggest that MKP1 may be another major candidate of ERK1/2 
phosophatase sensitive to oxidation inhibition in our model. As I have demonstrated the 
feasibility of the thiol affinity chromatography to enrich for reversibly thiol-oxidized proteins 
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(Chapter 4), future studies will be necessary to examine the thiol oxidation of MKP1 by either 
thiol affinity chromatography or non-denaturing SDS-PAGE (Kamata et al., 2005). Once the 
thiol oxidation of MKP1 is demonstrated, the activity of thiol-oxidized MKP1 can be examined 
by an immunoprecipitation phosphatase assay and specific cysteine residues being oxidized 
could be identified by mass spectrometry. 
6.2 OXIDATIVE STRESS-MEDIATED ZINC RELEASE IN ERK1/2-DEPENDENT 
NEURONAL DEATH  
Apart from affecting the redox state of signaling proteins, oxidative stress can also alter many 
metabolic and signaling pathways through triggering the release of intracellular stores of metal 
ions such as zinc. An indispensable trace element in human body, zinc is most abundant in the 
brain. Zinc deficiency causes severe symptoms in nervous system and excessive zinc has been 
found to be toxic to neurons in vitro (Koh and Choi, 1994; Canzoniero et al., 1999; Seo et al., 
2001). Moreover, zinc accumulation has been associated with neuronal death in both global 
ischemia and focal ischemia (Koh et al., 1996; Lee et al., 2002a). Although the sources of toxic 
zinc following neuronal injury in brain still remains controversial, a thiol oxidant, DTDP 
(Aizenman et al., 2000), and nitric oxide (Montoliu et al., 2000; Bossy-Wetzel et al., 2004) have 
been shown to trigger zinc release from the intracellular thiol-sensitive zinc-binding protein, 
metallothionein (MT). 
Zinc has been shown to induce neuronal death through its impact on the activation of 
various MAPK pathways. Thiol oxidizing agents and nitric oxide mediates intracelllular zinc 
release, which in turn, activates p38 MAPK and leads to cell death in cortical neurons 
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(McLaughlin et al., 2001; Bossy-Wetzel et al., 2004; Zhang et al., 2004). Exogenous zinc 
induces sustained ERK1/2 activation which contributes to neuronal death in PC12 cells (Park 
and Koh, 1999; Seo et al., 2001). ERK1/2-dependent neuronal death has also been reported in 
methylisothiazolinone (MIT)-induced toxicity (Du et al., 2002) and peroxynitrite-induced 
toxicity in mature oligodendrocytes (Zhang et al., 2006) through the release of intracellular zinc. 
However, the mechanism regulating zinc phosphorylation and activation of ERK1/2 pathway 
still remains largely unknown. One mechanism that might be responsible for zinc-mediated 
protein phosphorylation involves the inhibition of protein phosphatases. For example, in EGFR 
and IGF-1 mediated signaling, zinc enhances the phosphorylation of receptor tyrosine kinases 
(RTKs) through the inhibition of PTPs (Haase and Maret, 2003; Tal et al., 2006). Zinc has been 
found to inhibit PTPs (Brautigan et al., 1981; Haase and Maret, 2003) and PSTPs such as PP2A 
(Zhuo and Dixon, 1997) and PP2B (Takahashi et al., 2003) in vitro. Zinc inhibition of PSTP 
activity involves the competition with the metal in the active sites of PSTPs. Zinc competes with 
Mn2+ in PP2A and Ni2+ in PP2B (Zhuo and Dixon, 1997; Takahashi et al., 2003). Recently, it has 
been shown that zinc activates ERK1/2 in human airway epithelial cells by inhibiting ERK1/2-
directed phosphatases in vivo (Kim et al., 2006). 
The data presented in Chapter 3 confirm the role of oxidative stress in mediating 
intracellular zinc release. A general antioxidant, BHA, reduces zinc accumulation in oxidatively 
stressed HT22 cells and primary immature cortical neurons. Furthermore, I provided the 
evidence that intracellular zinc-mediated inhibition of ERK1/2 phosphatases links oxidative 
stress and ERK1/2-dependent neuronal death in HT22 cells and immature cortical neurons. This 
provides important insights into the mechanism of oxidative stress-induced ERK1/2-dependent 
neuronal death, highlighting the importance of the inhibition of ERK1/2 phosphatases. In 
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summary, I propose the following: Glutamate or HCA-induced oxidative stress triggers the 
intracellular accumulation of zinc, which together with ROS, inactivate ERK1/2 phosphatases. 
This leads to ERK1/2 hyperphosphorylation and activation, resulting in neuronal death in HT22 
cells and primary immature cortical neurons. Moreover, the results of U0126’s reduction of zinc 
release and restoration of ERK1/2 phosphatase activity suggest that ERK1/2 itself can function 
as a positive feedback to enhance zinc release triggered by ROS.  
The mechanisms of ERK1/2 itself acting to increase intracellular zinc accumulation still 
remain elusive. One mechanism may involve the requirement of ERK1/2 for ROS generation 
through the activation of NADPH oxidase as shown in a model of MIT-induced ERK-dependent 
neuronal death (Du et al., 2002). Although previous studies in the lab have shown that U0126 
does not reduce ROS generation by measuring DCF fluorescence  intensity (Stanciu et al., 2000; 
Levinthal and DeFranco, 2004), more sensitive detection methods may be needed in the future to 
re-evaluate these results. The role of ERK1/2-activated NADPH oxidase in generating ROS and 
subsequent zinc accumulation could be evaluated by the treatment of primary neurons with a 
selective NADPH oxidase inhibitor, apocynin, in the absence or presence of HCA and 
subsequent measurement of ROS levels and zinc accumulation. Molecular inhibitors of ERK1/2 
activation such as dominant negative MEK1 could be utiltized to confirm the impact of ERK1/2 
on zinc release.  
Although a direct role of ROS in triggering zinc accumulation has been shown in our 
study (Chapter 3), it is still not known which specific ROS is responsible for intracellular zinc 
accumulation following oxidative toxicity. The impact of specific ROS on intracellular zinc 
accumulation could be determined by measuring relative intracellular zinc levels in neurons 
following the treatment of neurons with pharmacological or molecular oxidant scavenging 
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reagents in the absence or presence of HCA (or glutamate). In addition, zinc accumulation is not 
only a mediator of ROS-induced toxicity but also an executor itself for ROS generation. Zinc has 
been found to inhibit mitochondrial respiration (Brown et al., 2000; Bossy-Wetzel et al., 2004) 
and induces mitochondrial ROS production (Sensi et al., 1999). The effect of zinc release on 
ROS generation in our model has not been evaluated. This could be addressed in the future by 
measuring ROS and/or RNS levels in oxidatively stressed neurons treated with TPEN, a chelator 
of zinc.  
Although we have observed the intracellular zinc accumulation following oxidative 
toxicity in neurons, the source of intracellular elevated zinc has not been identified yet. 
Extracellular zinc could be uptaken into cells through various routes including Zip family of zinc 
transporters and various zinc-permeable ion channels. Therefore, a cell impermeable zinc 
chelator, CaEDTA, will be used to evaluate the contribution of extracellular zinc in ROS-
mediated zinc accumulation. Inside the cells, one major cellular source of zinc is metallothionein 
(MT). Measurement of intracellular zinc levels in oxidatively stressed neurons that are 
transfected with MT expression plasmids will enable us to determine the contribution of MTs in 
releasing zinc in our model of neuronal oxidative stress. Recently, PKCδ has been shown to be 
activated by oxidative stress in glutamate-treated HT22 cells and immature cortical neurons 
(Choi et al., 2006). Moreover, PKCδ activation facilitates proteasomal degradation of MKP1 and 
contributes to ERK1/2 activation. Interestingly, PKCδ activated by oxidative stress releases zinc 
from its zinc-finger domain (Knapp and Klann, 2000; Korichneva et al., 2002), which suggests 
that PKCδ is another source of intracellular zinc. Taken together, it is very tempting to 
hypothesize that PKCδ may play a role in mediating ROS-induced zinc release and subsequent 
ERK-dependent oxidative toxicity. Future studies will be directed to examine the effect of PKCδ 
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inhibition in blocking oxidative stress-induced zinc release in glutamate or HCA-treated HT22 
cells or immature cortical neurons by utilizing specific pharmacological or molecular inhibitors 
of PKCδ.  
Study from our lab has shown that ERK1/2 activation is necessary but not sufficient in 
mediating glutmate-induced oxidative toxicity (Luo and DeFranco, 2006). Transfection of a  
constitutively active MEK1 failed to induce toxicity in HT22 cells despite a robust, persistent 
activation of ERK1/2 within either the cytoplasmic or nuclear compartment (Luo and DeFranco, 
2006). My data presented in Chapter 3 has revealed that chronically activated ERK1/2 in 
oxidatively stressed neurons functions as a positive feeback to maintain elevated intracellular 
levels of Zn2+ and subsequent Zn2+-dependent cell death. As discussed above, one mechanism 
responsible for ERK1/2-regulated intracellular zinc accumulation may be due to ROS generated 
by ERK1/2-activated NADPH oxidase. In our model, ROS acts as the trigger to promote the 
release of protein-bound Zn2+, perhaps through thiol oxidation of specific cysteine residues that 
participate in Zn2+ binding (Aizenman et al., 2000; St Croix et al., 2002). In this case, ERK1/2 
may also block the recovery  of oxidatively damaged Zn2+ binding proteins such as MT or limit 
their expression (Jiang et al., 2004a) and therefore, maintains intracellular neurotoxic levels of 
zinc. Thus, consistent with Luo’s study (2006), in the absence of oxidative damage to these 
redox-sensitive proteins, chronic ERK1/2 activation alone does not promote Zn2+-dependent 
neuronal death since it might not impact intracellular Zn2+ homeostasis. This hypothesis could 
be tested by measuring the intracellular zinc levels in HT22 cells transfected with a 
constitutively active MEK1 expression plasmid. 
My data presented in Chapter 3 has revealed a mechanism of dual regulation of ERK 
phosphatase by ROS and zinc. However, it is not known if these two processes are dependent or 
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independent events. It is possible that selective ERK phosphatase may need to be thiol oxidized 
to cause the change of its conformation to bind with the inhibitory zinc. An in vitro assay has 
been utilized to measure zinc bound to immunoprecipitated PKCδ in H2O2 treated lymphocytes  
by using a fluorescent zinc indicator dye (TSQ) (Korichneva et al., 2002).  In our case, PP2A or 
MKP1 could be immuoprecipitated from untreated or glutamate-treated HT22 cells and 
subjected to the above in vitro zinc binding assay. If oxidative stress does have an effect on the 
binding of zinc to PP2A or MKP1, we should observe an increase in the zinc associated with 
PP2A or MKP1 immunoprecipiated from glutamate-treated HT22 cells. 
Fig 6.1 summarizes the mechanism of regulating ERK phosphatases by ROS and zinc in 
glutathione-depletion induced oxidative toxicity in HT22 cells and primary neurons. 
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Figure 6.1 Summary of the mechanisms regulating ERK phosphatases by ROS and Zinc in 
glutamate-induced oxidative toxicity models. 
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Glutamate-induced toxicity in HT22 cells and primary immature cortical neurons 
provides an excellent in vitro model to study the role of oxidative stress in the pathogenesis of 
neurodegenerative diseases, particularly in the pathogenesis of neonatal hypoxia. This type of 
brain injury is often seen in neonates suffering from birth asphyxia and is a common cause for 
lifelong neurological disabilities. Oxidative stress is an early feature of ischemia in both adult 
and immature brains. Compared with adult brain, the immature brain is particularly vulnerable to 
oxidative stress due to its poor oxidant scavenging systems and high rate of energy consumption 
(Ferriero, 2004; Blomgren and Hagberg, 2006). Moreover, the vulnerability to oxidative stress is 
more selective for neurons than for glia cells. Therefore, oxidative stress may play a more 
important role in ischemia-induced neuronal death in immature brain by regulating the release of 
proapoptotic proteins from mitochondria (Blomgren and Hagberg, 2006). However, it should be 
borne in mind that oxidative toxicity and excitotoxicity all contribute to ischemia-induced 
neuronal death in both adult and immature brains. Thus, it would be difficult to clearly 
differentiate the contribution of oxidative toxicity and excitotoxicity in mediating neuronal death 
following ischemia in vivo although oxidative stress is known as an early triggering event in 
ischemia.  
To make our study have more pathological relevance, we adopted several in vivo models. 
One in vivo model is MCAO model in rodents which mimics stroke. Although the mechanisms 
of neuronal death in MCAO models involve both excitotoxicity and oxidative toxicity, this 
model still serves as an excellent paradigm to elucidate mechanisms of oxidative stressed-
induced signaling cascades and subsequent neuronal death in vivo. Scavenge of ROS generation 
significantly reduces neuronal death in MCAO models (Kuroda et al., 1999; Huang et al., 2001), 
suggesting the contribution of oxidative stress in the mechanism of neuronal death in MCAO 
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models. Consistent with our in vitro data, neuronal death in MCAO rodents is ERK1/2-
dependent, since the pharmacological inhibition of ERK1/2 activation decreases brain injury in 
rodent MCAO models (Alessandrini et al., 1999). ROS such as superoxide contribute to 
ERK1/2-dependent neuronal death in MCAO rodents since the overexpression of SOD1 in mice 
reduces brain injury by preventing ERK1/2 activation induced by ROS (Noshita et al., 2002). My 
data presented in Chapter 5 revealed that the inhibition of ERK1/2 phosphatases contributes to 
ERK1/2 activation following ischemia/reperfusion in MCAO mice. This is the first 
demonstration of the role of oxidative inhibition of ERK1/2 phosphatases in ERK1/2 activation 
in an in vivo model that involves oxidative toxicity. Furthermore, the activation of MEK1 in 
ischemic tissues is only modest (data not shown), which suggests that the inhibition of 
phosphatase may play a major role in mediating ERK1/2 activation in our case. Although I found 
that total ERK1/2-directed phosphatase activity is inhibited, it would be important to identify the 
specific ERK1/2 phosphatase being affected in ischemic tissues using an IP-phosphatase assay. 
Given the fact that zinc accumulation in ischemic brain tissues contributes to toxicity in ischemia 
models (Koh et al., 1996; Lee et al., 2002a), the MCAO model could also be utilized to study the 
role of zinc in mediating oxidative stress-induced neuronal toxicity by using the approaches 
outlined in our in vitro studies. The potential role of zinc in mediating toxicity in ischemia 
models could be confirmed by intraventricular administration of a cell impermeable cheltor of 
zinc, CaEDTA, which is neuroprotective, as shown in several studies from Choi’s group (Koh et 
al., 1996; Lee et al., 2002a). Once the neuroprotective effect of CaEDTA is confirmed in the 
MCAO model, we can proceed to examine the impact of zinc chelation in vivo on ERK1/2 
activation and ERK1/2 phosphatase activity. Another in vivo model that will allow us to study 
the impact of oxidation on the inhibition of ERK phosphatase is SOD1 transgenic mice. 
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Transgenic mice overexpressing SOD1 exhibit resistance to MCAO-induced neuronal injury by 
preventing ERK1/2 activation while no effect on MEK1 activation is observed (Noshita et al., 
2002). This suggests that SOD1 overexpression may prevent ERK1/2 activation by restoring 
ERK1/2 phosphatase activity. Thus, the analysis of ERK phosphatase activity in SOD1 
transgenic mice will allow us to understand the mechanisms responsible for SOD1 effects on 
ERK1/2 activation following MCAO and alternatively, the mechanism of superoxide-induced 
ERK1/2 activation. Taken altogether, these in vivo studies will provide novel insights into the 
mechanisms regulating ERK1/2 phosphatases and the impact on ERK1/2-dependent neuronal 
death in ischemia models. The information obtained could contribute to the development of 
novel therapeutic strategies that target ERK1/2 phosphatases and ERK1/2 activation during 
oxidative stress in vivo.  
Studies in another in vivo oxidative stress model, asphyxia-induced global ischemia 
model, have revealed a region-specific pattern of the inhibition of ERK phosphatase activity. 
ERK phosphatase activity was inhibited in the ischemic cerebral cortex but not in the ischemic 
hippocampus. Several possibilities could account for the region specificity in ERK phosphatase 
activity we have observed. In our study, we assume that the same level of ischemia/reperfusion 
affect all brain regions. However, changes in regional cerebral blood flow before, during, and 
after asphyxia-induced cardiac arrest were not monitored by laser-Doppler flowmetry. Therefore, 
recirculation failure for the various brain regions may account for the difference in observed 
inhibition of ERK phosphatase activity in different brain regions. Moreoever, even if different 
brain regions are subject to the same constant impact of ischemia/reperfusion, the extent of 
oxidative stress, i.e., the level of ROS generated, may be different. Difference in the level of 
ROS in specific brain regions following ischemia/reperfusion is very likely to explain the 
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specificity of ERK phosphatase inhibition. This will be addressed by measuring ROS levels in 
extracts of different brain regions following ischemia/reperfusion. By taking extracts from 
distinct brain regions, we assume that the complement of cell types in the extracts is the same 
(e.g., glia, neurons). It is also possible that the hippocampus has more glia cells in the extract and 
this explains the difference in measured phosphatase activity. However, this possibility is 
excluded since the proportion of glial cells has been analyzed by the Western blot analysis of 
their specific marker, GFAP, in both cortex and hippocampus. Same levels of GFAP have been 
found in both brain regions, suggesting that the difference in glial cell components could not 
account for the difference in phosphatase activity we observed. However, we did not measure the 
component of microglial cells in these two brain regions and this could be analyzed by using a 
specific marker of microglial cells. 
Similar to selective inhibition of JNK phosphatase in TNF-α- induced oxidative toxicity 
in fibroblasts and Concanavolin A-induced liver toxicity in mice (Kamata et al., 2005), a 
selective inhibition of ERK phosphatase has been revealed in both in vitro and in vivo studies of 
our oxidative stress models. Glutamate-induced oxidative stress in immature neurons does not 
significantly affect JNK phosphatase activity (Levinthal and DeFranco, 2005). These results 
suggest that even though MAPK phosphatases are oxidant sensitive, they are not globally 
inactivated by oxidative stress in cells. How the specificity of the oxidative inhibition of specific 
phosphatase is achieved still remains vague. As discussed before, depending upon the nature of 
the stimulus imposed upon cells, select protein phosphatases may be subjected to different 
levels of oxidation. For example, in Rat-1 cells, PDGF induces the oxidation of SHP-2 (Meng et 
al., 2002), whereas insulin induces the oxidation of PTP1B (Meng et al., 2004). The local 
regulation of ROS generation and the proximity between ROS and phosphatases may be critical 
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in determining the specificity of the phosphatases being affected. Nox4, a NADPH oxidase 
which was reported playing a role in the oxidative inhibition of PTP1B in the insulin-mediated 
signaling pathway (Mahadev et al., 2004), has been revealed co-localizing with PTP1B on 
intracellular membranes (Martyn et al., 2006). Therefore, selective MAPK phosphatase may be 
protected from the damaging effects of reactive species by sequestering within subcellular 
compartments that are inaccessible to short-lived oxidants. It is also possible that selective 
MAPK phosphatase may form multi-units protein complexes to protect the active cysteine 
residue(s) from exposing to reactive species. Similarly, zinc-binding sites in selective MAPK 
phosphatase may also be protected by the formation of multi-units protein complexes and this 
may explain for the selective inhibition of ERK phosphatase but not JNK phosphatase by 
exogenous zinc. 
In summary, the results presented in this thesis have definitively established the role of 
ERK1/2 phosphatases in contributing to ERK1/2 activation as well as subsequent ERK1/2-
dependent neuronal death in both in vivo and in vitro oxidative stress models. I have confirmed 
findings from previous studies (Levinthal and DeFranco, 2005) by showing that the inhibition of 
ERK1/2 phosphatases in HT22 cells and primary cortical neurons subjected to glutathione 
depletion is indeed the result of oxidative stress as phosphatase activity was restored, leading to 
reduced ERK1/2 activation upon treatment with the antioxidant BHA. Moreover, I have 
identified a novel mechanism of protein phosphatases regulation by oxidative stress, i.e., 
intracellular free zinc accumulation. Oxidative stress triggers the release of intracellular zinc, 
which reversibly inhibits protein phosphatases. This leads to the activation of a subset of 
signaling molecules (i.e., ERK1/2) and subsequent ERK1/2-dependent neuronal death. 
Furthermore, I have also identified a positive feedback loop driven by ERK1/2 that further 
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exacerbates cellular exposure to neurotoxic levels of free zinc. Altogether, my study has 
elucidated the mechanism of protein phosphatases regulation by oxidative stress and has 
established a role of zinc as an important regulator of protein phosphatases.  As a bridge between 
oxidative stress and the regulation of protein phosphatases, zinc could be the potential target of 
future therapeutic strategies for various neurological diseases that involve oxidative toxicity.  
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